ES2736005T3

Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab

Abstract

Pertuzumab, Trastuzumab and a carboplatin-based chemotherapy for use in the neoadjuvant treatment of early-stage HER2 positive breast cancer in a patient, in which early-stage HER2-positive breast cancer has not spread beyond breast or axillary lymph nodes and in which carboplatin-based chemotherapy comprises Docetaxel and Carboplatin.

ES2736005T3, drawing sheet 1 — Sheet 1 of 3

Term

6 yearsto projected expiry

Projected expiry 11 October 2032, counted from filing; an application has no term until it is granted.

2 claims: 2 independent, 0 dependent

1
REIVINDICACIONES 1. Pertuzumab, Trastuzumab y una quimioterapia basada en carboplatino para su uso en el tratamiento 5 neoadyuvante del cáncer de mama positivo para HER2 en fase precoz en un paciente, en el que el cáncer de mama positivo para HER2 en fase precoz no se ha diseminado más allá del seno o de los ganglios linfáticos axilares y en el que la quimioterapia basada en carboplatino comprende Docetaxel y Carboplatino.
2
Pertuzumab, Trastuzumab y la quimioterapia basada en carboplatino para el uso de la reivindicación 10 1, en el que Pertuzumab se administra simultáneamente con la quimioterapia basada en carboplatino. ES 2 736 005 T3 fil Fh i-l ül 0 ÍU ti > m — O 1 · 0*1 TO p ü> !> U qí to TO X Cí < § o fí 0 ¡y eq a üi 5« U3 i-q Q Üi ΓΊ TO CJ di pq M <Λ 2i O X 0 O O O M 0 Üd SI Íh> ts.i Región reguladora ES 2 736 005 T3 Variable ligera 10 20 3040 2C4 DTVilTQSHKIMSTfíVRDRVSTTC [KASQDVSIGVA] KYQQR1? * t +Oi * * *:574 DIQMTQSPSSLSASVGDkVTTTC [KASQDvSIGVA] WYQQKP * **M·.· hum κι DlQMTQSPSSLSASvGDRVTITC (RASQSISNYLA| WYQQKP 2.C4 GQSPKLLJY [SASYRYT] * * 574 GKAPKLLIY [SASYRYT] i· í t + ΐ ΐ &c o so GV PDRFTGSGSGTDFTFTIS SVQA ± i * i + GVPKHE'SGSGSGTDE'TLTISSLQ? hum Kl GKAPKÚLIY lAASSLESJ GVPSRFSGñGSGTDFTLTISSLQP 2C4 EDLAVYYC + * 90 EQQYYlYPYTj 100 FGGGTKLE1K A + {SEQ ID NO =5 ) 574 EDFATYYC [QQYYIYPYT] Jr -i- ΐ # FGQGTKVEIK {SEQ ID NO: 7 ) hum χϊ EDFATYYC [QQYNSLPWT] FGQGTKvEIK {SEQ ID NO: 9 ) Γ/U, ZA Variable pesada 40 10 ΞΟ 30 2C4 EVQLQGSGPELVKPGTSVKESCKAS -Λ· * * + ΐ í + [GFTFTDYTWÜl WVKQ3 ± * 574 EVQLVESGGGLVQPGGSLRLSCAAS jGFTFWY'ÍWj W T * λ WVRQA hum III EVQLVESGGGLVQPGGSLRLSCAAS [GFTFS5YWMS] WVRQA 50 a 60 70 30 2C4 HGKSLEWIG IT W * + íDVNPN5GGSIYNQPFKG) KASLTVDRSSRIVYM frír·#: ic Iri ΐ 1 w 574 FGKGLEWVA (DVN PN S GG S ϊ YM QR EKG 3 R ET LSV DRfí KNTl.YL ΐ s t + + * ± hum 111 PGKGLEWVA ÍVISGDGGSTYYADSVKG] PFTISRDHSKNTLYL 2C4 574 abe 90 lOOüb ELRQ LTFEDTAVYYCAR |NLGP5FYFDY] 4 + TÍ CHN S LRAEDTAVYYC.AR [ NhG Í?S FY FDY ] 110 WGQGTTLTVSS {SEQ ID NO»6) * * WGQGTLVTVSS (seq id no»8) hum III QMNSLRAEDTAVi'YCAR [GRVGYSLYDY1 WGQGTLVTVSf, (SEQ ID NO:10) ES 2 736 005 T3 Secuencia de aminoácidos para la cadena ligera de Pertuzumab 1 10 20 30 40 506ΰ \ \ \ \ \ \ \ \ \ \ \ \ \ DIQtTTQSPSSI^SASVGDFVTITCKASQDVSTGVA’WYQQRPGKAPKLTjI YSASYRYTGVPS 70 80 90 100 .ΓΙΟ120 I I I I I I I I I I I I ΕΕ5Ο£α5αΤΏΡΤΕΤΐ5εΒαΡΕΟΓΑΤΥΥ€ξΚ?ΪΪΙΪΡΪΤ?ϋΰ0ΤΚνΈΙΚΗΤνΑΑΡί5νΕΙΡΡΡ 130 140 150 160 170ISO I ! I I I I ! I I I ! I SDEQLKSGTASWCLLNNFYFREAKVQWKVDNAIjQSGNSQESVTEQDSKDSTYSLSSTLT 190 200210 lililí LSKADYEKHKVYACEVTNQGLSSPVTKSFNkGEC (SEQ ID NO: 11)

Independent claims2

1,702 paragraphs in 103 sections, as filed

SPANISH OFFICE OF

PATENTS AND TRADEMARKS

SPAIN lllllllllllllllllllllllllllllllllllllllllll © Publication number: 2 736 005 © Int. Cl .:

A61K 39/395

A61K 45/06

C07K 16/32 (2006.01) (2006.01) (2006.01)

TRANSLATION OF EUROPEAN PATENT

T3 @ Date of submission and number of the international application: 11.10.2012 PCT / US2012 / 059683 © Date and number of international publication: 18.04.2013 WO13055874 © Date of submission and number of the European application: 11.10.2012 E 12778010 (4 ) © Date and publication number of the European concession: 15.05.2019 EP 2766040 © Title: Pertuzumab, Trastuzumab, Docetaxel and Carboplatin for the treatment of early stage breast cancer © Priority:

14.10.2011 US 2011 61547535 P

05.12.2011 US 2011 61567015 P

08.06.2012 US 2012 61657669 P

10.08.2012 US 2012 61682037 P

29.08.2012 US 2012 61694584 P © Date of publication and mention in BOPI of the patent translation:

23.12.2019 © Owner / s:

F. HOFFMANN-LA ROCHE AG (100.0%) Grenzacherstrasse 124

4070 Basel, CH © Inventor / es:

ALAVATTAM, SREEDHARA; AMLER, LUKAS C .; BENYUNES, MARK C .; CLARK, EMMA L;

DE TOLEDO PELIZON, CHRISTINA H .; KWONG GLOVER, ZEPHANIA W .; MITCHELL, LADA;

RATNAYAKE, JAYANTHA; ROSS, GRAHAM A. and WALKER, RU-AMIR © Agent / Representative:

LINAGE GONZÁLEZ, Rafael

Observations:

See informative note (Remarks, Remarques or Bemerkungen) in the original brochure published by the European Patent Office

ES 2 736 005 T3

Notice: Within nine months from the date of publication in the European Patent Bulletin, of the mention of granting the European patent, any person may object to the European Patent Office to the granted patent. The opposition must be in writing and be motivated; It will only be considered as formulated once payment of the opposition fee has been made (art. 99.1 of the Convention on the Grant of European Patents).

ES 2 736 005 T3

DESCRIPTION

Pertuzumab, Trastuzumab, Docetaxel and Carboplatin for the treatment of early-stage breast cancer

Field of the Invention

The present invention relates to uses for Pertuzumab, a first-class HER2 dimerization inhibitor.

In particular, the invention relates to Pertuzumab, Trastuzumab and a carboplatin-based chemotherapy for use in the neoadjuvant treatment of early-stage HER2 positive breast cancer in a patient, in which the HER2-positive breast cancer in phase Precocious has not spread beyond the sinus or axillary lymph nodes and in which carboplatin-based chemotherapy comprises Docetaxel and carboplatin.

The disclosure refers to the combination of two antibodies against HER2 to treat HER2 positive cancer without increasing cardiac toxicity; treatment of breast cancer positive for early HER2; In addition, the disclosure refers to the extension of progression-free survival in a population of HER2-positive breast cancer patients; HER2 positive cancer treatment by co-administration of a mixture of Pertuzumab and Trastuzumab from the same intravenous pouch; treatment of metastatic gastric cancer positive for HER2; HER2 positive breast cancer treatment with Pertuzumab, Trastuzumab and Vinorelbine; HER2 positive breast cancer treatment with Pertuzumab, Trastuzumab and aromatase inhibitor; and treatment of ovarian, primary peritoneal or fallopian tube cancer with low HER3.

The disclosure also refers to an article of manufacture comprising a vial with Pertuzumab inside and a leaflet that provides safety and / or efficacy data thereon; a procedure for making the article of manufacture; and a procedure to ensure the safe and effective use of Pertuzumab related thereto.

In addition, the disclosure refers to an intravenous (iv) bag containing a stable mixture of Pertuzumab and Trastuzumab suitable for administration to a cancer patient.

Background of the invention

Members of the HER receptor tyrosine kinase family are important mediators of cell growth, differentiation and survival. The family of receptors includes four distinct members, including the epidermal growth factor receptor (EGFR, ErbB1 or HER1), HER2 (ErbB2 or pi85neu), HER3 (ErbB3) and HER4 (ErbB4 or tyro2). Members of the recipient family have been implicated in several types of human malignancy.

A recombinant humanized version of the murine anti-HER2 4D5 antibody (huMAb4D5-8, rhuMAb HER2, Trastuzumab or HERCEPTIN®; U.S. Patent No. 5,821,337) is clinically active in patients with metastatic breast cancers that overexpress HER2 who have received prior comprehensive antineoplastic treatment (Baselga et al., J. Clin. Oncol. 14: 737-744 (1996)).

Trastuzumab received marketing approval from the US Food and Drug Administration on September 25, 1998 for the treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein. Currently, Trastuzumab is approved for use as a single agent or in combination with chemotherapy or hormonal treatment in the metastatic context, and as a single agent or in combination with chemotherapy as an adjuvant treatment for patients with early HER2 positive breast cancer. The treatment based on the use of Trastuzumab is now the recommended treatment for patients with early-stage breast cancer positive for HER2 that has no contraindications to its use (Herceptin® prescription information; NCCN guidelines, version 2.2011). Trastuzumab plus Docetaxel (or paclitaxel) is a reference treatment registered in the field of first-line metastatic breast cancer (CMM) treatment (Slamon et al. N Engl J Med. 2001; 344 (11): 783-792. ; Marty et al. J Clin Oncol. 2005; 23 (19): 4265-4274).

While the administration of Trastuzumab has produced excellent results in the treatment of breast cancer, recent data from a clinical trial of lapatinib seems to suggest that even with the administration of Trastuzumab, HER2 plays an active role in tumor biology (Geyer et al., N Engl J Med 2006; 355: 2733-2743).

Patients treated with the antibody against HER2 Trastuzumab are selected for treatment based on HER2 expression. See, for example, documents WO99 / 31140 (Paton al.), US2003 / 0170234A1 (Hellmann, S.) and US2003 / 0147884 (Paton et al.); in addition to the documents

ES 2 736 005 T3

WO01 / 89566, US2002 / 0064785 and US2003 / 0134344 (Mass et al.). See also US Pat. UU. No. 6,573,043, U.S. Pat. UU. No. 6,905,830 and US2003 / 0152987, Cohen et al., in connection with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect overexpression and amplification of HER2. Therefore, the optimal management of metastatic breast cancer now takes into account not only the general condition of the patient, the medical history and the condition of the recipient, but also the HER2 status.

Pertuzumab (also known as recombinant humanized monoclonal antibody 2C4 (rhuMAb 2C4); Genentech, Inc, South San Francisco) represents the first in a new class of agents known as HER dimerization inhibitors (HDI) and works to inhibit the ability to HER2 to form active heterodimers or homodimers with other HER receptors (such as EGFR / HER1, HER2, HER3 and HER4). See, for example, Harari and Yarden Oncogene 19: 6102-14 (2000); Yarden and Sliwkowski. Nat Rev Mol Cell Biol 2: 127-37 (2001); Sliwkowski Nat Struct Biol 10: 158-9 (2003); Cho et al. Nature 421: 756-60 (2003); and Malik et al. Pro Am Soc Cancer Res 44: 176-7 (2003).

Pertuzumab blockade of the formation of HER2-HER3 heterodimers in tumor cells has been shown to inhibit critical cell signaling, resulting in reduced tumor proliferation and survival (Agus et al. Cancer Cell 2: 127-37 (2002 )).

Pertuzumab has been tested as a single agent in the clinical setting with a phase Ia trial in patients with advanced cancers and phase II trials in patients with ovarian cancer and breast cancer, as well as lung and prostate cancer. In a Phase I study, patients with incurable, locally advanced, recurrent or metastatic solid tumors that had progressed during or after standard treatment were treated with Pertuzumab administered intravenously every 3 weeks. Pertuzumab was generally well tolerated. Tumor regression was achieved in 3 of 20 evaluable patients for the response. Two patients had confirmed partial responses. A stable disease that lasted more than 2.5 months was observed in 6 of 21 patients (Agus et al. Pro Am Soc Clin Oncol 22: 192 (2003)). At a dose of 2.0-15 mg / kg, the pharmacokinetics of Pertuzumab was linear, and the mean clearance varied from 2.69 to 3.74 ml / day / kg and the average terminal elimination half-life ranged from 15.3 to 27.6 days No antibodies against Pertuzumab were detected (Allison et al. Pro Am Soc Clin Oncol 22: 197 (2003)).

US 2006/0034842 describes procedures for treating ErbB-expressing cancer with combinations of anti-ErbB2 antibodies. U.S. Patent UU. No. 2008/0102069 describes the use of Trastuzumab and Pertuzumab in the treatment of metastatic cancer positive for HER2, such as breast cancer. Baselga et al., J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I, Col. 25, No. 18S (June 20 Supplement), 2007: 1004 report the treatment of patients with breast cancer positive for pre-treated HER2, which has progressed during treatment with Trastuzumab, with a combination of Trastuzumab and Pertuzumab. Portera et al., J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007: 1028 evaluated the efficacy and safety of Trastuzumab + Pertuzumab polytherapy in patients with HER2-positive breast cancer, who had progressive disease in Trastuzumab-based treatment. The authors concluded that an additional evaluation of the efficacy of combination treatment was required to define the overall risk and benefit of this treatment regimen.

Pertuzumab has been evaluated in Phase II studies in combination with Trastuzumab in patients with HER2 positive metastatic breast cancer who have previously received Trastuzumab for metastatic disease. A study, conducted by the National Cancer Institute (NCI), included 11 patients with metastatic breast cancer positive for HER2 previously treated. Two of the 11 patients showed a partial response (RP) (Baselga et al., J Clin Oncol 2007 ASCO Annual Meeting Proceedings; 25: 18S (June 20 Supplement): 1004. The results of a neoadjuvant Phase II study evaluating the effect of a new combination regimen of Pertuzumab and T rastuzumab plus chemotherapy (Docetaxel) in women with early HER2 positive breast cancer, presented at the Breast Cancer Symposium of San Antonio CTRC-aAcR (sAbCS) from December 8 to 12, 2010, showed that the two antibodies against HER2 plus Docetaxel administered in the neoadjuvant context before surgery significantly improved the rate of complete tumor disappearance (complete pathological response rate, RpC, 45.8 percent) in the breast in more than half compared to Trastuzumab plus Docetaxel (RpC of 29.0 percent), p = 0.014.

WO 2009/154651 describes the combined treatment of Trastuzumab, Pertuzumab and a taxane in metastatic breast cancer positive for HER2.

Patent publications related to antibodies against HER2 include: US Pat. UU. No. 5,677,171; 5,720,937; 5,720,954; 5,725,856; 5,770,195; 5,772,997; 6,165,464; 6,387,371; 6,399,063; 6,015,567; 6,333,169; 4,968,603; 5,821,337; 6,054,297; 6,407,213; 6,639,055; 6,719,971; 6,800,738;

8.075.890; 5.648.237; 7.018.809; 6.267.958; 6.685.940; 6.821.515; 7.060.268; 7.682.609; 7.371.376;

6.127.526; 6.333.398; 6.797.814; 6.339.142; 6.417.335; 6.489.447; 7.074.404; 7.531.645; 7.846.441;

7.892.549; 8.075.892; 6.573.043; 6.905.830; 7.129.051; 7.344.840; 7.468.252; 7.674.589; 7.919.254;

ES 2 736 005 T3

6.949.245; 7.485.302; 7.498.030; 7.501.122; 7.537.931; 7.618.631; 7.862.817; 7.041.292; 6.627.196;

7.371.379; 6.632.979; 7.097.840; 7.575.748; 6.984.494; 7.279.287; 7.811.773; 7.993.834; 8.076.066;

8.044.017; 7.435.797; 7.850.966; 7.485.704; 7.807.799; 8.142.784; 7.560.111; 7.879.325; 8.241.630;

<td colspan="3"> 7.449.184; 8.163.287; 7.700.299;</td><td colspan="2"> 7.981.418; 8.247.397;</td><td rowspan="2">and US</td><td rowspan="2">papers 2006/0099201;</td><td rowspan="2">US US</td><td rowspan="2"> 2010/0016556; 2010/0158899;</td><td rowspan="2">US US</td>

2012/0121586.

Summary of the invention

The invention relates to Pertuzumab, Trastuzumab and a carboplatin-based chemotherapy for use in the neoadjuvant treatment of early HER2 positive breast cancer in a patient, in which early-stage HER2 positive breast cancer is not It has spread beyond the breast or axillary lymph nodes and in which carboplatin-based chemotherapy comprises Docetaxel and Carboplatin.

In one aspect, the disclosure refers to a method for extending progression-free survival in a population of HER2-positive breast cancer patients in 6 months or more, which comprises administering Pertuzumab, Trastuzumab and chemotherapy (e.g., taxane, such as Docetaxel) to patients in the population. Optionally, the procedure results in an objective response rate of 80% or more in patients in the population. Breast cancer is optionally metastatic or locally recurrent, unresectable breast cancer or de novo stage IV disease. In one example, patients in the population have not received prior treatment or have relapsed after adjuvant treatment, have a left ventricular ejection fraction (LVEF) of> 50% in the reference value, and / or have a functional status of the Eastern Cooperative Oncology Group (ECOG PS) of 0 or 1. Optionally, HER2 positive breast cancer is defined as immunohistochemistry (IHC) 3+ and / or fluorescence in situ hybridization amplification ratio (FISH)> 2.0. Optionally, the method reduces the risk of death by approximately 34% or more in relation to a patient treated with Trastuzumab and chemotherapy.

In another aspect, the disclosure refers to a procedure for combining two antibodies against HER2 to treat HER2 positive cancer without increasing cardiac toxicity in a population of patients with HER2 positive cancer, which comprises administering Pertuzumab, Trastuzumab and chemotherapy to patients. population patients. Optionally, cardiac toxicity in the patient population is monitored to detect the incidence of left ventricular systolic dysfunction (LVD) or symptomatic congestive heart failure (CHF), or to decrease the left ventricular ejection fraction (LVEF). HER2-positive cancer is optionally breast cancer, for example, non-resectable metastatic or locally recurrent breast cancer, or stage IV de novo disease.

In another aspect, the disclosure refers to an article of manufacture comprising a vial with Pertuzumab and a leaflet, in which the leaflet provides the safety data in Table 3 or Table 4 and / or the efficacy data in the Table 2, Table 5, Figure 8 or Figure 10.

The disclosure further relates to a process for manufacturing a manufacturing article comprising packaging a vial with Pertuzumab and a leaflet together, in which the leaflet provides the safety data in Table 3 or Table 4 and / or the data of efficacy in Table 2, Table 5, Figure 8 or Figure 10.

ES 2 736 005 T3

In a related aspect, the disclosure refers to a procedure to ensure the safe and effective use of Pertuzumab which comprises packaging a vial with Pertuzumab and a leaflet, in which the leaflet provides the safety data in Table 3 or Table 4. and / or the efficacy data in Table 2, Table 5, Figure 8 or Figure 10.

Optionally, the article of manufacture comprises a single dose vial containing approximately 420 mg of Pertuzumab.

Optionally, the leaflet further comprises the warning box in Example 4.

Optionally, the package leaflet also provides the overall survival efficacy (OS) data in Example 9 or Table 14.

In another aspect, the invention relates to a neoadjuvant procedure for treating early-stage HER2 positive breast cancer comprising administering Pertuzumab, Trastuzumab and chemotherapy to a patient with breast cancer, in which chemotherapy comprises carboplatin-based chemotherapy. selected from Docetaxel and Carboplatin, in which early-stage HER2 positive breast cancer has not spread beyond the breast or axillary lymph nodes. Optionally, Pertuzumab is administered simultaneously with carboplatin-based chemotherapy. In one embodiment of this procedure, administration of Pertuzumab does not increase cardiac toxicity in relation to treatment without Pertuzumab. The disclosure further relates to a procedure for treating HER2 positive cancer in a patient comprising the co-administration of a mixture of Pertuzumab and Trastuzumab from the same intravenous pouch to the patient. Said procedure optionally further comprises administering chemotherapy to the patient.

In a related aspect, the disclosure provides an intravenous (iv) bag containing a stable mixture of Pertuzumab and Trastuzumab suitable for administration to a cancer patient. The mixture is optionally in saline solution; for example, which comprises NaCl at about 0.9% or NaCl at about 0.45%. The iv bag is optionally an infusion bag of polyolefin or polyvinyl chloride with 250 ml of 0.9% saline. In one example, the iv bag contains a mixture of about 420 mg or about 840 mg of Pertuzumab and about 200 mg to about 1000 mg of Trastuzumab. In one example, the mixture is stable for up to 24 hours at 5 ° C or 30 ° C. The stability of the mixture can be evaluated by one or more tests selected from: color, appearance and clarity (CAC), concentration and turbidity analysis, particle analysis, size exclusion chromatography (SEC), ion exchange chromatography (IEC ), zonal capillary electrophoresis (CZE), isoelectric capillary imaging approach (iCIEF) or power test.

The present disclosure provides a new treatment regimen for gastric cancer. In particular, the present disclosure relates to the treatment of gastric cancer positive for HER2 in human subjects with a combination of Trastuzumab, Pertuzumab and at least one chemotherapy.

In one aspect, the disclosure relates to a procedure for treating gastric cancer positive for HER2 in a human subject, which comprises administering the subject Pertuzumab, Trastuzumab and chemotherapy.

In one aspect, the disclosure relates to a procedure for treating gastric cancer in a human subject comprising administering Pertuzumab to the subject with gastric cancer, in which Pertuzumab is administered at a dose of 840 mg in all treatment cycles.

In another aspect, the disclosure refers to a procedure for improving the survival of a human subject with gastric cancer positive for HER2, which comprises administering the subject Pertuzumab, Trastuzumab and chemotherapy.

In yet another aspect, the disclosure refers to Pertuzumab for use in the treatment of gastric cancer positive for HER2 in a human subject in combination with Trastuzumab and chemotherapy.

In another aspect, the disclosure refers to the use of Pertuzumab in the preparation of a drug for the treatment of gastric cancer positive for HER2, in which the treatment comprises the administration of Pertuzumab in combination with Trastuzumab and chemotherapy.

In another additional aspect, the disclosure refers to the use of Trastuzumab in the preparation of a drug for the treatment of gastric cancer positive for HER2, in which the treatment comprises the administration of Trastuzumab in combination with Pertuzumab and chemotherapy.

In another aspect, the disclosure relates to a kit comprising a container comprising Pertuzumab and instructions for administration of Pertuzumab to treat gastric cancer positive for HER2 in a subject in combination with Trastuzumab and chemotherapy.

ES 2 736 005 T3

In yet another aspect, the disclosure relates to a kit comprising a container comprising Trastuzumab and instructions for administration of Trastuzumab to treat gastric cancer positive for HER2 in a subject in combination with Pertuzumab and chemotherapy.

In all aspects of the disclosure, gastric cancer may be, for example, locally advanced unresectable gastric cancer, or metastatic gastric cancer, or advanced postoperative recurrent gastric cancer, which may not be susceptible to curative treatment by known procedures. In all aspects of the disclosure, gastric cancer includes adenocarcinoma of the stomach or gastroesophageal junction. In all aspects of the disclosure, in a particular example, the patient did not receive a previous antineoplastic treatment for metastatic gastric cancer. In all aspects of the disclosure, in a particular example, chemotherapy comprises the administration of a platinum and / or fluoropyrimidine. In a certain example, platinum is cisplatin. In other examples, fluoropyrimidine comprises capecitabine and / or 5-fluorouracil (5-Fu). In all aspects, the positive state for the patient's hER2 may be, for example, IHC 3+ or IHC 2+ / ISH +. In all aspects, in particular embodiments, the treatment improves survival, including overall survival (OS) and / or progression-free survival (SSP) and / or response rate (RR). In all aspects of the disclosure, in particular examples, the patient has a PS ECOG of 0-1. In all aspects of the disclosure, treatment cycles in general are separated from each other by four weeks or less, or by three weeks or less, or by two weeks or less, or by a week or less.

In a particular aspect, the disclosure refers to a procedure for treating metastatic or non-resectable adenocarcinoma positive for HER2 of the stomach or gastroesophageal junction in a human patient who did not receive prior chemotherapy for metastatic disease, except prior adjuvant or neoadjuvant treatment. completed more than six months before the current treatment, which includes administering Pertuzumab, Trastuzumab, cisplatin and capecitabine and / or fluorouracil (5-FU) to the patient in an amount to improve progression-free survival (SSP) and / or overall survival (OS), in which the patient has a PS ECOG of 0-1. In a particular example of the disclosure, the patient did not receive prior treatment with a platinum.

In another aspect, the disclosure refers to a procedure for improving progression-free survival in a patient with non-resectable or metastatic adenocarcinoma positive for HER2 of the stomach or the gastroesophageal junction comprising administering Pertuzumab to the patient in combination with Trastuzumab and chemotherapy.

In another additional aspect, the disclosure refers to a procedure for treating HER2 positive breast cancer in a patient comprising administering Pertuzumab, Trastuzumab and Vinorelbine to the patient. Optionally, Pertuzumab and Trastuzumab are co-administered to the patient from a single intravenous pouch. Breast cancer is optionally metastatic or locally advanced. In an example of the disclosure, the patient has not previously received systemic non-hormonal antineoplastic treatment in the metastatic context.

In another aspect, the disclosure relates to a procedure for treating HER2 positive breast cancer in a patient comprising administering Pertuzumab, Trastuzumab and aromatase inhibitor (eg, anastrazole or letrozole) to the patient. Optionally, breast cancer is an advanced breast cancer positive for hormonal receptors, in which the hormonal receptor is the estrogen receptor (RE) and / or the progesterone receptor (RPg), for example. According to this example of the disclosure, the patient has not previously received systemic non-hormonal antineoplastic treatment in the metastatic context. In addition, the patient herein optionally receives induction chemotherapy (for example, which comprises taxane).

In a further example, the invention relates to a method for treating a cancer patient comprising administering to the patient an initial dose of 840 mg of Pertuzumab followed every 3 weeks thereafter by a dose of 420 mg of Pertuzumab, and which also includes re-administering a dose of 840 mg of Pertuzumab to the patient if the time between two sequential doses of 420 mg is 6 weeks or more. Optionally, the method further comprises administering 420 mg of Pertuzumab every 3 weeks after the re-administered dose of 840 mg. In one example, the cancer patient has HER2 positive breast cancer.

In a further aspect, the disclosure refers to a procedure for treating metastatic or locally recurrent breast cancer positive for HER2 in a patient comprising administering Pertuzumab, Trastuzumab and taxoid (eg, Docetaxel, Paclitaxel or nab-paclitaxel) to the patient , in which the patient has previously been treated with a Trastuzumab and / or lapatinib as an adjuvant or neoadjuvant treatment.

In another aspect, the disclosure refers to a procedure for treating ovarian cancer, primary peritoneal or fallopian tube cancer with low HER3 in a patient comprising administering Pertuzumab and chemotherapy to the patient, in which chemotherapy comprises taxoid ( for example, paclitaxel) or topotecan.

ES 2 736 005 T3

In a further aspect, the disclosure relates to a procedure for treating ovarian cancer, primary peritoneal or fallopian tube cancer with low HER3 in a patient comprising administering Pertuzumab and chemotherapy to the patient, in which cancer with HER3 low expresses the mRNA of HER3 in a concentration ratio equal to or less than about 2.81 as evaluated by the polymerase chain reaction (PCR). In one example, chemotherapy comprises gemcitabine, carboplatin, paclitaxel, docetaxel, topotecan or pegylated liposomal doxorubicin (PLD). Optionally, chemotherapy comprises paclitaxel or topotecan. In an example of the disclosure, cancer is an epithelial ovarian cancer that is platinum resistant or platinum refractory.

Brief description of the drawings

Figure 1 provides an outline of the structure of the HER2 protein and amino acid sequences for Domains I-IV (SEQ ID NOS. 1-4, respectively) of the extracellular domain thereof.

Figures 2A and 2B represent alignments of the amino acid sequences of the variable light domains (Vl) (Fig. 2A) and heavy variable (Vh) (Fig. 2B) murine monoclonal antibody 2C4 (SEQ ID NOS. 5 and 6) , respectively); Vl and Vh domains of the 574 / Pertuzumab variant (SEQ ID NOS. 7 and 8, respectively) and human Vl and Vh consensus structural regions (hum κ1, subgroup I light kappa; humIII, heavy subgroup III) (SEQ ID NOS. 9 and 10, respectively). Asterisks identify the differences between the variable domains of Pertuzumab and the murine monoclonal antibody 2C4 or between the variable domains of Pertuzumab and human structural regions. Complementarity determining regions (CDR) are in parentheses.

Figures 3A and 3B show the light chain amino acid sequences of Pertuzumab (Fig. 3A; SEQ ID NO. 11) and heavy chain (Fig. 3B; SEQ ID NO. 12). The CDRs are shown in bold. The calculated molecular masses of light chain and heavy chain are 23,526.22 Da and 49,216.56 Da (cysteines in reduced form). The glycidic moiety is attached to Asn 299 of the heavy chain.

Figures 4A and 4B show the light chain (Fig. 4A; SEQ ID NO. 13) and heavy chain (Fig. 4B; SEQ ID NO. 14) amino acid sequences of Trastuzumab, respectively. The limits of variable light domains and heavy variable domains are indicated by arrows.

Figures 5A and 5B represent a variant Pertuzumab light chain sequence (Fig. 5A; SEQ ID NO. 15) and a variant Pertuzumab heavy chain sequence (Fig. 5B; SEQ ID NO. 16), respectively.

Figure 6 shows the study scheme in Example 1. ECOG = Eastern Cooperative Oncology Group; PD = progressive disease. Note: Trastuzumab, Pertuzumab and Cisplatin are administered by iv infusion on Day 1 of each 3-week cycle. Capecitabine is administered orally twice a day, from the afternoon of Day 1 until the morning of Day 15 of each 3-week cycle. (a) HER2 positive tumor defined as IHC 3+ or IHC 2+ in combination with ISH + (ie, IHC 3 + / ISH + or IHC 2 + / ISH +); (b) Trastuzumab at a loading dose of 8 mg / kg for Cycle 1 and a dose of 6 mg / kg for subsequent cycles; (c) Pertuzumab on Day 1 of each cycle, at a loading dose of 840 mg for Cycle 1 and a dose of 420 mg for Cycles 2-6.

Figure 7 represents the enrollment, intention to treat and safety populations, and withdrawals of patients in the study of Example 3.

Figure 8 is a Kaplan-Meier curve of progression-free survival (SSP) as assessed by an Independent Review Center (IRF) for the study of Example 3.

Figure 9 represents the SSP by subgroup of patients for the study of Example 3.

Figure 10 represents the overall survival for the study of Example 3.

Figure 11 is an overview of the dosing schedule in patients with neoadjuvant breast cancer positive for HER2, patients with low cardiac risk factors of Example 5. Radiation therapy, hormonal treatment and additional postoperative chemotherapy and during adjuvant treatment with Trastuzumab were allowed if the investigator considered it necessary.

Figure 12 shows the mean change in LVEF (central readings) for the study of Example 5.

Figure 13 shows the complete pathological response (RpC) for the study of Example 5.

Figure 14 shows the complete pathological response according to the hormonal receptor status in the study of Example 5.

ES 2 736 005 T3

Figure 15 shows the Pertuzumab SEC profile of the Pertuzumab / Trastuzumab mixture (840 mg) at 30 ° C in IV infusion bags of PO with 0.9% saline (1) Time = 0; (2) Time = 24 h. Enlarged view; Full view (box).

Figure 16 shows the Trastuzumab SEC profile of the Pertuzumab / Trastuzumab mixture (840 mg) at 30 ° C in IV infusion bags of PO with 0.9% saline (1) Time = 0; (2) Time = 24 h. Enlarged view; full view (box).

Figure 17 shows the Pertuzumab IEC profile of the Pertuzumab / Trastuzumab mixture at 30 ° C in IV infusion bags of PO with 0.9% saline (1) Time = 0; (2) Time = 24 h. Full view.

Figure 18 shows the Trastuzumab IEC profile of the Pertuzumab / Trastuzumab mixture at 30 ° C in iv infusion bags of PO with 0.9% saline solution (1) Time = 0; (2) Time = 24 h. Enlarged view; Full view (box).

Figure 19 shows the non-reduced CE-SDS EIF profile of the Pertuzumab / Trastuzumab mixture at 30 ° C in IV iv infusion bags with 0.9% saline (1) Time = 0; (2) Time = 24 h. Enlarged view.

Figure 20 shows the reduced CE-SDS LIF profile of the Pertuzumab / Trastuzumab mixture at 30 ° C in iv infusion bags of Po with 0.9% saline (1) Time = 0; (2) Time = 24 h. Enlarged view.

Figure 21 is a CZE of the Pertuzumab / Trastuzumab mixture at 30 ° C in IV infusion bags of PO with 0.9% saline (1) Time = 0; (2) Time = 24 h. Full view.

Figure 22 shows the iCIEF of the Pertuzumab / Trastuzumab mixture at 30 ° C in IV infusion bags of PO with 0.9% saline solution (1) Time = 0; (2) Time = 24 hours. Full view.

Figure 23 shows the dose-response power curves (pg / ml versus RFU) of the Pertuzumab / Trastuzumab, Pertuzumab alone and Trastuzumab alone in iv IV infusion bags with 0.9% saline solution (1) Time = 0; (2) Time = 24 hours.

Figure 24 shows the Pertuzumab SEC profile of the Pertuzumab / Trastuzumab mixture (1560 mg) in iv infusion bags with 0.9% saline (1) PO, 5 ° C, T0; (2) PO, 5 ° C, T24h; (3) PO, 30 ° C, T0; (4)

PO, 30 ° C, T24h; (5) PVC, 5 ° C, T0; (6) PVC, 5 ° C, T24h; (7) PVC, 30 ° C, T0; (8) PVC, 30 ° C, T24h. Enlarged view; full view (box).

Figure 25 shows the Trastuzumab SEC profile of the Pertuzumab / Trastuzumab mixture (1560 mg) in iv infusion bags with 0.9% saline solution (1) PO, 5 ° C, T0; (2) PO, 5 ° C, T24h; (3) PO, 30 ° C, T0; (4)

PO, 30 ° C, T24h; (5) PVC, 5 ° C, T0; (6) PVC, 5 ° C, T24h; (7) PVC, 30 ° C, T0; (8) PVC, 30 ° C, T24h. Enlarged view; full view (box).

Figure 26 shows the Pertuzumab (Pertuzumab-rapid) IEC profile of the mixture

Pertuzumab / Trastuzumab (1560 mg) in iv infusion bags with 0.9% saline (1) PO, 5 ° C, T0; (2) PO, 5 ° C, T24h; (3) PO, 30 ° C, T0; (4) PO, 30 ° C, T24h; (5) PVC, 5 ° C, T0; (6) PVC, 5 ° C, T24h; (7) PVC, 30 ° C, T0; (8) PVC, 30 ° C, T24h. Full view.

Figure 27 shows the Trastuzumab IEC profile of the Pertuzumab / Trastuzumab mixture (1560 mg) in iv infusion bags with 0.9% saline solution (1) PO, 5 ° C, T0; (2) PO, 5 ° C, T24h; (3) PO, 30 ° C, T0; (4) PO, 30 ° C, T24h; (5) PVC, 5 ° C, T0; (6) PVC, 5 ° C, T24h; (7) PVC, 30 ° C, T0; (8) PVC, 30 ° C, T24h. Full view.

Figure 28 represents the study scheme for Example 7.

Figure 29 shows the study design for Example 8.

Figure 30 shows the study design for Part 1 of Example 11.

Figure 31 shows the study design for Part 2 of Example 11.

Figure 32 shows the samples taken and the time points for the gastric cancer (CG) phase study of Example 1.

Figure 33 shows the demographic data of the patient population in the two groups of the CG study, treated with 420 mg (Group A) or 840 mg (Group B) of Pertuzumab.

ES 2 736 005 T3

Figure 34 shows the history of CG of patients in Groups A and B, respectively.

Figure 35 shows the disposition of patients with CG in Groups A and B, respectively.

Figure 36 shows the overall response rate in Groups A and B, respectively, of the CG study.

Figure 37 shows the results of the evaluation of the concentration of Pertuzumab on Day 42 in gastric cancer (GC) versus metastatic breast cancer (CMM). The minimum concentration (Cmin.) On Day 42 is ~ 37% lower in GC (JOSHUA 840/420 mg) compared to CMM (CLEO 840/420 mg). The JOSHUA 840/420 mg and 840/840 mg regimens both result in a Cmin. on Day 42> 20 pg / ml in 90% of patients. The JOSHUA 840/840 mg regimen results in a Cmin. on Day 42 in GC comparable to that observed in CMM (CLEO 840/420 mg).

Detailed description of preferred embodiments

Glossary of some abbreviations used in this document: adverse drug reaction (RA), adverse event (AA), alkaline phosphatase (aLp), absolute neutrophil count (ANC), area under the concentration-time curve (ABC), capillary zone electrophoresis (CZE), color , appearance and clarity (CAC), clinical evaluation of Pertuzumab and Trastuzumab (CLEOPATRA), confidence interval (CI), chromogenic in situ hybridization (CISH), maximum concentration (Cmax), complete response (CR), collection notebook data (CRD), computed tomography (CT), common terminology criteria for adverse events (CTCAE), Docetaxel (D), dose-limiting toxicity (DLT), ethics committee (EC), epirubicin, cisplatin and 5-fluorouracil (ECF), echocardiogram (ECHO), epidermal growth factor receptor (EGFR), European Union (EU), estrogen receptor (RE), 5-fluorouracil, methotrexate and doxorubicin (FAMTX), fluorescence in situ hybridization (FISH), 5-fluorouracil (5-FU), instantaneous risk ratio (CRI), human epidermal growth factor receptor (EGFRh), gastric cancer (CG), good clinical practice (BPC), human epidermal growth factor receptor 2 (HER2), ion exchange chromatography (IEC ), immunohistochemistry (IHC), independent review center (IRF), institutional review board (IRB), in situ hybridization (ISH), intravenous (iv), capillary isoelectric imaging approach (iCIEF), Left ventricle expulsion fraction (LVEF), mitomycin C, cisplatin and 5-fluorouracil (MCF), magnetic resonance imaging (MRI), metastatic breast cancer (CMM), nuclear ventriculography (MUGA), not significant (NS), overall survival (OS), complete pathological response (RpC), polyolefin (PO), polyvinyl chloride (PVC), progressive disease (PD), progression-free survival (SSP), pharmacokinetics (FC), partial response (RP), receptor of progesterone (RPg), Response evaluation criteria in solid tumors (RECIST), serious adverse events (AAG), size exclusion chromatography (SEC), stable disease (EE), study management team (EGE), sterile injectable water (AEPI) , time to maximum plasma concentration (tmax), upper limit of normal range (LSN).

I. Definitions

The term "chemotherapy," as used herein, refers to the treatment comprising the administration of chemotherapy, as defined hereinbelow.

"Survival" refers to patient survival and includes overall survival as well as progression-free survival.

"Global survival" or "OS" refers to the patient remaining alive for a defined period of time, such as 1 year, 5 years, etc., from the moment of diagnosis or treatment. For the purposes of the clinical trial described in the example, overall survival (OS) is defined as the time from the date of randomization of the patient population to the date of death from any cause.

"Progression-free survival" or "SSP" means that the patient is still alive, without the cancer progressing or getting worse. For the purpose of the clinical trial described in the example, progression-free survival (SSP) is defined as the time from randomization of the study population to the first documented progressive disease, or unmanageable toxicity, or death from any cause, Let it happen first. The progression of the disease can be documented by any clinically accepted procedure, such as, for example, progressive radiographic disease, as determined by the Criteria for Evaluation of Response in Solid Tumors (RECiSt) (Therasse et al., J Natl Ca Inst 2000; 92 (3): 205-216), carcinomatous meningitis diagnosed by cytological evaluation of the cerebrospinal fluid and / or medical photography to control recurrence in the chest wall of subcutaneous lesions.

By "extension of survival" is meant to increase overall or progression-free survival in a patient treated in accordance with the present invention in relation to an untreated patient and / or a patient treated with one or more approved anti-tumor agents, but which They do not receive treatment in accordance with the present invention. In a particular example, "extending survival" means extending progression-free survival (SSP) and / or overall survival (OS) of cancer patients receiving the

ES 2 736 005 T3 polytherapy of the present invention (for example, treatment with a combination of Pertuzumab, Trastuzumab and chemotherapy) in relation to patients treated with Trastuzumab and chemotherapy alone. In another particular example, "extending survival" means extending progression-free survival (SSP) and / or overall survival (OS) of cancer patients receiving polytherapy of the present invention (eg, treatment with a combination of Pertuzumab , Trastuzumab and chemotherapy) in relation to patients treated with Pertuzumab and chemotherapy only.

An "objective response" refers to a measurable response, including the complete response (CR) or the partial response (RP).

By "complete response" or "RC" means the disappearance of all signs of cancer in response to treatment. This does not always mean that the cancer has been cured.

The "partial response" or "RP" refers to a decrease in the size of one or more tumors or lesions, or the extent of cancer in the body, in response to treatment.

An "HER receptor" is a receptor tyrosine kinase protein that belongs to the family of HER receptors and includes the EGFR, HER2, HER3 and HER4 receptors. The HER receptor will generally comprise an extracellular domain, which can bind to an HER ligand and / or dimerize with another HER receptor molecule; a lipophilic transmembrane domain; a conserved intracellular tyrosine kinase domain; and a carboxyl-terminal signaling domain that hosts several tyrosine residues that can be phosphorylated. The HER receptor may be a "natural sequence" HER receptor or an "amino acid sequence variant" thereof. Preferably, the HER receptor is the natural sequence human HER receptor.

The terms "ErbB2" and "HER2" are used interchangeably herein and refer to the human HER2 protein described, for example, in Semba et al., PNAS (USA) 82: 6497-6501 (1985) and Yamamoto et al. Nature 319: 230-234 (1986) (Genebank accession number X03363). The term "erbB2 refers to the gene that encodes human ErbB2 and" neu refers to the gene that encodes p185neu of rat. The preferred HER2 is the natural sequence human HER2.

In this document, "extracellular domain of HER2" or "ECD of HER2" refers to a domain of HER2 that is outside a cell, either anchored to a cell membrane, or in circulation, including fragments thereof. The amino acid sequence of HER2 is shown in Figure 1. In one embodiment, the extracellular domain of HER2 may comprise four domains: "Domain I" (amino acid residues of approximately 1-195; SEQ ID NO: 1), "Domain II" (amino acid residues of approximately 196-319 ; SEQ ID NO: 2), "Domain III" (amino acid residues of approximately 320-488: SEQ ID NO: 3) and "Domain IV" (amino acid residues of approximately 489-630; SEQ ID NO: 4) ( residue numbering without signal peptide). See Garrett et al. Mol. Cell 11: 495-505 (2003), Cho et al. Nature 421: 756-760 (2003), Franklin et al. Cancer Cell 5: 317-328 (2004), and Plowman et al. Proc. Natl Acad Sci. 90: 1746-1750 (1993), as well as Fig. 6 in this document.

"HER3" or "ErbB3" herein refers to the receiver as disclosed, for example, in US Pat. UU. No. 5,183,884 and 5,480,968, as well as in Kraus et al. PNAS (USA) 86: 9193-9197 (1989).

A "low HER3" cancer is one that expresses HER3 at a level below the median level for the expression of HER3 in the type of cancer. In one example of the disclosure, cancer with low HER3 is epithelial ovarian, peritoneal or fallopian tube cancer. The level of HER3 DNA, protein and / or mRNA in cancer can be evaluated to determine if the cancer is a low HER3 cancer. See, for example, US Pat. UU. No. 7,981,418 for additional information on cancer with low HER3. Optionally, an HER3 mRNA expression assay is performed to determine that the cancer is a low HER3 cancer. In one example of the disclosure, the level of HER3 mRNA in cancer is evaluated, for example, using polymerase chain reaction (PCR), such as quantitative reverse transcription PCR (qRT-PCR). Optionally, cancer expresses HER3 in a concentration ratio equal to or less than about 2.81 according to the evaluation by qRT-PCR, for example, using a COBAS z480® instrument.

An "HER dimer" herein is a non-covalently associated dimer comprising at least two HER receptors. Such complexes can be formed when a cell expressing two or more HER receptors is exposed to an HER ligand and can be isolated by immunoprecipitation and analyzed by SDS-PAGE as described in Sliwkowski et al., J. Biol. Chem. , 269 (20): 14661-14665 (1994), for example. Other proteins, such as a cytokine receptor subunit (for example, gp130) may be associated with the dimer. Preferably, the HER dimer comprises HER2.

An "HER heterodimer" herein is a non-covalently associated heterodimer comprising at least two different HER receptors, such as EGFR-HER2, HER2-HER3 or HER2-HER4 heterodimers.

ES 2 736 005 T3

An "antibody against HER" is an antibody that binds to an HER receptor. Optionally, the antibody against HER also interferes with the activation or function of HER. Preferably, the antibody against hEr binds to the HER2 receptor. The antibodies against HER2 of interest herein are Pertuzumab and Trastuzumab.

"HER activation" refers to the activation, or phosphorylation, of one or more HER receptors. In general, HER activation results in signal transduction (for example, that caused by an intracellular kinase domain of an HER receptor that phosphorylates tyrosine residues in the HER receptor or a substrate polypeptide). The activation of HER may be mediated by the binding of the HER ligand to an HER dimer comprising the HER receptor of interest. Binding of the HER ligand to an HER dimer can activate a kinase domain of one or more of the HER receptors in the dimer and, thus, results in the phosphorylation of tyrosine residues in one or more of the HER receptors and / or phosphorylation of tyrosine residues in additional substrate polypeptides, such as Akt or MAPK intracellular kinases.

"Phosphorylation" refers to the addition of one or more phosphate groups to a protein, such as a HER receptor or a substrate thereof.

An antibody that "inhibits HER dimerization" is an antibody that inhibits, or interferes with, the formation of an HER dimer. Preferably, said antibody binds to HER2 at the heterodimeric binding site thereof. The most preferred dimerization inhibitor antibody herein is Pertuzumab or MAb 2C4. Other examples of antibodies that inhibit HER dimerization include antibodies that bind to EGFR and inhibit dimerization thereof with one or more other HER receptors (eg, monoclonal antibody EGFR 806, MAb 806, which binds to activated EGFR or "free" see Johns et al., J. Biol. Chem. 279 (29): 30375-30384 (2004)); antibodies that bind to HER3 and inhibit dimerization thereof with one or more HER receptors; and antibodies that bind to HER4 and inhibit dimerization thereof with one or more HER receptors.

An "HER2 dimerization inhibitor" is an agent that inhibits the formation of a dimer or heterodimer comprising HER2.

A "heterodimeric binding site" in HER2 refers to a region in the extracellular domain of HER2 that contacts, or interconnects, with a region in the extracellular domain of EGFR, HER3 or HER4 after the formation of a dimer therewith. . The region is located in Domain II of HER2 (SEQ ID NO: 15). Franklin et al. Cancer Cell 5: 317-328 (2004).

An antibody against HER2 that "binds to a heterodimeric binding site" of HER2 binds to residues of Domain II (SEQ ID NO: 2) and, optionally, also binds to residues of other domains of the extracellular domain of HER2, such as domains I and III, SEQ ID NO: 1 and 3), and can sterically hinder, at least to some extent, the formation of an HER2-EGFR, HER2-HER3 or HER2-HER4 heterodimer. Franklin et al. Cancer Cell 5: 317-328 (2004) characterize the crystalline structure of HER2-Pertuzumab, deposited in the RCSB protein database (identification code IS78), which illustrates an exemplary antibody that binds to the heterodimeric binding site of HER2 .

An antibody that binds to domain II of HER2 binds to residues from domain II (SEQ ID NO: 2) and optionally to residues from other domains of HER2, such as domains I and III (SEQ ID NO: 1 and 3, respectively) ). Preferably, the antibody that binds to domain II binds to the junction point between domains I, II and III of HER2.

For the purposes of this document, "Pertuzumab" and "rhuMAb 2C4", which are used interchangeably, refer to an antibody comprising the light and heavy variable amino acid sequences of SEQ ID NO: 7 and 8, respectively. When Pertuzumab is an intact antibody, it preferably comprises an IgG1 antibody; In one embodiment, it comprises the light chain amino acid sequence of SEQ ID NO: 11 or 15 and the heavy chain amino acid sequence of SEQ ID NO: 12 or 16. The antibody is optionally produced by Chinese hamster ovary cells (CHO) recombinants. The terms "Pertuzumab" and "rhuMAb 2C4" in this document cover biosimilar versions of the drug with the name adopted by the United States (USAN) or the international common denomination (DCI): Pertuzumab.

For the purposes of this document, "Trastuzumab" and "rhuMAb4D5", which are used interchangeably, refer to an antibody comprising the light and heavy variable amino acid sequences within SEQ ID NO: 13 and 14, respectively. When Trastuzumab is an intact antibody, it preferably comprises an IgG1 antibody; In one embodiment, it comprises the light chain amino acid sequence of SEQ ID NO: 13 and the heavy chain amino acid sequence of SEQ ID NO: 14. The antibody is optionally produced by Chinese hamster ovary (CHO) cells. The terms "Trastuzumab" and "rhuMAb4D5" in this document cover biosimilar versions of the drug with the

ES 2 736 005 T3

Name adopted by the United States (USAN) or the international common denomination (DCI): Trastuzumab.

The term "antibody" herein is used in the broadest sense and specifically encompasses monoclonal antibodies, polyclonal antibodies, multispecific antibodies (eg, bispecific antibodies) and antibody fragments, provided they show the desired biological activity.

The "humanized" forms of non-human antibodies (eg, murine) are chimeric antibodies that contain a minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (receptor antibody) in which the residues of a hypervariable region of the receptor are replaced by residues of a hypervariable region of a non-human species (donor antibody), such as mouse, rat, rabbit or non-human primate, which has the desired specificity, affinity and capacity. In some cases, the structural region (FR) residues of the human immunoglobulin are replaced by the corresponding non-human residues. In addition, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications can be made to further refine the functioning of the antibody. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody will also optionally comprise at least a portion of a constant region (Fc) of immunoglobulin, typically that of a human immunoglobulin. For more details, see Jones et al., Nature 321: 522-525 (1986); Riechmann et al., Nature 332: 323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2: 593-596 (1992). Humanized HER2 antibodies specifically include Trastuzumab (HERCEPTIN®) as described in Table 3 of US Pat. UU. No. 5,821,337 and as defined herein; and humanized 2C4 antibodies such as Pertuzumab as described and defined herein.

An "intact antibody" herein is one that comprises two antigen binding regions and an Fc region. Preferably, the intact antibody has a functional Fc region.

The "antibody fragments" comprise a portion of an intact antibody, which preferably comprises the antigen binding region thereof. Examples of antibody fragments include Fab, Fab ', F (ab') 2 and Fv fragments; diabody linear antibodies; single chain antibody molecules; and multispecific antibodies formed from antibody fragments.

"Natural antibodies" are usually heterotetramer glycoproteins of approximately 150,000 daltons, composed of two identical light chains (L) and two identical heavy chains (H). Each light chain is linked to a heavy chain by a covalent disulfide bond, although the number of disulfide bonds varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intracatenary disulfide bridges. Each heavy chain has at one end a variable domain (Vh) followed by a series of constant domains. Each light chain has a variable domain at one end (Vl) and a constant domain at its other end. The constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the variable domain of the light chain is aligned with the variable domain of the heavy chain. It is believed that particular amino acid residues form an interface between the light chain and heavy chain variable domains.

The term "hypervariable region", when used herein, refers to the amino acid residues of an antibody that are responsible for antigen binding. The hypervariable region generally comprises amino acid residues of a "complementarity determining region" or "CDR" (eg, residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) of the variable domain light chain and 31-35 (H1), 50-65 (H2) and 95-102 (H3) of the heavy chain variable domain; Kabat et al., Sequences of Proteins of Immunological Interest, 5to Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and / or those residues of a "hypervariable loop" (for example, residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) of the light chain variable domain and 26- 32 (H1), 53-55 (H2) and 96-101 (H3) of the heavy chain variable domain; Chothia and Lesk J. Mol. Biol. 196: 901-917 (1987)). The "structural region" or "FR" residues are those variable domain residues different from the hypervariable region residues, as defined herein.

The term "Fc region" herein is used to define a terminal C region of an immunoglobulin heavy chain, including natural sequence Fc regions and variant Fc regions. Although the limits of the Fc region of an immunoglobulin heavy chain may vary, the human IgG heavy chain Fc region is normally defined to extend from an amino acid residue in the Cys226 position, or from Pro230, to the carboxylic end of the same. The terminal C lysine (residue 447 according to the EU numbering system) of the Fc region can be removed, for example, during the production or purification of the antibody, or by recombinant genomanipulation of the nucleic acid encoding a heavy chain of the antibody. Accordingly, an intact antibody composition may comprise antibody populations with all K447 residues removed, antibody populations without residues

ES 2 736 005 T3

K447 withdrawals and antibody populations that have a mixture of antibodies with and without the K447 residue.

Unless otherwise indicated, the numbering of residues of an immunoglobulin heavy chain in this document is that of the EU index as in Kabat et al. Protein sequences of immunological interest, 5to Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991). The "EU index according to Kabat" refers to the numbering of residues of the human IgG1 EU antibody.

A "functional Fc region" has an "effector function" of a natural sequence Fc region. Exemplary "effector functions" include C1q binding; complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cellular cytotoxicity (ADCC); phagocytosis; regulation by decrease of cell surface receptors (eg, B-cell receptor; BCR), etc. Such effector functions generally require that the Fc region be combined with a binding domain (eg, an antibody variable domain) and can be evaluated using various assays as disclosed, for example, herein.

A "natural sequence Fc region" comprises an amino acid sequence identical to the amino acid sequence of an Fc region found in nature. Natural sequence human Fc regions include a natural sequence human IgG1 Fc region (allotypes A and non-A), natural sequence human IgG2 Fc region, natural sequence human IgG3 Fc region and human IgG4 Fc region of natural sequence, as well as natural variants thereof.

A variant Fc region comprises an amino acid sequence that differs from that of a natural sequence Fc region by virtue of at least one amino acid modification, preferably one or more amino acid substitutions. Preferably, the variant Fc region has at least one amino acid substitution compared to a natural sequence Fc region or with the Fc region of an original polypeptide, for example, from about one to about ten amino acid substitutions and, preferably, from about one to approximately five amino acid substitutions in a natural sequence Fc region or in the Fc region of the original polypeptide. The variant Fc region herein will preferably possess a homology of at least about 80% with a natural sequence Fc region and / or with an Fc region of an original polypeptide and, most preferably, a homology of at least about one 90% with it, more preferably a homology of at least about 95% with it.

Depending on the amino acid sequence of the constant domain of their heavy chains, intact antibodies can be assigned to different "classes." There are five main classes of intact antibodies: IgA, IgD, IgE, IgG and IgM, and several of them can be further divided into subclasses ”(isotypes), for example, IgG1, IgG2, IgG3, IgG4, IgA and IgA2. The constant heavy chain domains that correspond to the different classes of antibodies are called α, δ, ε, γ and μ, respectively. The subunit structures and three-dimensional configurations of the different classes of immunoglobulins are well known.

An "unlabeled antibody" is an antibody that is not conjugated to a heterologous molecule, such as a cytotoxic or radiomarker moiety.

An "matured affinity" antibody is one with one or more alterations in one or more hypervariable regions thereof that results in an improvement in the affinity of the antibody for the antigen, compared to an original antibody that does not possess such alterations. Preferred mature affinity antibodies have nanomolar or even picomolar affinities for the target antigen. Matured affinity antibodies are produced by methods known in the art. Marks et al. Bio / Technology 10: 779783 (1992) describe the maturation of affinity by transposition of the VH and VL domains. The random mutagenesis of the CDR residues and / or the structural region is described by: Barbas et al. Proc Nat. Acad. Sci, USA 91: 3809-3813 (1994); Schier et al. Gene 169: 147-155 (1995); Yelton et al. J. Immunol. 155: 1994-2004 (1995); Jackson et al., J. Immunol. 154 (7): 3310-9 (1995); and Hawkins et al, J. Mol. Biol. 226: 889896 (1992).

A "deamidated" antibody is one in which one or more asparagine residues thereof have been derivatized, for example, to an aspartic acid, a succinimide or an isoaspartic acid.

The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.

"Gastric cancer" specifically includes non-resectable metastatic or locally advanced gastric cancer, including, without limitation, adenocarcinoma of the stomach or histologically confirmed gastroesophageal junction with an inoperable (non-resectable) locally advanced or metastatic disease, not amenable to treatment. curative, and postoperative recurrent advanced gastric cancer, such as stomach adenocarcinoma or gastroesophageal junction, when the goal of surgery was to cure the disease.

ES 2 736 005 T3

An "advanced" cancer is one that has spread outside the site or organ of origin, either by local invasion or metastasis. Consequently, the term "advanced" cancer includes both locally advanced and metastatic disease.

A "treatment-resistant" cancer is one that progresses even though an antitumor agent, such as chemotherapy, is being administered to the cancer patient. An example of a treatment-resistant cancer is one that is resistant to platinum treatment.

A “relapsing” cancer is one that has grown back, at the initial site or at a distant site, after a response to the initial treatment, such as surgery.

A "locally recurrent" cancer is cancer that reappears after treatment in the same place as a previously treated cancer.

A “non-resectable” or “unresectable” cancer cannot be removed (resected) by surgery.

"Breast cancer in the early stage", herein, refers to breast cancer that has not spread beyond the breast or axillary lymph nodes. This type of cancer is usually treated with neoadjuvant or adjuvant treatment.

"Neoadjuvant treatment" refers to the systemic treatment administered before surgery.

"Adjuvant treatment" refers to systemic treatment administered after surgery.

"Metastatic" cancer refers to cancer that has spread from one part of the body (for example, the breast) to another part of the body.

In this document, a "patient" or "subject" is a human patient. The patient can be a "cancer patient", that is, one who suffers or is at risk of suffering one or more symptoms of cancer, in particular gastric or breast cancer.

A "patient population" refers to a group of cancer patients. Such populations can be used to demonstrate the statistically significant efficacy and / or safety of a drug, such as Pertuzumab.

A relapsed patient is one who has signs or symptoms of cancer after remission. Optionally, the patient has relapsed after adjuvant or neoadjuvant treatment.

A biological or cancer sample that exhibits HER expression, amplification or activation is one that, in a diagnostic test, expresses (including overexpressed) an HER receptor, has the amplified HER gene and / or otherwise demonstrates the activation or phosphorylation of an HER receptor.

A biological or cancer sample that "shows the activation of HER" is one that, in a diagnostic test, demonstrates the activation or phosphorylation of an HER receptor. Such activation can be determined directly (for example, by measuring HER phosphorylation by ELISA) or indirectly (for example, by gene expression profile or by detecting HER heterodimers, as described herein).

A cancer cell with "overexpression or amplification of the HER receptor" is one that has significantly higher levels of a protein or gene of the HER receptor compared to a non-cancerous cell of the same type of tissue. Such overexpression may be caused by gene amplification or by an increase in transcription or translation. Overexpression or amplification of the HER receptor can be determined in a diagnostic or prognostic assay by evaluating increased levels of the HER protein present on the surface of a cell (for example, through an immunohistochemical assay; IHC). Alternatively, or additionally, the levels of HER encoding nucleic acid in the cell can be measured, for example, by means of in situ hybridization (ISH), including fluorescence in situ hybridization (FISH; see WO98 / 45479 published in October 1998) and in situ chromogenic hybridization (CISH; see, for example, Tanner et al., Am. J. Pathol. 157 (5): 1467-1472 (2000); Bella et al., J. Clin Oncol 26: (May 20 suppl; abstr 22147) (2008)), Southern blotting or polymerase chain reaction (PCR) techniques, such as quantitative real-time PCR (qRT-PCR). Overexpression or amplification of the HER receptor can also be studied by measuring the circulating antigen (eg, extracellular HER domain) in a biological fluid such as serum (see, for example, U.S. Pat. No. 4,933,294, issued June 12, 1990; WO91 / 05264 published on April 18, 1991; the US patent. UU. No. 5,401,638, issued March 28, 1995; and Sias et al. J. Immunol. Methods 132: 73-80 (1990)). Apart from the previous tests, experts have several in vivo tests. For example,

ES 2 736 005 T3 the cells of the patient's body can be exposed to an antibody that is optionally labeled with a detectable label, for example, a radioactive isotope, and the binding of the antibody to the patient's cells can be evaluated, for example, by external scanning of radioactivity or by analysis of a biopsy taken from the patient who has previously been exposed to the antibody.

A "HER2 positive" cancer comprises cancer cells that have higher than normal levels of HER2. Examples of HER2 positive cancer include HER2 positive breast cancer and HER2 positive gastric cancer. Optionally, HER2-positive cancer has an immunohistochemical (IHQ) score of 2+ or 3+ and / or an in situ hybridization amplification (ISH) ratio of> 2.0.

Here, an "antitumor agent" refers to a drug used to treat cancer. Non-limiting examples of antitumor agents herein include chemotherapy agents, HER dimerization inhibitors, antibodies against HER, antibodies directed against tumor associated antigens, antihormonal compounds, cytokines, drugs directed to EGFR, antiangiogenic agents, inhibitors of tyrosine kinase, growth inhibiting agents and antibodies, cytotoxic agents, apoptosis inducing antibodies, COX inhibitors, farnesyltransferase inhibitors, antibodies that bind to oncofetal CA 125 protein, vaccines against HER2, Raf or ras inhibitors, liposomal doxorubicin, topotecan, taxane, double tyrosine kinase inhibitors, TLK286, EMD-7200, Pertuzumab, Trastuzumab, Erlotinib and Bevacizumab.

The "2C4 epitope" is the region of the extracellular domain of HER2 to which the 2C4 antibody binds. To detect antibodies that bind essentially to the 2C4 epitope, a routine cross-block assay such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988) can be performed. Preferably, the antibody blocks the binding of 2C4 to HER2 by approximately 50% or more. Alternatively, epitope mapping can be performed to assess whether the antibody essentially binds to the 2C4 epitope of HER2. Epitope 2C4 comprises residues of Domain II (SEQ ID NO: 2) in the extracellular domain of HER2. 2C4 and Pertuzumab bind to the extracellular domain of HER2 at the junction point of domains I, II and III (SEQ ID NO: 1, 2 and 3, respectively). Franklin et al. Cancer Cell 5: 317-328 (2004).

The "4D5 epitope" is the region of the extracellular domain of HER2 to which the 4D5 antibody (ATCC CRL 10463) and Trastuzumab bind. This epitope is close to the transmembrane domain of HER2 and within Domain IV of HER2 (SEQ ID NO: 4). To detect antibodies that bind to the 4D5 epitope essentially, a routine cross-block assay such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988) may alternatively be performed. you can perform epitope mapping to assess whether the antibody essentially binds to the 4D5 epitope of HER2 (for example, one or more residues in the region from about residue 529 to about residue 625, including the HER2 ECD, numbering of residues including the signal peptide).

"Treatment" refers to both therapeutic treatment and prophylactic or preventive measures. Those who need treatment include those who already have cancer, as well as those who want to prevent cancer. Therefore, the patient to be treated in this document is both the person to whom the cancer has been diagnosed and the person who is predisposed or is susceptible to cancer.

The term "effective amount" refers to an amount of a drug that is effective for treating cancer in the patient. The effective amount of drug can reduce the number of cancer cells; reduce the size of the tumor; inhibit (i.e., slow to a certain extent and preferably stop) the infiltration of cancer cells in the peripheral organs; inhibit (i.e., slow to a certain extent and preferably stop) tumor metastasis; inhibit to some extent tumor growth; and / or relieve to some extent one or more symptoms associated with cancer. To the extent that the drug can prevent growth and / or destroy existing cancer cells, it can be cytostatic and / or cytotoxic. The effective amount can extend progression-free survival (for example, as measured by Response Evaluation Criteria for solid tumors, RECIST, or changes in CA-125), resulting in an objective response (including a partial response, RP , or complete response, CR), increase overall survival time and / or improve one or more cancer symptoms (for example, as evaluated by FOSI).

The term "cytotoxic agent", as used herein, refers to a substance that inhibits or prevents the function of cells and / or causes the destruction of cells. The term is intended to include radioactive isotopes (for example, At211I131I125, Y90, Re186, Re188, Ye153, Bi212, P32 and radioactive isotopes of Lu), chemotherapeutic agents and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and / or variants thereof.

A "chemotherapy" is the use of a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents used in chemotherapy include alkylating agents such as thiotepa and CYTOXAN® cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines

ES 2 736 005 T3 such as benzodopa, carboquone, meturedopa and uredopa; ethyleneimines and methylamelamines including altretamine, triethylenemelamine, triethylene phosphoramide, triethylenediophosphoramide and trimethylolomelamine; TLK 286 (TELCYTA ™); acetogenins (especially bullatacin and bullatacinone); delta-9-tetrahydrocannabinol (dronabinol, MARINOL®); beta-lapachone; lapachol colchicines; betulinic acid; a camptothecin (including the synthetic topotecan analogue (HYCAMTiN®), CPT-11 (irinotecan, CAMPTOSAR®), acetylcamptothecin, scopolectin and 9-aminocamptothecin; briostatin; calistatin; CC-1065 (including its synthetic analogs adozelesin, carzelesin and bizelesin); podophyllotoxin; podophyllinic acid; teniposide; cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancystintin; a sarcodictine; spongistatin; nitrogen mustards such as chlorambucil, chlornafazine, colophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine hydrochloride, melphalan, novembiquina, phenesterine, prednimustine, trophophamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine and ranimnustine; bisphosphonates such as clodronate; antibiotics such as enediine antibiotics (for example, calicheamycin, especially calicheamycin gamma11 and calicheamycin omega I1 (see, for example, Agnew. Chem Intl. Ed. Engl., 33: 183-186 (1994)) and anthracyclines such as annamicin, AD 32, alcarubicin, daunorubicin, dexrazoxane, DX-52-1, epirubicin, GPX-100, idarubicin, KRN5500, menogaril, dynemycin, including dynemycin A, a speramycin, chromophore Neocarzinostatin and chromophores of related Enediine chromoprotein antibiotics, clarcinomisins, actinomycin, autramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, cromomycins, dactinomycin, detorubicin, 6-diazo-5-oxo-Lnorleucina, ADRIAMYCIN® doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2pirrolino-doxorubicin, liposomal doxorubicin, and deoxydoxorubicin), esorubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfiromycin, puromycin, chelamicin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin and zorubicin; folic acid analogs such as denopterin, pteropterin and trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine and thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine and floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane and testolactone; antisuprarrenales such as aminoglutethimide, mitotane and trilostane; folic acid filler such as folinic acid (leucovorin); aceglatone; antineoplastic anti-folate agents such as ALIMTA®, LY231514 pemetrexed, dihydrofolate reductase inhibitors such as methotrexate, antimetabolites such as 5fluorouracil (5-FU) and their prodrugs such as UFT, S-1 and capecitabine, and thymidylate inhibitors of glycinamide ribonucleotide formyltransferase such as raltitrexed (TOMUDEXRM, TDX); dihydropyrimidine dehydrogenase inhibitors such as enyluracil; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucilo; bisantrene; edatraxate; Demecolcin Diaziquone Defofamin; elfornithine; elliptinium acetate; an epothilone; ethtoglucid; gallium nitrate; hydroxyurea; lentinano; lonidainin; maitansinoids such as maitansin and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerin; pentostatin; fenamet; pyrarubicin; losoxantrone; 2-ethylhydrazide; procarbazine; PSK7 polysaccharide complex (JHS Natural Products, Eugene, OR); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2 ', 2-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridine A and anguidine); urethane; vindesine (ELDISINE®, FILDESIN®); dacarbazine; manomustine; mitobronitol; mitolactol; pipobroman; gacitosina; arabinoside (Ara-C); cyclophosphamide; thiotepa; taxanes; chlorabucil; gemcitabine (GEMZAR®); 6-thioguanine; mercaptopurine; platinum; platinum analogs or platinum-based analogs such as cisplatin, oxaliplatin and carboplatin; vinblastine (VELBAN®); etoposide (VP-16); ifosfamide; mitoxantrone; vincristine (ONCOVIN®); vinca alkaloid; vinorelbine (NAVELBINE®); novantrone; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; topoisomerase inhibitor RFS 2000; difluoromethylornitine (DMFO); retinoids such as retinoic acid, pharmaceutically acceptable salts, acids or derivatives of any of the foregoing, as well as combinations of two or more of the foregoing, such as CHOP, an abbreviation for a combined treatment of cyclophosphamide, doxorubicin, vincristine and prednisolone, and FOLFOX, an abbreviation for an oxaliplatin (ELOXATIN ™) treatment regimen combined with 5-FU and leucovorin.

Also included in this definition are anti-hormonal agents that act to regulate or inhibit the action of the hormone on tumors, such as antiestrogens and selective estrogen receptor modulators (SERM), which include, for example, tamoxifen (including tamoxifen NOLVADEX ®), raloxifene, droloxifene, 4-hydroxy tamoxifen, trioxyphene, keoxifen, LY117018, onapristone and FARESTON® toremifene; aromatase inhibitors; and antiandrogens such as flutamide, nilutamide, bicalutamide, leuprolide and goserelin; as well as troxacitabine (a cytosine nucleoside 1,3-dioxolane analog); antisense oligonucleotides, particularly those that inhibit the expression of genes in signaling pathways involved in aberrant cell proliferation, such as, for example, PKC-alpha, Raf, H-Ras and the epidermal growth factor receptor (EGF-R) ; vaccines such as those for gene treatment, for example, the ALLOVECTIN® vaccine, the LEUVECTIN® vaccine and the VAXID® vaccine; PROLEUKIN® rIL-2; topoisomerase 1 LURTOTECAN® inhibitor; rmRH ABARELIX®; and pharmaceutically acceptable salts, acids or derivatives of any of the foregoing.

A "taxane" is a chemotherapy that inhibits mitosis and interferes with microtubules. Examples of taxanes include Paclitaxel (TAXOL®; Bristol-Myers Squibb Oncology, Princeton, NJ); formulation of

ES 2 736 005 T3 paclitaxel or naó-paclitaxel nanoparticles free of cremophors and manipulated with albumin (ABRAXANE ™; American Pharmaceutical Partners, Schaumberg, Illinois); and Docetaxel (TAXOTERE®; Rhone-Poulenc Rorer, Antony, France).

An "anthracycline" is a type of antibiotic that comes from the fungus Streptococcus peucetius, examples include: daunorubicin, doxorubicin and epirubicin, etc.

"Anthracycline-based chemotherapy" refers to chemotherapy regimens that consist of or include one or more anthracyclines. Examples include 5-FU, epirubicin and cyclophosphamide (FEC); 5-FU, doxorubicin and cyclophosphamide (FAC); doxorubicin and cyclophosphamide (AC); epirubicin and cyclophosphamide (CD); etc.

For the purposes of this document, "carboplatin-based chemotherapy" refers to a chemotherapy regimen that consists of or includes one or more carboplatins. An example is TCH (Docetaxel / TAXOL®, Carboplatin and Trastuzumab / HERCEPTIN®).

An "aromatase inhibitor" inhibits the aromatase enzyme that regulates estrogen production in the adrenal glands. Examples of aromatase inhibitors include: 4 (5) -imidazoles, aminoglutethimide, megestrol acetate MEGASE®, exemestane AROMASIN®, formmestanie, fadrozole, vorozole RIVISOR®, letrozole FEMARA® and anastrozole ARIMIDEX®. In one example, the aromatase inhibitor herein is letrozole or anastrozole.

An "antimetabolite chemotherapy" is the use of an agent that is structurally similar to a metabolite, but that the body cannot use productively. Chemotherapy with many antimetabolites interferes with the production of nucleic acids, RNA and DNA. Examples of antimetabolite chemotherapeutic agents include gemcitabine (GEMZAR®), 5-fluorouraciIo (5-FU), capecitabine (XELODA ™), 6mercaptopurine, methotrexate, 6-thioguanine, pemetrexed, raltitrexed, arabinosylcytosine-ARA (C ®), dacarbazine (DTIC-DOME®), azocytosine, deoxycytosine, pyridimidene, fludarabine (FLUDARA®), cladrabine, 2-deoxy-D-glucose, etc.

"Chemotherapy-resistant cancer" means that the cancer patient has progressed while receiving a chemotherapy regimen (that is, the patient is "chemotherapy-resistant"), or the patient has progressed within 12 months (for example, within 6 months) after completing a chemotherapy regimen.

The term "platinum" is used herein to refer to platinum-based chemotherapy, including, without limitation, cisplatin, carboplatin and oxaliplatin.

The term "fluoropyrimidine" is used herein to refer to chemotherapy with antimetabolites, including, without limitation, capecitabine, floxuridine and fluorouracil (5-FU).

A "fixed" or "constant" dose of a therapeutic agent herein refers to a dose that is administered to a human patient regardless of the weight (P) or body surface area (SC) of the patient. The fixed or constant dose, therefore, is not provided as a dose of mg / kg or a dose of mg / m2, but rather as an absolute amount of the therapeutic agent.

A loading dose herein generally comprises an initial dose of a therapeutic agent administered to a patient, and is followed by one or more maintenance doses thereof. In general, a single loading dose is administered, but multiple loading doses are contemplated herein. Normally, the amount of the administered loading dose (s) exceeds the quantity of the administered maintenance dose (s) and / or the loading dose (s) is administered more frequently than the maintenance dose (s), in order to achieve the desired equilibrium concentration of the therapeutic agent earlier than can be achieved with the maintenance dose (s).

A maintenance dose herein refers to one or more doses of a therapeutic agent administered to the patient during a period of treatment. Normally, maintenance doses are administered at spaced treatment intervals, such as approximately every week, approximately every 2 weeks, approximately every 3 weeks or approximately every 4 weeks, preferably every 3 weeks.

Infusion or infusion refers to the introduction of a solution containing drug into the body through a vein for therapeutic purposes. In general, this is achieved by means of an intravenous infusion bag (iv).

An intravenous infusion bag, IV bag or IV bag is a bag that can contain a solution that can be administered through a patient's vein. In one embodiment, the solution is a saline solution (for example, NaCl at about 0.9% or about 0.45%).

ES 2 736 005 T3

Optionally, the iv bag is made of polyolefin or polyvinyl chloride.

By "joint administration" is meant the intravenous administration of two (or more) drugs during the same administration, rather than sequential infusions of the two or more drugs. In general, this will involve combining the two (or more) drugs in the same IV bag before their co-administration.

"Cardiac toxicity" refers to any toxic side effects resulting from the administration of a drug or combination of drugs. Cardiac toxicity can be assessed based on one or more of the following: incidence of symptomatic left ventricular systolic dysfunction (LVEF) or congestive heart failure (CHF), or decreased left ventricular ejection fraction (LVEF).

The phrase "without increasing cardiac toxicity" for a combination of drugs including Pertuzumab refers to an incidence of cardiac toxicity that is equal to or less than that observed in patients treated with drugs other than Pertuzumab in the combination of drugs (eg, same or less than that resulting from administration of Trastuzumab and chemotherapy, for example, Docetaxel).

A vial is a suitable container for containing a liquid or a lyophilized preparation. In one example, the vial is a single use vial, for example, a 20 cc vial of a single use with a cap.

A “leaflet” is a booklet that, by order of the Food and Drug Administration (FDA) or other Regulatory Authority, should be placed inside the package of each prescription drug. The brochure generally includes the registered trademark of the drug, its generic name and its mechanism of action; establishes its indications, contraindications, warnings, precautions, adverse effects and pharmaceutical forms; and includes instructions for the recommended dose, time and route of administration.

The term "safety data" refers to data obtained in a controlled clinical trial that shows the prevalence and severity of adverse events to guide the user regarding the safety of the drug, including a guide on how to monitor and prevent reactions. Adverse to the drug. Table 3 and Table 4 of this document provide safety data for Pertuzumab. The safety data comprises one or more (for example, two, three, four or more) of the most common adverse events (AA) or adverse reactions (RA) in Tables 3 and 4. For example, the safety data comprises information on neutropenia, febrile neutropenia, diarrhea and / or cardiac toxicity as disclosed herein.

"Efficacy data" refers to data obtained in a controlled clinical trial that shows that a drug effectively treats a disease, such as cancer. The efficacy data for Pertuzumab are provided in the examples in this document. Regarding non-resectable, metastatic or locally recurrent breast cancer, positive for HER2, the efficacy data for Pertuzumab are found in Table 2, Table 5, Figure 8 and Figure 10 of this document. The safety data comprise one or more (for example, two, three, four or more) of the main assessment criteria (progression-free survival (SSP) by IRF) and / or secondary assessment criteria (overall survival (OS); survival no progression (SSP) by the researcher; objective response rate (ORT), including complete response (CR), partial response (PR), stable disease (EE) and progressive disease (PD) and / or duration of response) in Table 2, Table 5, Figure 8 and Figure 10. For example, efficacy data include information on progression-free survival (SSP) and / or overall survival (OS) as disclosed herein.

By "stable mixture" when referring to a mixture of two or more drugs, such as Pertuzumab and Trastuzumab, it means that each of the drugs in the mixture essentially retains its physical and chemical stability in the mixture as evaluated by one or more analytical tests. Exemplary analytical tests for this purpose include: color, appearance and clarity (CAC), concentration and turbidity analysis, particle analysis, size exclusion chromatography (SEC), ion exchange chromatography (IEC), capillary zone electrophoresis (CZE) ), isoelectric capillary image approach (iCIEF) and power test. In one example, the mixture has proven stable for up to 24 hours at 5 ° C or 30 ° C.

A drug that is administered "concurrently" with one or more other drugs is administered during the same treatment cycle, on the same treatment day as the one or more other drugs and, optionally, at the same time as the one or More than other drugs. For example, for cancer treatments administered every 3 weeks, drugs administered concurrently are each administered on Day 1 of a 3-week cycle.

II. Antibody compositions and chemotherapy

The HER2 antigen to be used for antibody production can be, for example, a soluble form of the extracellular domain of an HER2 receptor or a portion thereof, which contains the desired epitope. Alternatively, cells that express HER2 on their cell surface (for example, cells

ES 2 736 005 T3

NIH-3T3 transformed to overexpress HER2; or a carcinoma cell line such as SKBR-3 cells, see Stancovski et al. PNAS (USA) 88: 8691-8695 (1991)) can be used to generate antibodies. Other forms of HER2 receptor useful for generating antibodies will be apparent to those skilled in the art.

Several methods for making monoclonal antibodies herein are available in the art. For example, monoclonal antibodies can be prepared using the hybridoma method described first by Kohler et al., Nature, 256: 495 (1975), by recombinant DNA methods (U.S. Patent No. 4,816,567 ).

The anti-HER2 antibodies used in accordance with the present invention, Trastuzumab and Pertuzumab, are commercially available.

(i) Humanized antibodies

Procedures for humanizing non-human antibodies have been described in the art. Preferably, a humanized antibody has one or more amino acid residues introduced into it from a source that is not human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from a variable "import" domain. Humanization can be performed essentially following the procedure of Winter et al. (Jones et al., Nature, 321: 522-525 (1986); Riechmann et al., Nature, 332: 323-327 (1988); Verhoeyen et al. , Science, 239: 1534-1536 (1988)), replacing the sequences of the hypervariable region with the corresponding sequences of a human antibody. Accordingly, said "humanized" antibodies are chimeric antibodies (US Pat. No. 4,816,567), in which substantially less than one intact human variable domain has been replaced by the corresponding sequence of a non-human species. In practice, humanized antibodies are typically human antibodies in which some residues of the hypervariable region and possibly some FR residues are replaced by residues of similar sites in rodent antibodies.

The choice of human variable domains, both light and heavy, to be used in the preparation of humanized antibodies is very important to reduce antigenicity. According to the so-called best fit procedure, the variable domain sequence of a rodent antibody is screened against the entire collection of known human variable domain sequences. Next, the human sequence that is closest to that of the rodent is accepted as the human structural (FR) region for the humanized antibody (Sims et al., J. Immunol., 151: 2296 (1993); Chothia et al ., J. Mol. Biol., 196: 901 (1987)). Another method uses a particular structural region derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same structural region can be used for several different humanized antibodies (Carter et al., Proc. Natl. Acad. Sci. USA, 89: 4285 (1992); Presta et al., J. Immunol., 151: 2623 (1993 )).

It is also important that antibodies be humanized with high affinity retention for the antigen and other favorable biological properties. To achieve this objective, according to a preferred method, humanized antibodies are prepared by a method of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are known to those skilled in the art. Computer programs are available that illustrate and present probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. The inspection of these presentations allows the analysis of the probable role of residues in the functioning of the candidate immunoglobulin sequence, that is, the analysis of residues that influence the ability of the candidate immunoglobulin to bind to its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic is achieved, such as an affinity increased by the target antigen (s). In general, hypervariable region residues are directly and more substantially involved in influencing antigen binding.

U.S. Patent UU. No. 6,949,245 describes the production of exemplary humanized antibodies against HER2 that bind HER2 and block ligand activation of an HER receptor.

Humanized HER2 antibodies specifically include Trastuzumab (HERCEPTIN®) as described in Table 3 of US Pat. UU. 5,821,337 and as defined herein; and humanized 2C4 antibodies such as Pertuzumab as described and defined herein.

The humanized antibodies herein may, for example, comprise residues of the non-human hypervariable region incorporated into a human heavy variable domain and may further comprise a substitution of the structural region (FR) at a position selected from the group consisting of 69H , 71H and 73H using the variable domain numbering system established in Kabat et al., Sequences of Proteins of Immunological Interest, 5to Ed. Public Health Service, National Institutes of Health, Bethesda, MD

ES 2 736 005 T3 (1991). In one embodiment, the humanized antibody comprises FR substitutions in two or all of the 69H, 71H and 73H positions.

An example of a humanized antibody of interest herein comprises the GFTFTDYTMX heavy variable domain complementarity determining residues (SEQ ID NO: 17), wherein X is preferably D or S; DVNPNSGGSIYNQRFKG (SEQ ID NO: 18); and / or NLGPSFYFDY (SEQ ID NO: 19), which optionally comprises amino acid modifications of those CDR residues, for example, when the modifications essentially maintain or improve the affinity of the antibody. For example, an antibody variant for use in the methods of the present invention may have from about one to about seven or about five amino acid substitutions in the above heavy variable CDR sequences. Such antibody variants can be prepared by affinity maturation, for example, as described below.

The humanized antibody may comprise the complementarity determining residues of the light variable domain KASQDVSIGVA (SEQ ID NO: 20); SASYX1X2X3, in which X1 it is preferably R or L, X2 it is preferably Y or E, and X3 it is preferably T or S (SEQ ID NO: 21); and / or QQYYIYPYT (SEQ ID NO: 22), for example, in addition to the variable heavy domain CDR residues of the preceding paragraph. Such humanized antibodies optionally comprise amino acid modifications of the above CDR residues, for example, when the modifications essentially maintain or improve the affinity of the antibody. For example, the antibody variant of interest may have from about one to about seven or about five amino acid substitutions in the above variable light CDR sequences. Such antibody variants can be prepared by affinity maturation, for example, as described below.

The present application also contemplates affinity matured antibodies that bind HER2. The parental antibody may be a human antibody or a humanized antibody, for example, one comprising the light variable (VL) and / or heavy variable (VH) sequences of SEQ ID NOS. 7 and 8, respectively (that is, they comprise VL and / or Pertuzumab VH). An affinity matured Pertuzumab variant preferentially binds to the HER2 receptor with an affinity greater than that of murine 2C4 or Pertuzumab (for example, an improved affinity of about two or about four times, about 100 times or about 1000 times, example, as evaluated using an extracellular domain ELISA (ECD) of HER2). Exemplary heavy variable CDR residues for replacement include H28, H30, H34, H35, H64, H96, H99 or combinations of two or more (eg, two, three, four, five, six or seven of these wastes). Examples of light variable CDR residues for alteration include L28, L50, L53, L56, L91, L92, L93, L94, L96, L97 or combinations of two or more (for example, two to three, four, five or even about ten of this waste).

Humanization of the murine 4D5 antibody to generate humanized variants thereof, including Trastuzumab, is described in US Pat. UU. No. 5,821,337, 6,054,297, 6,407,213, 6,639,055,

6,719,971 and 6,800,738, as well as in Carter et al. PNAS (USA), 89: 4285-4289 (1992). HuMAb4D5-8 (Trastuzumab) bound HER2 antigen 3 times more closely than mouse 4D5 antibody, and had a secondary immune function (ADCC) that allowed a targeted cytotoxic activity of the humanized antibody in the presence of human effector cells. HuMAb4D5-8 comprised light variable CDR residues (Vl) incorporated into a consensus structural region of subgroup I κ Vl, and heavy variable CDR residues (Vh) incorporated into a consensus structural region of subgroup III Vh. The antibody further comprised substitutions of the structural region (FR) as positions: 71, 73, 78 and 93 Vh (Kabat numbering of FR residues); and a substitution of FR at position 66 of Vl (Kabat numbering of FR residues). Trastuzumab comprises the human Fc region of the non-A γ 1 allotype.

Various forms of the humanized antibody or affinity matured antibody are contemplated. For example, the humanized antibody or affinity matured antibody can be an antibody fragment. Alternatively, the humanized antibody or affinity matured antibody may be an intact antibody, such as an intact IgG1 antibody.

(ii) Pertuzumab compositions

In an example of an antibody composition against HER2, the composition comprises a mixture of a main species of the Pertuzumab antibody and one or more variants thereof. The preferred example herein of a major Pertuzumab antibody species is one that comprises the light variable and heavy variable amino acid sequences of SEQ ID NO. 7 and 8, and more preferably comprising a light chain amino acid sequence of SEQ ID NO. 11, and a heavy chain amino acid sequence of SEQ ID NO. 12 (including deamidated and / or oxidized variants of these sequences). In one example, the composition comprises a mixture of the main Pertuzumab antibody species and a variant of the amino acid sequence thereof comprising an aminoterminal leader extension. Preferably, the aminoterminal leader extension is in a light chain of the antibody variant (for example, in one or two light chains of the antibody variant). The main species of

ES 2 736 005 T3 antibody against HER2 or the antibody variant may be a full length antibody or an antibody fragment (eg, Fab fragments of F (ab =) 2), but preferably both are full length antibodies. The antibody variant herein may comprise an aminoterminal leader extension in one or more heavy or light chains thereof. Preferably, the aminoterminal leader extension is in one or two light chains of the antibody. The aminoterminal leader extension preferably comprises or consists of HSV-. The presence of the aminoterminal leader extension in the composition can be detected by various analytical techniques that include, but are not limited to, the analysis of the N-terminal sequence, the charge heterogeneity assay (for example, cation exchange chromatography or capillary electrophoresis zonal), mass spectrometry, etc. The amount of the antibody variant in the composition in general varies from an amount that constitutes the detection limit of any assay (preferably N-terminal sequence analysis) used to detect the variant to an amount less than the amount of the species antibody. principal. In general, about 20% or less (for example, from about 1% to about 15%, for example 5% to about 15%) of the antibody molecules in the composition comprise an aminoterminal leader extension. Said percentage amounts are preferably determined using a quantitative N-terminal sequence analysis or a cation exchange analysis (preferably using a high resolution weak cation exchange column, such as a PROPAC WCX-10 ™ cation exchange column). Apart from the aminoterminal leader extension variant, other alterations of the amino acid sequence of the antibody of the main species and / or the variant are contemplated, including but not limited to an antibody comprising a terminal C-lysine residue in one or more both heavy chains thereof, a deamidated antibody variant, etc.

In addition, the main species antibody or variant may further comprise glycosylation variations, the non-limiting examples of which include an antibody comprising an oligosaccharide structure G1 or G2 linked to the Fc region thereof, an antibody comprising a glycidic moiety linked to a chain light thereof (for example, one or two carbohydrate residues, such as glucose or galactose, attached to one or two light chains of the antibody, for example, linked to one or more lysine residues), an antibody comprising one or two non-glycosylated heavy chains or an antibody comprising a sialidated oligosaccharide bound to one or two heavy chains thereof, etc.

The composition can be recovered from a genetically modified cell line, for example, a Chinese hamster ovary (CHO) cell line that expresses the antibody against HER2, or can be prepared by peptide synthesis.

For more information on Pertuzumab's exemplary compositions, see US Pat. UU. No. 7,560,111 and 7,879,325, as well as US Pat. UU. No. 2009 / 0202546A1.

(iii) Trastuzumab compositions

The Trastuzumab composition generally comprises a mixture of a main species antibody (comprising light and heavy chain sequences of SEQ ID NO: 13 and 14, respectively) and variant forms thereof, in particular acid variants (including deamidated variants) . Preferably, the amount of said acidic variants in the composition is less than about 25%, or less than about 20%, or less than about 15%. See, for example, US Pat. UU. No. 6,339,142. See, also, Harris et al., J. Chromatography, B 752: 233-245 (2001) on Trastuzumab forms that can be resolved by cation exchange chromatography, including Peak A (Asn30 deamidated to Asp in both light chains); Peak B (Asn55 deamidated to isoAsp in a heavy chain); Peak 1 (Asn30 deamidated to Asp in a light chain); Peak 2 (Asn30 deamidated to Asp in a light chain, and Asp 102 isomerized to isoAsp in a heavy chain); Peak 3 (main peak form, or main species antibody); Peak 4 (Asp102 isomerized to isoAsp in a heavy chain); and Peak C (succinimide Asp 102 (Asu) in a heavy chain). Such variant forms and compositions are included in the invention herein.

(iv) 5-FU and Cisplatin

There is no single, standard and globally accepted chemotherapeutic regimen for advanced gastric cancer, but 5-fluorouracil (5-FU) plus cisplatin is widely used for this indication. In Phase II studies in patients without previous chemotherapy, 5-FU + cisplatin produced response rates of approximately 40% and a median overall survival of 7-10.6 months (Lacave AJ, Baron FJ, Anton LM, et al. Ann Oncol 1991; 2: 751-754; Rougier P, Ducreux M, Mahjoubi M, et al. Eur J Cancer 1994; 30A: 1263-1269; Vanhoefer U, Wagner T, Lutz M, et al. Eur J Cancer 2001; 37 Suppl 6: abstract S27.) (V) Capecitabine

Capecitabine has been extensively tested in patients with advanced gastric cancer. The Phase II efficacy results for capecitabine monotherapy show response rates of 19% and 26% and a

ES 2 736 005 T3 overall survival of 8.1 and 10.0 months in studies conducted by Koizumi et al. 2003 (Koizumi W, Kurihara M, Sasai T, et al. Cancer 1993; 72: 658-62; Sakamoto J, Chin K, Kondo K et al., Anti-Cancer Drugs 2006; 17: 2331-6). For capecitabine in combination with platinum, there are a number of studies that show response rates that vary from 28% to 65%, a time to progression of 5.8 to 9 months and an overall survival of 10.1 to 12 months (Kang Y, Kang WK, Shin DB et al. J Clin Oncology 2006; 24 Suppl 18: abstract LBA4018; Park Y, Kim B, Ryoo B et al. Proc Am Soc Clin Oncol 2006; 24 Suppl 18: abstract 4079; Kim TW, Kang YK, Ahn JH et al. Ann Oncol 2002; 13: 1893-8; Park YH, Kim BS, Ryoo BY et al. Br J Cancer 2006; 94: 95963).

III. Patient selection for treatment

HER2 detection can be used to select patients for treatment according to the present invention. Several commercial trials approved by the FDA are available to identify HeR2 positive cancer patients. These procedures include HERCePtEST® (Dako) and PATHWAY® HER2 (immunohistochemical assays (IHC)) and PathVysion® and HER2 FISH pharmDx ™ (FISH assays). Users should consult specific test kit leaflets for information on the validation and performance of each trial.

For example, overexpression of HER2 can be analyzed by IHC, for example, using HERCEPTEST® (Dako). Sections of tissue included in paraffin from a tumor biopsy can be subjected to the IHC assay and will be given the following criteria for staining intensity of the HER2 protein:

Score 0 if no staining is observed or membrane staining is observed in less than 10% of tumor cells.

Score 1+ if a weak / barely noticeable membrane staining is detected in more than 10% of tumor cells. The cells only stain in part of their membrane.

Score 2+ if a complete membrane staining of weak to moderate is observed in more than 10% of tumor cells.

Score 3+ if moderate to strong complete membrane staining is observed in more than 10% of tumor cells.

Tumors with 0 or 1+ scores for the evaluation of HER2 overexpression can be characterized as negative for HER2, while tumors with 2+ or 3+ scores can be characterized as positive for HER2.

Tumors that overexpress HER2 can be classified by immunohistochemical scores corresponding to the number of copies of HER2 molecules expressed per cell, and can be determined biochemically:

= 0-10,000 copies / cell,

1+ = at least approximately 200,000 copies / cell,

2+ = at least approximately 500,000 copies / cell,

3+ = at least approximately 2,000,000 copies / cell.

Overexpression of HER2 at level 3+, which leads to the independent activation of tyrosine kinase ligand (Hudziak et al., Proc. Natl. Acad. Sci. USA, 84: 7159-7163 (1987)), occurs in approximately 30% of breast cancers and, in these patients, non-relapse survival and overall survival decrease (Slamon et al., Science, 244: 707-712 (1989); Slamon et al., Science, 235: 177-182 (1987)).

The presence of HER2 protein overexpression and gene amplification are highly correlated; therefore, alternatively, or additionally, in situ hybridization (ISH) assays, for example, fluorescence in situ hybridization (FISH), to detect gene amplification can also be employed for the selection of appropriate patients for the treatment according to the present invention. FISH assays such as INFORM ™ (sold by Ventana, Arizona) or PathVysion® (Vysis, Illinois) can be performed on tumor tissue included in paraffin and fixed with formalin to determine the extent (if any) of the amplification of HER2 in the tumor.

More commonly, the positive state of HER2 is confirmed using tumor tissue included in archival paraffin, using any of the above procedures.

ES 2 736 005 T3

Preferably, patients with a HER2 positive tumor who have an IHC score of 2+ or 3+ or who test positive for FISH or ISH are selected for treatment according to the present invention.

See also US Pat. UU. No. 7,981,418 and Example 11 for alternative trials for screening patients for treatment with Pertuzumab.

IV. Pharmaceutical formulations

The therapeutic formulations of the HER2 antibodies used in accordance with the present invention are prepared for storage by mixing an antibody having the desired degree of purity with pharmaceutically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences, 16to edition, Osol, A. Ed. (1980)), in general in the form of lyophilized formulations or aqueous solutions. Antibody crystals are also contemplated (see US patent application 2002/0136719). Acceptable carriers, excipients or stabilizers are not toxic to the receptors at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkylparabenos such as methylparaben or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol and m-cresol); low molecular weight polypeptides (less than about 10 residues); proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt forming counterions such as sodium; metal complexes (for example, Zn-protein complexes) and / or non-ionic surfactants such as TWEEN ™, PLURONICS ™ or polyethylene glycol (PEG). Exemplary lyophilized antibody formulations are described in WO 97/04801.

Lyophilized antibody formulations are described in US Pat. UU. No. 6,267,958, 6,685,940 and 6,821,515. The preferred formulation of HERCEPTIN® (Trastuzumab) is a sterile lyophilized powder, white to pale yellow, free of preservatives for intravenous (iv) administration comprising 440 mg of Trastuzumab, 400 mg of α, α-trehalose dehydrated, 9.9 mg of L-histidine-HCl, 6.4 mg of L-histidine and 1.8 mg of polysorbate 20, USP. The reconstitution of 20 ml of bacteriostatic water for injection (BWFI), which contains 1.1% benzyl alcohol as a preservative, produces a multi-dose solution containing 21 mg / ml of Trastuzumab at a pH of approximately 6.0. For more details, see the prescription information for Trastuzumab.

The preferred Pertuzumab formulation for therapeutic use comprises 30 mg / ml Pertuzumab in 20 mM histidine acetate, 120 mM sucrose, 0.02% polysorbate 20, pH 6.0. An alternative formulation of Pertuzumab comprises 25 mg / ml of Pertuzumab, 10 mM histidine-HCl buffer, 240 mM sucrose, 0.02% polysorbate 20, pH 6.0.

The placebo formulation used in the clinical trials described in the Examples is equivalent to Pertuzumab, without the active agent.

The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect the other. Several drugs that can be combined with the HER dimerization inhibitor are described in the Methods section below. Such molecules are suitably present in combination in amounts that are effective for the intended purpose.

The formulations to be used for in vivo administration must be sterile. This is easily achieved by filtration through sterile filtration membranes.

V. Treatment procedures

In a first aspect of a treatment procedure herein, a procedure is provided to extend progression-free survival (SSP) in a population of HER2-positive breast cancer patients in 6 months or more, which comprises administering Pertuzumab, Trastuzumab and chemotherapy (for example, taxane such as Docetaxel) to patients in the population. Optionally, the patient population includes an adequate number of patients (for example, 200 or more, 300 or more or 400 or more patients) so that a statistically significant extension of the SSP in the population can be evaluated.

The phase III CLEOPATRA clinical data in Example 3 below show that the median SSP evaluated by the researchers was 12.4 months with placebo plus Trastuzumab plus Docetaxel and 18.5 months with Pertuzumab plus Trastuzumab plus Docetaxel, for what the improvement in the median sSp was of

ES 2 736 005 T3 months or more (for example, 6.1 months) in relation to patients who do not receive Pertuzumab (that is, patients who only receive Trastuzumab and Docetaxel).

In a further or alternative example of the disclosure a procedure is provided to obtain an objective response rate of 80% or more in a population of patients with HER2 positive breast cancer comprising administering Pertuzumab, Trastuzumab and chemotherapy (eg, taxane , such as Docetaxel) to patients in the population.

In a related aspect, a procedure is provided to combine two antibodies against HER2 to treat HER2 positive cancer without increasing cardiac toxicity in a population of HER2 positive cancer patients comprising administering Pertuzumab, Trastuzumab and chemotherapy to patients in the population. . Optionally, the patient population includes an adequate number of patients (for example, 200 or more, 300 or more or 400 or more patients) so that a statistically significant evaluation of the lack of cardiac toxicity resulting from the combination can be performed. The phase III CLEOPATRA clinical data in Example 3 below shows that the combination of Pertuzumab and Trastuzumab does not exacerbate cardiac toxicity. Cardiac toxicity can be monitored to determine the incidence of symptomatic left ventricular systolic dysfunction (LVEF) or congestive heart failure (CHF), or the decrease in the left ventricular ejection fraction (LVEF), for example, as reported in Example 3 below.

Optionally, breast cancer is metastatic or locally recurrent, non-resectable breast cancer, or de novo stage IV disease, which is defined as immunohistochemistry (IHC) 3+ and / or fluorescence in situ hybridization amplification ratio (FISH )> 2.0.

Optionally, patients in the population have not received prior treatment or who have relapsed after adjuvant treatment, have a left ventricular ejection fraction (LVEF) of> 50% at the start of the study and / or have a functional status of the Eastern Cooperative Oncology Group (ECOG PS) of 0 or 1.

In an alternative embodiment, the invention relates to a method for treating early-stage HER2 positive breast cancer comprising administering Pertuzumab, Trastuzumab and chemotherapy to a patient with breast cancer, in which chemotherapy comprises chemotherapy based in carboplatin. This aspect of the invention is supported by the clinical data of Example 5. In one example of the disclosure, chemotherapy comprises anthracycline-based chemotherapy, for example, comprising 5FU, epirubicin and cyclophosphamide (FEC). In an alternative embodiment, chemotherapy comprises carboplatin-based chemotherapy, for example, comprising taxane (eg, Docetaxel), Carboplatin, in addition to HERCEPTIN® / Trastuzumab (eg, TCH regimen). In one embodiment, Pertuzumab is administered simultaneously with carboplatin-based chemotherapy, for example, in which Pertuzumab, Trastuzumab and chemotherapy are administered in 3-week cycles with Pertuzumab, Trastuzumab and chemotherapy being administered on Day 1 of each cycle. The data in the examples herein demonstrate that administration of Pertuzumab does not increase cardiac toxicity in relation to treatment without Pertuzumab (i.e., with respect to Trastuzumab with anthracycline-based chemotherapy (eg, FEC) and without Pertuzumab; or in relation to Trastuzumab with carboplatin-based chemotherapy and without Pertuzumab (i.e., TCH). The early stage HER2 positive breast cancer treatment contemplated herein includes neoadjuvant treatment.

The disclosure herein also refers to a procedure for treating HER2 positive cancer in a patient comprising the co-administration of a mixture of Pertuzumab and Trastuzumab from the same intravenous bag to the patient. This example is applicable to the treatment of any HER2 positive cancer, including HER2 positive breast cancer, HER2 positive gastric cancer, unresectable, metastatic or locally recurrent HER2 positive breast cancer, or de novo stage disease IV, breast cancer positive for early HER2, etc. Optionally, this procedure also includes administering chemotherapy to the patient.

In yet another example of the disclosure, the treatment procedures comprise, consist essentially of, or consist of the administration of Pertuzumab, Trastuzumab and chemotherapy, such as a platinum (for example, cisplatin) and / or a fluoropurimidine (for example, Capecitabine and / or 5-fluorouracil (5FU)) to treat gastric cancer positive for HER2.

In particular, the methods of treatment of the disclosure comprise, consist essentially of, or consist of the administration of Pertuzumab, Trastuzumab and chemotherapy, such as a platinum and / or a fluoropurimidine, for example, cisplatin and / or capecitabine and / or 5-fluorouracil (5-FU), to a human patient with metastatic gastric cancer, locally advanced unresectable gastric cancer or recurrent postoperative gastric cancer. In certain examples of the disclosure, gastric cancer is not susceptible to curative treatment.

An alternative example of the disclosure provides a procedure to treat breast cancer.

ES 2 736 005 T3 positive for HER2 in a patient comprising administering Pertuzumab, Trastuzumab and vinorelbine to the patient. Breast cancer according to this example is optionally metastatic or locally advanced. Optionally, the patient has not previously received a systemic non-hormonal antineoplastic treatment in the metastatic context.

In another aspect, the disclosure provides a procedure for treating HER2 positive breast cancer in a patient comprising administering Pertuzumab, T rastuzumab and aromatase inhibitor (eg, anastrazole or letrozole) to the patient. According to this example of the disclosure, breast cancer is an advanced breast cancer, including hormonal receptor-positive breast cancer such as estrogen receptor-positive (RE) and / or progesterone receptor-positive breast cancer ( RPg). Optionally, the patient has not previously received systemic non-hormonal antineoplastic treatment in the metastatic context. This treatment procedure further comprises optionally administering induction chemotherapy (for example, which comprises taxane) to the patient.

The treatment according to the present invention extends progression-free survival (SSP) and / or overall survival (OS) of the treated patient.

Antibody and chemotherapeutic treatments are administered to a human patient according to known procedures. Specific administration guidelines and formulations are described in the examples herein.

According to one embodiment, Pertuzumab is administered at a dose that produces a Cmin. in equilibrium of> 20 pg / ml in 90% of patients receiving Pertuzumab and Trastuzumab.

According to a particular embodiment of the invention, Pertuzumab is administered at a dose of approximately 840 mg (loading dose), followed by one or more doses of approximately 420 mg (maintenance dose) of the antibody. Maintenance doses are preferably administered approximately every 3 weeks, for a total of at least two doses, until a progressive clinical disease or unmanageable toxicity occurs, preferably up to approximately 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or more doses. Longer treatment periods are also contemplated, which include more treatment cycles.

According to another particular embodiment, Pertuzumab is administered at a dose of 840 mg for all treatment cycles.

Trastuzumab is typically administered as an intravenous loading dose of approximately 8 mg / kg, followed by administration of doses of 6 mg / kg in subsequent cycles. Trastuzumab is typically administered every 3 weeks until a progressive clinical illness or unmanageable toxicity occurs, preferably up to about 17 or more doses.

In a particular embodiment, Trastuzumab is administered as an intravenous (iv) infusion on Day 1 of each treatment cycle until the progression of the disease evaluated by the investigator or up to an unmanageable toxicity, at a loading dose of 8 mg / kg for Cycle 1 and a dose of 6 mg / kg for subsequent cycles.

In another particular embodiment, Pertuzumab is administered as an iv infusion on Day 1 of each cycle, for a total of six cycles or until the progression of the disease evaluated by the investigator or until an unmanageable toxicity, whichever occurs first, already either at a loading dose of 840 mg for Cycle 1 and a dose of 420 mg for subsequent cycles, or a loading dose of 840 mg for Cycle 1 and a dose of 840 mg for subsequent cycles.

In another aspect of the disclosure, to treat gastric cancer, Cisplatin 80 mg / m2 It is typically given as an iv infusion on Day 1 of each cycle, for a total of at least six cycles.

In another aspect of the disclosure, to treat gastric cancer, Capecitabine 1000 mg / m2 It is typically administered orally twice a day, from the afternoon of Day 1 to the morning of Day 15 of each cycle, for a total of at least six cycles. The administration of Capecitabine can be prolonged at the doctor's discretion after a careful risk-benefit assessment for individual patients.

Doses and guidelines for chemotherapy used to treat HER2-positive breast cancer are disclosed in the examples below, but other doses and guidelines in accordance with the invention are known and contemplated herein.

SAW. Manufacturing items

An example of a manufacturing article herein comprises an intravenous bag (iv) that

ES 2 736 005 T3 contains a stable mixture of Pertuzumab and Trastuzumab suitable for administration to a cancer patient. Optionally, the mixture is in saline solution; for example, which comprises NaCl at about 0.9% or NaCl at about 0.45%. An example of an iv bag is an infusion bag of polyolefin or polyvinyl chloride, for example, an iv bag of 250 ml. According to an example of the invention, the mixture includes about 420 mg or about 840 mg of Pertuzumab and about 200 mg to about 1000 mg of Trastuzumab (for example, about 400 mg to about 900 mg of Trastuzumab).

Optionally, the mixture in the iv bag is stable for up to 24 hours at 5 ° C or 30 ° C. The stability of the mixture can be evaluated by one or more tests selected from the group consisting of: color, appearance and clarity (CAC), concentration and turbidity analysis, particle analysis, size exclusion chromatography (SEC), chromatography of ion exchange (IEC), capillary zone electrophoresis (CZE), image capillary isoelectric focusing (iCIEF) and power test.

In an alternative example, the invention provides a manufacturing article comprising a vial with Pertuzumab and a leaflet, in which the leaflet provides the safety data of Table 3 or Table 4 and / or the efficacy data of the Table. 2, Table 5, Figure 8 or Figure 10. Optionally, the vial is a single dose vial containing approximately 420 mg of Pertuzumab. In one example, the vial is provided inside a cardboard box.

In a related aspect, the disclosure refers to a process for manufacturing a manufacturing article comprising packaging a vial with Pertuzumab and a leaflet together, in which the leaflet provides the safety data of Table 3 or Table 4 and / or the efficacy data of Table 2, Table 5, Figure 8 or Figure 10.

In another related aspect, the disclosure provides a procedure to ensure the safe and effective use of Pertuzumab, which comprises packaging a vial with Pertuzumab and a leaflet, in which the leaflet provides the safety data from Table 3 or Table 4 and / or the efficacy data of Table 2, Table 5, Figure 8 or Figure 10.

VII. Deposit of biological materials

The following hybridoma cell lines have been deposited in the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, USA. UU. (ATCC):

Antibody designation

4D5

2C4

ATCC No.

ATCC CRL 10463

ATCC HB-12697

Deposit date May 1990 April 1999

More details of the invention are illustrated by the following Examples.

EXAMPLE 1

Phase IIa study evaluating Pertuzumab in combination with Trastuzumab and chemotherapy in patients with advanced gastric cancer positive for HER2

Despite a sharp worldwide decline in incidence and a reduction in mortality during the second half of the 20th century, gastric cancer remains the second leading cause of cancer mortality worldwide after lung cancer (Parkin, D. Oncogene 23: 6329-40 (2004)). The incidence of gastric cancer varies widely according to geographic region (Kelley et al. J Clin Epidemiol 56: 1-9 (2003); Plummer et al. Epidemiology of gastric cancer. In: Butlet et al., Editors. Mechanisms of carcinogenesis: contribution of molecular epidemiology. Lyon: Scientific publications of IARC No. 157, IARC (2004)). In Japan, Korea, China and certain countries of Central and South America, the incidence is 20 to 95 cases per 100,000 men. In contrast, in the United States, India and Thailand, the incidence is 4 to 8 cases per 100,000 men. The incidence in Western Europe varies from 37 cases per 100,000 men in parts of Italy to 12 per 100,000 men in France. The incidence in women follows a similar geographical pattern, but is approximately 50% lower than in men. There are clear epidemiological differences between cancer located in the gastric heart (gastroesophageal junction) and that located in the rest of the stomach. Cardiac cancer accounts for 39% of cases of gastric cancer in white men in the United States, but only 4% of gastric cancers in men in Japan. For reasons that are not clear, gastric and lower esophageal cancer has increased rapidly in developed countries since the 1970s.

To date, the only potentially curative treatment for gastric cancer is surgery. Survival rates for gastric cancer improved significantly in Japan in recent years as

ES 2 736 005 T3 results from earlier detection and better surgical techniques (Inoue et al. Postgrad Med J 81: 41924 (2005)). However, in Western Europe and North America, gastric cancer is often diagnosed at a late stage, when resection is no longer possible. Consequently, the 5-year overall survival in these populations does not exceed 25% (Ajani, J. The Oncologist 10 Suppl 3: 49-58 (2005); Catalano et al. Clin Rev Oncol / Hematol 54: 209-41 ( 2005)).

Regardless of their geographic region, patients with unresectable disease due to locally advanced growth or metastatic dissemination have an unfavorable prognosis, with a 5-year overall survival within the range of 5% -15% (Cunningham et al., Annals of Oncology 16 Suppl 1: i22-3 (2005)). For patients with non-resectable disease at the time of diagnosis and for patients with recurrent disease after surgery, the main therapeutic option is chemotherapy (National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Gastric cancer. Version 1. National Comprehensive Cancer Network, (2006)). Chemotherapy administered with palliative intent has been shown to be superior to the best supportive care in patients with advanced gastric cancer (Wagner et al. J Clin Oncol 24: 2903-9 (2006)).

The BO18255 (ToGA) study was a randomized, open, multicenter, international, comparative Phase III trial, designed to assess the efficacy and safety of Trastuzumab in combination with chemotherapy compared to chemotherapy alone as a first-line treatment in patients with adenocarcinoma of the stomach or the positive gastroesophageal junction for locally advanced or recurrent HER2 and / or inoperable metastatic. The main objective of the study was to compare the overall survival of patients treated with Trastuzumab combined with fluoropyrimidine (5-FU or capecitabine) plus cisplatin. The results of the BO18255 study demonstrated a significant clinical benefit when Trastuzumab was used in combination with chemotherapy in patients with gastric cancer. Overall survival, the main endpoint, significantly improved in the Trastuzumab group plus chemotherapy compared to the chemotherapy group alone (p = 0.0045, logarithmic order test; instantaneous risk ratio, 0.74). The median survival time was 13.8 months in the Trastuzumab plus chemotherapy group and 11.1 months in the chemotherapy group alone, and the risk of death was reduced by 26% for patients in the Trastuzumab group. more chemotherapy All other secondary assessment criteria demonstrated clinical importance with an instantaneous risk ratio and similar odds ratio. (See, for example, Bang et al., Lancet 28; 376 (9742): 687-97 (2010)).

As a result of this study, the use of Trastuzumab is now indicated, including the EU and the United States, in combination with cisplatin plus capecitabine or 5-FU, for the treatment of patients with gastric adenocarcinoma or of the metastatic gastroesophageal junction positive for HER2 who have not received prior treatment for metastatic disease.

There is currently no single, standard and globally accepted chemotherapeutic regimen for advanced gastric cancer. Despite the success of the ToGA trial, there is a great need to provide new and effective treatment options for this serious condition. In particular, there is a need for novel therapeutic approaches that seek to avoid treatment-related morbidity and / or increase the survival of patients with gastric cancer. Consequently, this example is a randomized, multicenter, open study that evaluates two different doses of Pertuzumab in patients with adenocarcinoma of the stomach or of the gastroesophageal junction positive for HER2. Patients are randomized in a 1: 1 ratio to two treatment groups. Patients in Group A receive a loading dose of Pertuzumab of 840 mg in Cycle 1 and a dose of 420 mg in Cycles 2-6, and patients in Group B receive Pertuzumab 840 mg in all six cycles. Patients in both treatment groups receive Trastuzumab, cisplatin and capecitabine. The study scheme is found in Figure 6. The duration of the study is approximately 24 months (4 months for recruitment and 20 months of follow-up after the last patient recruited). The end of the study will be when there is a progressive disease in all patients, or when all patients have withdrawn or have abandoned the study, whichever comes first.

Target population

The trial involves approximately 30 patients.

Patients must meet the following criteria to enter the study:

• Adenocarcinoma of the stomach or histologically confirmed gastroesophageal junction with inoperable locally advanced or metastatic disease, not susceptible to curative treatment.

• Patients with advanced disease who have a recurrence after surgery (when the intention of the surgery was cure) are also suitable for admission.

• Measurable disease, according to the Criteria for evaluation of response in solid tumors

ES 2 736 005 T3 (RECIST), v1.1, evaluated by imaging techniques (computed tomography (CT) or nuclear magnetic resonance imaging (MRI)), or non-measurable disease that can be followed.

• HER2 positive tumor defined as IHC 3+ or IHC 2+ in combination with ISH +, evaluated by the central laboratory in primary or metastatic tumors. The ISH positivity is defined as a ratio of> 2.0 for the number of copies of the HER2 gene with respect to the number of signals for CEP17.

• The availability of formalin-bound paraffin-fixed tissue (FFPE) with at least 5 mm of invasive tumor for central confirmation of eligibility for HER2 is mandatory.

• Functional status of the Eastern Cooperative Oncology Group (ECOG) of 0 or 1.

• Basal left ventricular ejection fraction (LVEF)> 55% (measured by echocardiogram (ECHO) or nuclear ventriculography (MUGA)).

• Life expectancy of at least 3 months.

• Male or female.

• Age> 18 years.

• Signed informed consent.

• For women of childbearing age and male participants with partners of childbearing age: agreement to use a highly effective non-hormonal contraceptive method or two effective non-hormonal contraceptive methods by the patient and / or the partner.

• Contraceptive use should continue for the duration of the study treatment and for at least 6 months after the last dose of study medication.

Patients who meet any of the following criteria are excluded from enrollment in the study:

• Previous chemotherapy for advanced or metastatic disease, unless prior adjuvant or neoadjuvant therapy is allowed if at least 6 months have elapsed between the end of adjuvant or neoadjuvant therapy and enrollment in the study.

• Adjuvant or neoadjuvant treatment with a platinum is not allowed.

• Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome (for example, patients with partial or total gastrectomy may participate in the study, but not those with a jejunostomy tube).

• Active gastrointestinal bleeding (significant or uncontrolled).

• Relevant residual toxicity resulting from previous treatment (eg, neurological toxicity of Grade> 2 (NCI CTCAE)), with the exception of alopecia.

• Other malignant neoplasms in the last 5 years, except in situ carcinoma of the cervix or basal cell carcinoma.

• Abnormal values in any of the following abnormal laboratory tests immediately before randomization:

Total serum bilirubin> 1.5 times the upper limit of the normal range (LSN) or, for patients with known Gilberts syndrome, total serum bilirubin> 2 χ LSN

In patients without liver and bone metastases:

AST or ALT> 2.5 χ LSN, and alkaline phosphatase (ALP)> 2.5 χ LSN

In patients with liver metastases and without bone metastases: AST or ALT> 5 χ LSN, and ALP> 2.5 χ LSN

In patients with liver metastases and bone metastases: AST or ALT> 5 χ LSN, and ALP> 10 χ LSN;

In patients with bone metastases and without liver metastases: AST or ALT> 2.5 χ LSN, and ALP> 10 χ LSN

ES 2 736 005 T3

Albumin <25 g / l

Creatinine clearance <60 ml / min

Total white blood cell count (GB) <2500 ^ jl (<2.5 χ 109/ l)

Absolute neutrophil count (ANC) <1500 ^ l (<1.5 χ 109/ l)

Platelets <100,000 / μΙ_ (<100 χ 109/ l) • Serious heart disease or medical conditions that include but are not limited to:

history of documented heart failure or systolic dysfunction (LVEF <50%);

uncontrolled high-risk arrhythmias, such as atrial tachycardia with a resting heart rate> 100 / min;

significant ventricular arrhythmia (ventricular tachycardia) or higher grade AV block (type 2 second degree AV block (Mobitz II) or third degree AV block);

angina pectoris that requires antianginal medication;

clinically significant valvular heart disease;

ECG transmural infarction tests; poorly controlled hypertension (for example, systolic blood pressure> 180 mmHg or diastolic blood pressure> 100 mmHg);

dyspnea at rest due to complications of advanced malignancy or other disease, or need for supportive oxygen treatment;

chronic or high dose treatment with corticosteroids;

Inhaled steroids and short oral steroid cycles are allowed for antiemesis or as an appetite stimulant;

clinically significant hearing abnormality; known deficiency of dihydropyrimidine dehydrogenase;

history or clinical tests of brain metastases; severe uncontrolled intercurrent systemic disease (for example, infections or poorly controlled diabetes).

• Pregnancy or breastfeeding

Women of childbearing age should have a negative serum pregnancy test within 7 days prior to randomization, regardless of the contraceptive method used.

• Radiation therapy within 4 weeks prior to the start of the study treatment, or within 2 weeks prior to the start of the study treatment if palliative radiotherapy is administered to the bone metastatic site peripherally and the patient recovers from any acute toxicity.

• Major surgery within 4 weeks prior to the start of the study treatment, without complete recovery .

• Active infection known for HIV, hepatitis B virus or hepatitis C virus.

• Known hypersensitivity to any of the study drugs.

• Inability to comply with follow-up tests or procedures, as determined by the investigator.

Medical products in clinical research phase: Dose, route and regimen

The treatment cycles are 3 weeks long.

• Trastuzumab is administered as an intravenous (iv) infusion on Day 1 of each cycle until the disease progression assessed by the investigator or up to an unmanageable toxicity, at a loading dose of 8 mg / kg for Cycle 1 and one dose 6 mg / kg for subsequent cycles.

EN 2 736 005 T3 • Pertuzumab is administered as an intravenous infusion on Day 1 of each cycle, for a total of six cycles or until the progression of the disease evaluated by the investigator or to an unmanageable toxicity, whichever comes first, of the following way for each group:

Group A: Patients receive Pertuzumab at a loading dose of 840 mg for Cycle 1 and a dose of 420 mg for Cycles 2-6.

Group B: Patients receive Pertuzumab at 840 mg for Cycles 1-6.

Medical products that are not in the clinical research phase

The treatment cycles are 3 weeks long.

• Cisplatin 80 mg / m2 It is given as an iv infusion on Day 1 of each cycle, for a total of six cycles.

• Capecitabine 1000 mg / m2 It is administered orally twice a day, from the afternoon of Day 1 to the morning of Day 15 of each cycle, for a total of six cycles. (Capecitabine may be prolonged at the discretion of the investigator after a careful risk-benefit assessment for individual patients).

Formulations

Pertuzumab formulation

Each batch of recombinant antibodies produced for clinical purposes meets the viral safety requirements and the United States Pharmacopoeia and the European Pharmacopoeia requirements for sterility. Each lot meets the required specifications of identity, purity and potency.

Pertuzumab is provided as a single-use formulation containing 30 mg / ml of Pertuzumab formulated in 20 mM L-histidine-acetate (pH 6.0), 120 mM sucrose and 0.02% 20 polysorbate.

Each 20 cc vial (14.0 ml solution per vial) contains approximately 420 mg of Pertuzumab.

Trastuzumab formulation

Trastuzumab in the clinical research phase is supplied as a lyophilized preparation with a nominal content of 150 mg per vial in most countries (vial size varies by country).

Trastuzumab is formulated in histidine, trehalose and polysorbate 20. Once reconstituted, each solution contains 21 mg / ml of active drug at a pH of approximately 6.0.

Valuations

Effectiveness

The tumor response evaluated by the investigator is used to better summarize the overall response at the end of Cycles 3 and 6 for each treatment group, defined as patients with a complete or partial response as determined by the RECIST criteria.

Security

Safety will be assessed through summaries of adverse events, changes in the results of laboratory tests and changes in vital signs.

Pharmacokinetics / Pharmacodynamics

The minimum serum concentration (Cmin.) Will be evaluated for Pertuzumab on Day 43. In addition, the HR parameters such as CL, Vss, ABC and half-life will be estimated. The evaluation of HR parameters from the data collected until Day 43 will allow modeling and simulation of an estimated dose that predicts a minimum equilibrium concentration of> 20 pg / ml in 90% of patients.

Statistical analysis

Pharmacokinetic Analysis

ES 2 736 005 T3

Individual and average serum Pertuzumab concentration-time data will be tabulated and represented by dose level. Pertuzumab serum pharmacokinetics will be summarized by estimating the total exposure (area under the curve (ABC)), the maximum serum concentration (Cmax.), The minimum serum concentration (Cmin.), The time to Cmax. and Cmín. in equilibrium, total serum clearance, distribution volume and elimination half-life (t1Z). The estimates for these parameters will be tabulated and summarized using descriptive statistics (mean, standard deviation, minimum and maximum). Depending on the observed concentration-time data of serum Pertuzumab, a population FC approach can be used to estimate the dose that will achieve the target FC concentrations.

The Cmax and the Cmín. observed for Trastuzumab will be tabulated and summarized using descriptive statistics for each specified HR sampling time point. In all HR analyzes, the actual sample collection times (instead of the programmed ones) will be used.

The parameters of FC (ABC, Cmax., T1X) from Pertuzumab will be calculated using non-compartmental procedures, and systemic clearance will be derived from plasma concentrations through standard procedures.

Analysis Populations

Population intended to treat

All randomized patients who receive at least one dose of the study medication will be included in the population by intention to treat (patients will be assigned to the treatment groups as randomized for analysis purposes).

Security population

All patients who received at least one dose of study medication will be included in the evaluable safety population (patients will be assigned to treatment groups as they are treated).

Sample size

The purpose of this study is to evaluate the Cmín. for Pertuzumab on Day 43 in patients receiving two different dose regimens of Pertuzumab. Next, these data will be analyzed using a population FC model to identify a dose of Pertuzumab that will achieve a minimum objective concentration of HR of> 20 pg / ml in approximately 90% of patients with advanced gastric cancer. Analyzes based on the assumption that Pertuzumab behaves similarly to Trastuzumab in advanced gastric cancer suggest that with a sample size of 15 patients per group (a total of 30 patients in this study), the dose to reach The desired target concentration can be estimated with an acceptable degree of accuracy (coefficient of variation <15%).

Clinical results

The clinical results of this phase IIa study of gastric cancer (GC) are shown in Figures 32-37.

Figure 32 shows the samples taken and the time points.

Figure 33 shows the demographic data of the patient population in the two groups of the CG study, treated with 420 mg (Group A) or 840 mg (Group B) of Pertuzumab.

Figure 34 shows the CG history of patients in Groups A and B, respectively.

Figure 35 shows the disposition of patients in Groups A and B, respectively.

Figure 36 shows the overall response rate in Groups A and B, respectively.

security data

Diarrhea was the most common event that occurred in 90% of the subjects and was typically Grade 1 and 2 beginning in Cycle 1; No patient discontinued treatment due to diarrhea.

Adverse events (AA) of grades> 3 (> 13%) included diarrhea, stomatitis, fatigue / asthenia, decreased appetite, hyponatremia, anemia and neutropenia. With the exception of neutropenia and hyponatremia (higher in Group A) and decreased appetite (higher in Group B), the incidence of these events was similar in the standard and high-dose Pertuzumab groups.

ES 2 736 005 T3

Asymptomatic change in expulsion fraction (EF), neutropenic fever, rash and hypersensitivity reaction to the drug were not associated with the highest dose of Pertuzumab.

Serious adverse events (AAG) occurred in 60% of patients, and the incidence was not associated with high doses of Pertuzumab.

Although more patients withdrew from treatment in Group B, it is not clear that this was due to a higher dose of Pertuzumab, since the events related to treatment discontinuation were not uniform.

Pharmacokinetic Results (HR)

Figure 37 shows the results of the evaluation of the concentration of Pertuzumab on Day 42 in gastric cancer (GC) (JOSHUA) versus metastatic breast cancer (CMM) (CLEOPATRA).

Summary of the results

- The minimum concentrations of Pertuzumab are lower in GC compared to CMM.

• Intercycle concentrations (ie, day 7, 14) are in line with the expected CMM concentrations, since the clearance is linear at these higher concentrations.

• The minimum dose levels of 840/420 mg are approximately 37% lower compared to the CLEOPATRA test (Example 3), probably due to a nonlinear clearance at lower concentrations (incomplete saturation of the recipient).

- The dose of 840/840 mg in GC provides minimum concentrations similar to the dose of 840/420 mg in CMM.

- Covariates have no impact on HR.

Conclusions

Based on Pertuzumab FC in GC, a dose of 840/840 mg will be used for the treatment of gastric cancer. It is expected that this dose will maintain the minimum levels above the target of> 20 pg / ml in 90% of patients, and provide minimum levels similar to those observed in CMM.

EXAMPLE 2

Phase III study evaluating Pertuzumab in combination with Trastuzumab and chemotherapy in patients with advanced advanced gastric cancer for HER2

This is a phase III, randomized, open, multicenter, clinical study designed to evaluate the efficacy of Pertuzumab in combination with Trastuzumab and chemotherapy in patients with locally advanced or metastatic gastric cancer positive for HER2.

Patients in the treatment group receive Trastuzumab, cisplatin and capecitabine and / or 5-fluorouracil. In the other group, patients receive placebo or Pertuzumab.

Treatment regimens:

Pertuzumab:

Dose of 840 mg for cycles 1-6.

Trastuzumab

Loading dose of 8 mg / kg, followed by 6 mg / kg c3s

Capecitabine

1000 mg / m2 bid d1-14 c3s x 6

5-Fluorouracil

800 mg / m continuous intravenous infusion2/ day d1-5 c3s x 6

ES 2 736 005 T3

Cisplatin

800 mg / m2 c3s x 6

Main valuation criteria:

Global Survival (SG)

Secondary assessment criteria:

Survival without progression (SSP), time to disease progression (TTP), objective response rate (TRO), clinical benefit rate, duration of response, CdV, safety, pain intensity, consumption of analgesics, change of Weight, pharmacokinetics.

Main criteria for patient selection

Inclusion criteria:

• Stomach adenocarcinoma or gastroesophageal junction • Inoperable locally advanced and / or metastatic disease • Non-measurable or measurable disease (RECIST) • Positive tumor for HER2: IHC 2+ or 3+ and / or ISH + • Adequate organ function and condition functional ECOG <2 • Written informed consent

Exclusion criteria • Prior adjuvant chemotherapy in 6 months • Chemotherapy for advanced disease • Congestive heart failure or baseline LVEF <50% • Creatinine clearance <60 ml / min

The treatment procedures described herein, which include the administration of Pertuzumab, Trastuzumab and chemotherapy (s), for example, cisplatin and capecitabine, are expected to meet the main assessment criteria (OS). In particular, the treatment procedures herein are expected to be therapeutically effective in patients with treated gastric cancer, for example, extending survival, including overall survival (OS) and / or progression-free survival (SSP) and / or disease progression time (TTP) and / or objective response rate (TRO) with respect to treatment with Trastuzumab and chemotherapy only.

EXAMPLE 3

Results of a randomized, double-blind, placebo-controlled Phase III registry trial to evaluate the efficacy and safety of Placebo + Trastuzumab + Docetaxel versus Pertuzumab + Trastuzumab + Docetaxel in patients with non-HER2 positive metastatic breast cancer previously treated (CLEOPATRA)

A protocol to evaluate Pertuzumab in HER2 positive metastatic breast cancer is found at http://clinicaltrials.gov/ct2/show/NCT00567190 and in US Pat. UU. No. 2009/0137387, as well as in WO2009 / 154651.

This example refers to the clinical data obtained in the randomized, double-blind, placebo-controlled Phase III trial in patients with CMM positive for HER2 who had not received chemotherapy or biological treatment for their metastatic disease. Patients were randomized 1: 1 to receive placebo + Trastuzumab + Docetaxel or Pertuzumab + Trastuzumab + Docetaxel. The primary endpoint was progression-free survival (SSP), based on tumor evaluations. SSP was defined as the time from randomization to the first documented progressive disease (PD)

ES 2 736 005 T3 radiographically according to the criteria for evaluation of solid tumor response (RECIST) version 1.0 (Therasse et al. J Natl Cancer Inst 92: 205-16 (2000)) or death from any cause, if it occurred within 18 weeks after the last evaluation of the patient's tumor. Secondary assessment criteria included overall survival (OS), the SSP evaluated by the investigator, the objective response rate (ORT) and safety.

Patients: Suitable patients had locally recurrent, non-resectable or metastatic breast cancer, or de novo stage IV disease positive for centrally confirmed HER2 (defined as immunohistochemistry (IHC) 3+ and / or fluorescence in situ hybridization amplification ratio (FISH)> 2.0) (Carlson et al. J Natl Compr Canc Netw 4 Suppl 3: S1-22 (2006)). The patients were aged> 18 years, had a left ventricular ejection fraction (LVEF)> 50% at the start of the study (determined by echocardiogram or nuclear ventriculography) and a functional status of the Eastern Cooperative Oncology Group (ECOG PS) of 0 or 1. Patients may have received a hormonal treatment for CMM before randomization, or treatment for neoadjuvant or adjuvant systemic breast cancer including Trastuzumab and / or taxanes, provided they have experienced a disease-free interval of> 12 months between the end of neoadjuvant treatment. or adjuvant and the diagnosis of metastatic disease. Exclusion criteria included treatment for CMM (other than described above); metastasis in the central nervous system; history of exposure to a cumulative dose of doxorubicin> 360 mg / m2 or its equivalent; history of decreased LVEF to <50% during or after previous treatment with Trastuzumab; current uncontrolled hypertension; history of impairment of cardiac function; impaired bone marrow, kidney or liver function; current known infection with HIV, HBV or HCV; pregnancy; lactation; and refusal to use non-hormonal contraceptives.

Procedures: Patients received a loading dose of 8 mg / kg of Trastuzumab, followed by a maintenance dose of 6 mg / kg every 3 weeks until radiographic or clinical PD evaluated by the investigator or up to uncontrollable toxicity. Docetaxel was administered every 3 weeks at an initial dose of 75 mg / m2, reaching 100 mg / m2 If tolerated. According to the protocol, the researcher could reduce the dose by 25% to 55 mg / m2 or 75 mg / m2 (if the dose had been increased to the patient) to manage tolerability. It was recommended that patients receive at least 6 cycles of Docetaxel. Pertuzumab or placebo was administered at a fixed loading dose of 840 mg, followed by 420 mg every 3 weeks until radiographic or clinical PD evaluated by the investigator or up to uncontrollable toxicity. In the case of chemotherapy discontinuation due to cumulative toxicity, antibody treatment was continued until PD, unacceptable toxicity or withdrawal of consent. All drugs were administered intravenously.

Evaluations: The SSP was evaluated according to the standard methodology accepted by RECIST every 9 weeks by each center and by the IRF until the EP evaluated by the IRF. The LVEF evaluations were performed at the beginning of the study, every 9 weeks during the treatment period, at the interruption of the treatment, every 6 months during the first year after the interruption of the treatment and then annually up to 3 years in the follow-up period Laboratory parameters and ECOG status were evaluated in each cycle. Adverse events (AA) were monitored continuously and rated according to version 3.0 of NCI-CTCAE. All cardiac events and serious adverse events (AAG) that were ongoing at the time of discontinuation of treatment were followed until resolution or stabilization up to 1 year after the final dose. Cardiac events and AAG related to treatment with post-treatment onset

RESULTS

Study population: A total of 808 patients were included and randomized to receive placebo plus Trastuzumab plus Docetaxel (n = 406) or Pertuzumab plus Trastuzumab plus Docetaxel (n = 402) (Figure 7). Baseline characteristics were similar between treatment groups (Table 1).

ES 2 736 005 T3

<td>Table 1: Baseline characteristics of the population</td><td>by intention to try Placebo + Trastuzumab + Docetaxel (n = 406)</td><td>Pertuzumab + Trastuzumab + Docetaxel (n = 402)</td>

<td>Woman</td><td> 404 (99,5)</td><td> 402 (100,0)</td>

<td>Age, years</td><td></td><td></td>

<td>Median</td><td> 54,0</td><td> 54,0</td>

<td>Interval</td><td> 27-89</td><td> 22-82</td>

<td>Asian</td><td> 133 (32,8)</td><td> 128 (31,8)</td>

<td>Black</td><td> 20 (4,9)</td><td> 10 (2,5)</td>

<td>White</td><td> 235 (57,9)</td><td> 245 (60,9)</td>

<td>Other *</td><td> 18 (4,4)</td><td> 19 (4,7)</td>

<td>Region, n (%)</td><td></td><td></td>

<td>Europe</td><td> 152 (37,4)</td><td> 154 (38,3)</td>

<td>North America</td><td> 68 (16,7)</td><td> 67 (16,7)</td>

<td>South America</td><td> 58 (14,3)</td><td> 56 (13,9)</td>

<td>ECOG Status, n (%)</td><td></td><td></td>

<td>State of prior treatment, n (%)</td><td></td><td></td>

<td>Previous adjuvant or neoadjuvant treatment</td><td> 192 (47,3)</td><td> 184 (45,8)</td>

<td>Previous treatment with Trastuzumab, n (%)</td><td> 41 (10,1)</td><td> 47 (11,7)</td>

<td>Previous anthracycline treatment, n (%)</td><td> 164 (40,4)</td><td> 150 (37,3)</td>

<td>Previous treatment with taxane, n (%)</td><td> 94 (23,2)</td><td> 91 (22,6)</td>

<td>Previous hormonal treatment *, n (%)</td><td> 107 (26,4)</td><td> 114 (28,4)</td>

<td>Type of disease in screening, n (%)</td><td></td><td></td>

<td>Non visceral</td><td> 90 (22,2)</td><td> 88 (21,9)</td>

<td>Visceral</td><td> 316 (77,8)</td><td> 314 (78,1)</td>

<td>Hormone receptor status, n (%)</td><td></td><td></td>

<td>RE and / or positive RPg</td><td> 199 (49,0)</td><td> 189 (47,0)</td>

<td>RE and negative RPg</td><td> 196 (48,3)</td><td> 212 (52,7)</td>

<td>Unknown</td><td> 11 (2,7)</td><td> 1 (0,2)</td>

<td>HER2 IHC status, n (%)</td><td> 405 (100)</td><td> 401 (100)</td>

<td>HER2 FISH Status, n (%)</td><td> 387 (100)</td><td> 385 (100)</td>

<td>Positive</td><td> 383 (99,0)</td><td> 384 (99,7)</td>

<td>Negative</td><td> 4 (1,0)</td><td> 1 (0,3)</td>

* Includes American Indian and Alaska Native f No prior chemotherapy or biological treatment * In the neoadjuvant / adjuvant or metastatic context

ES 2 736 005 T3

Progression-free survival: Treatment with Pertuzumab plus Trastuzumab plus Docetaxel significantly improved SSP-IRF, stratified by prior treatment status and region, compared with placebo plus Trastuzumab plus Docetaxel (CRI = 0.62; 95% CI: 0 , 51 to 0.75; p <0.0001) (Figure 8). The median SSP-IVRF lasted 6.1 months from 12.4 months with placebo plus Trastuzumab plus Docetaxel to 18.5 months with Pertuzumab plus Trastuzumab plus Docetaxel. The SSP benefit of the Pertuzumab plus Trastuzumab plus Docetaxel treatment was observed in all predefined subgroups (Figure 9).

The evaluation of the SSP by the researchers coincided closely with the SSP-IRF. The median SSP evaluated by the researchers was 12.4 months with placebo plus Trastuzumab plus Docetaxel and 18.5 months with Pertuzumab plus Trastuzumab plus Docetaxel (CRI = 0.65; 95% CI 0.54 to 0, 78; p <0.0001).

Main criteria of secondary efficacy assessment: The intermediate analysis of the OS took place when 43% of the events (n = 165) that were planned for the final analysis of the OS had occurred. More deaths occurred in the placebo group plus Trastuzumab plus Docetaxel (n = 96; 23.6%) than in the Pertuzumab group plus Trastuzumab plus Docetaxel (n = 69; 17.2%) (Figure 10). The CRI (0.64; 95% CI 0.47 to 0.88; p = 0.0053) for the SG did not comply with the O'Brien-Fleming detention delimiter of Lan's α spending function -DeMets for this intermediate survival analysis (CRI <0.603, p <0.0012) and, therefore, was not statistically significant. However, the data showed a strong trend that suggests a survival benefit in favor of Pertuzumab plus Trastuzumab plus Docetaxel. At the time of data cutting, patients in both treatment groups had been followed for OS for a median of 19.3 months (Kaplan-Meier estimate).

The ORT was 69.3% and 80.2% in the placebo group plus Trastuzumab plus Docetaxel and in the Pertuzumab plus Trastuzumab plus Docetaxel group, respectively. The difference in response rates between the treatment groups was 10.8% (95% CI 4.2 to 17.5; p = 0.0011) (Table 2).

Table 2: Overall response rate

Placebo + Pertuzumab +

Trastuzumab + Trastuzumab +

Docetaxel Docetaxel

<td>Patients with measurable disease assessed by IRF at baseline, n (%)</td><td> 336 (100)</td><td> 343 (100)</td>

<td>Objective Response Rate</td><td> 233 (69,3)</td><td> 275 (80,2)</td>

<td>Full response rate</td><td> 14 (4,2)</td><td> 19 (5,5)</td>

<td>Partial response rate</td><td> 219 (65,2)</td><td> 256 (74,6)</td>

<td>Stable disease</td><td> 70 (20,8)</td><td> 50 (14,6)</td>

<td>Progressive disease</td><td> 28 (8,3)</td><td> 13 (3,8)</td>

<td>Cannot be evaluated</td><td> 2 (0,6)</td><td> 2 (0,6)</td>

<td>There is no response evaluation</td><td> 3 (0,9)</td><td> 3 (0,9)</td>

IRF (Independent Review Facility), independent review center

Treatment exposure: The median number of cycles administered per patient was 15 and 18 with an estimated median treatment time of 11.8 and 18.1 months for placebo plus Trastuzumab plus Docetaxel and for Pertuzumab plus Trastuzumab plus Docetaxel, respectively. . Dose reductions were not allowed for placebo, Pertuzumab or Trastuzumab. Patients received a median of eight cycles of Docetaxel in each group. Based on the safety population, 61 (15.4%) patients in the placebo group plus Trastuzumab plus Docetaxel received an increase in the dose of Docetaxel to 100 mg / m2 in any cycle, compared to 48 (11.8%) patients in the Pertuzumab plus Trastuzumab plus Docetaxel group. The median dose intensity of Docetaxel was 24.8 mg / m2/ week in the placebo group plus Trastuzumab plus Docetaxel and 24.6 mg / m2/ week in the Pertuzumab plus Trastuzumab plus Docetaxel group. The reasons for the permanent interruption of the entire study treatment are presented in Figure 7.

Tolerability and cardiac safety: The profile of AA during the treatment period was generally balanced between the treatment groups (Table 3). The incidence of the following AA (all grades) was> 5% higher with Pertuzumab plus Trastuzumab plus Docetaxel: diarrhea, rash, mucosal inflammation, febrile neutropenia and dry skin.

ES 2 736 005 T3

Table 3: Adverse events (all grades) with> 25% incidence in each group or> 5% difference between groups and adverse events of grade> 3 with> 2% incidence in the safety population

<td></td><td>Placebo + Trastuzumab + Docetaxel (n = 397)</td><td>Pertuzumab + Trastuzumab + Docetaxel (n = 407)</td>

<td>Most common AA (all grades), n (%) Diarrhea</td><td> 184 (46,3)</td><td> 272 (66,8)</td>

<td>Alopecia</td><td> 240 (60,5)</td><td> 248 (60,9)</td>

<td>Neutropenia</td><td> 197 (49,6)</td><td> 215 (52,8)</td>

<td>Sickness</td><td> 165 (41,6)</td><td> 172 (42,3)</td>

<td>Fatigue</td><td> 146 (36,8)</td><td> 153 (37,6)</td>

<td>Eruption</td><td> 96 (24,2)</td><td> 137 (33,7)</td>

<td>Decreased appetite</td><td> 105 (26,4)</td><td> 119 (29,2)</td>

<td>Inflammation of the mucosa</td><td> 79 (19,9)</td><td> 113 (27,8)</td>

<td>Asthenia</td><td> 120 (30,2)</td><td> 106 (26,0)</td>

<td>Peripheral edema</td><td> 119 (30,0)</td><td> 94 (23,1)</td>

<td>Constipation</td><td> 99 (24,9)</td><td> 61 (15,0)</td>

<td>Febrile neutropenia</td><td> 30 (7,6)</td><td> 56 (13,8)</td>

<td>Grade AA> 3 with an incidence rate> 2%, n (%) Neutropenia</td><td> 182 (45,8)</td><td> 199 (48,9)</td>

<td>Febrile neutropenia</td><td> 30 (7,6)</td><td> 56 (13,8)</td>

<td>Leukopenia</td><td> 58 (14,6)</td><td> 50 (12,3)</td>

<td>Diarrhea</td><td> 20 (5,0)</td><td> 32 (7,9)</td>

<td>Peripheral neuropathy</td><td> 7 (1,8)</td><td> 11 (2,7)</td>

<td>Anemia</td><td> 14 (3,5)</td><td> 10 (2,5)</td>

<td>Asthenia</td><td> 6 (1,5)</td><td> 10 (2,5)</td>

<td>Fatigue</td><td> 13 (3,3)</td><td> 9 (2,2)</td>

<td>Granulocytopenia</td><td> 9 (2,3)</td><td> 6 (1,5)</td>

<td>Left ventricular systolic dysfunction</td><td> 11 (2,8)</td><td> 5 (1,2)</td>

<td>Dyspnoea</td><td> 8 (2,0)</td><td> 4 (1,0)</td>

AA, adverse event

The incidence of the following AA grade> 3 was> 2% higher with Pertuzumab plus Trastuzumab plus Docetaxel: neutropenia, febrile neutropenia and diarrhea (Table 3). The incidence of febrile neutropenia of grade> 3 in Asian patients was 12% in the placebo group plus Trastuzumab plus Docetaxel and 26% in the Pertuzumab plus Trastuzumab plus Docetaxel group; In all other geographical regions the incidence was <10% in both groups.

DSVI (all grades) was reported more frequently in the placebo group plus Trastuzumab plus Docetaxel compared to the Pertuzumab plus Trastuzumab plus Docetaxel group (8.3% and 4.4%, respectively). Grade-3 DSVI was reported in 2.8% of patients who received placebo plus Trastuzumab plus Docetaxel and in 1.2% of patients receiving Pertuzumab plus Trastuzumab plus Docetaxel. Among patients with a post-initiation evaluation of LVEF, LVEF decreases of> 10 percentage points were reported from the start to <50% at any stage during treatment in 6.6% and 3.8% of patients in the placebo group plus Trastuzumab plus Docetaxel and the Pertuzumab group plus Trastuzumab plus Docetaxel, respectively.

In the safety population, the majority of deaths in both treatment groups were attributed to PD (81 (20.4%) in the placebo group, 57 (14.0%) in the Pertuzumab group). Deaths due to causes other than PD were generally balanced and a similar number of patients died due to AA (10 (2.5%) in the placebo group, 8 (2.0%) in the Pertuzumab group) , infections being the most common cause of death from an AA.

ANALYSIS

ES 2 736 005 T3

These data show that the combination of anti-HER2 monoclonal antibodies Pertuzumab and Trastuzumab with Docetaxel prolongs SSP in patients with CMM positive for HER2 in the first-line context. Treatment with Pertuzumab plus Trastuzumab plus Docetaxel exceeded expectations, resulting in a statistically significant reduction in the risk of SSP (CRI = 0.62) and an improvement in the median SSP of 6.1 months.

The combination was well tolerated and Pertuzumab did not increase the rates of symptomatic or asymptomatic cardiac dysfunction. Prior to the data herein, treatment with two antibodies against HER2 was expected to exacerbate cardiac toxicity. However, these data show that this was not the case based on the evidence in this document to assess cardiac toxicity: incidence of symptomatic left ventricular systolic dysfunction (LVDD) including congestive heart failure (CHF), decreased ejection fraction of the left ventricle (LVEF).

The AA related to the use of Pertuzumab, which include rash, inflammation of the mucosa and dry skin, were mostly mild. There was an increase in the rate of diarrhea and febrile neutropenia of grade> 3 with treatment with Pertuzumab plus Trastuzumab plus Docetaxel. The control group in CLEOPATRA had an SSP similar to that of previous randomized studies that showed that the combination of Trastuzumab and Docetaxel in CMM positive for HER2 had a median SSP of 11.7 months. Marty et al. J Clin Oncol 23: 4265-74 (2005).

Without being limited by any theory, these data indicate that HER2-positive tumors treated with two anti-HER2 monoclonal antibodies with complementary mechanisms of action result in a more complete blockade of HER2 and highlight the clinical importance of preventing the formation of dimers of HER2-dependent ligands to optimally silence HER2 signaling. This study has shown that the combined blockade of HER2 with Trastuzumab and Pertuzumab improves the outcome of patients with advanced positive disease for HER2 in the first-line context. These data are significant because they support the first approved use of an HER2 dimerization inhibitor for the treatment of patients with HER2 positive cancer.

EXAMPLE 4

Manufacturing item including Pertuzumab

Phase III clinical data of Example 3 was used in the development of a manufacturing article comprising a vial (eg, a single dose vial) with Pertuzumab and a leaflet that provides information on the safety and / or efficacy thereof. , as well as a process for manufacturing a manufacturing article comprising packaging Pertuzumab together in a vial (for example, single dose vial) and a leaflet with prescription information about Pertuzumab in a leaflet as indicated below in this document.

Pertuzumab is a sterile, transparent to slightly opalescent, colorless to pale yellow liquid for intravenous infusion. Each single-use vial contains 420 mg of Pertuzumab at a concentration of 30 mg / ml in 20 mM L-histidine acetate (pH 6.0), 120 mM sucrose and 0.02% polysorbate 20.

Pertuzumab is supplied in a single dose vial containing liquid concentrate without preservatives, at a concentration of 30 mg / ml ready for infusion. Each vial of Pertuzumab drug contains a total of 420 mg of Pertuzumab. Store the vials in a refrigerator at a temperature of 2 ° C to 8 ° C (36 ° F to 46 ° F) until the time of use. Keep the vial in the outer packaging to protect it from light.

FULL PRESCRIPTION INFORMATION

WARNING: EMBRIOFETAL TOXICITY

Exposure to PERTUZUMAB can cause embryo-fetal death and congenital defects. Animal studies have resulted in oligohydramnios, delayed renal development and death. Patients should be advised about these risks and the need to use an effective contraceptive. (5.1,8.1, 8.6)

INDICATIONS AND USE

Pertuzumab is indicated for use in combination with Trastuzumab and Docetaxel for the treatment of patients with HER2 positive metastatic breast cancer who have not received anti-HER2 treatment or previous chemotherapy for metastatic disease.

DOSAGE AND ADMINISTRATION

ES 2 736 005 T3

2.1 Recommended dose and guidelines

The initial dose of Pertuzumab is 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter from a 420 mg dose administered as an intravenous infusion for 30 to 60 minutes. When administered with Pertuzumab, the recommended initial dose of Trastuzumab is 8 mg / kg administered as a 90-minute intravenous infusion, followed every 3 weeks thereafter from a 6 mg / kg dose administered as an intravenous infusion for 30 90 minutes When administered with Pertuzumab, the recommended starting dose of Docetaxel is 75 mg / m2 administered as an intravenous infusion. The dose can be increased up to 100 mg / m2, administered every 3 weeks if the initial dose is well tolerated.

2.2 Dose modification

For delayed or missed doses, if the time between two sequential infusions is less than 6 weeks, the dose of 420 mg Pertuzumab should be administered. Do not wait until the next planned dose. If the time between two sequential infusions is 6 weeks or more, the initial dose of 840 mg of Pertuzumab should be re-administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter from a dose of 420 mg administered as an intravenous infusion for 30 to 60 minutes. The infusion rate of Pertuzumab can be reduced or interrupted if the patient develops a reaction associated with the infusion. The infusion should be stopped immediately if the patient experiences a severe hypersensitivity reaction [see Warnings and precautions (5.2)].

Left ventricular ejection fraction (LVEF):

Stop the dose of Pertuzumab and Trastuzumab for at least 3 weeks in case of:

• a drop in LVEF to less than 40% or • LVEF from 40% to 45% with an absolute decrease of 10% or more below pre-treatment values [see Warnings and precautions (5.2)]

The use of Pertuzumab can be resumed if LVEF has recovered to more than 45% or up to 40% to 45% associated with an absolute decrease of less than 10% below the pre-treatment values.

If, after repeated evaluation within approximately 3 weeks, the LVEF has not improved or has decreased further, the interruption of Pertuzumab and Trastuzumab should be seriously considered, unless the benefits for the individual patient are considered to exceed the risks [see Warnings and precautions (5.2)]. The use of Pertuzumab should be discontinued or discontinued if treatment with Trastuzumab is suspended or discontinued. If Docetaxel treatment is discontinued, treatment with Pertuzumab and Trastuzumab may continue. No dose reductions are recommended for Pertuzumab. For dose modifications of Docetaxel, see the prescription information for Docetaxel.

2.3 Preparation for administration

Administer only as an intravenous infusion. Do not administer intravenously or as a bolus. Do not mix Pertuzumab with other drugs.

Preparation: Prepare the solution for infusion, using an aseptic technique, as follows:

• Parenteral drugs should be visually inspected for particles and discoloration before administration.

• Extract the appropriate volume of Pertuzumab solution from the vial (s).

• Dilute in a PVC or non-PVC polyolefin infusion bag with 0.9% sodium chloride of 250 ml.

• Mix the diluted solution by gentle inversion. Not shake.

• Administer immediately once prepared.

• If the diluted infusion solution is not used immediately, it can be stored between 2 ° C and 8 ° C for a maximum of 24 hours.

• Dilute only with 0.9% sodium chloride injection. Do not use a dextrose solution (5%).

Pharmaceutical forms and concentrations

ES 2 736 005 T3

Pertuzumab 420 mg / 14 ml (30 mg / ml) in a single-use vial

Contraindications

Any

Warnings and precautions 5.1 Embryofetal toxicity

Pertuzumab can cause fetal harm when administered to a pregnant woman. Treatment of cynomolgus monkeys pregnant with Pertuzumab resulted in oligohydramnios, delayed fetal renal development and embryofetal death. If Pertuzumab is administered during pregnancy, or if the patient becomes pregnant while receiving this drug, she should be informed about the potential danger to a fetus [see Use in specific populations (8.1)]. Check the state of pregnancy before the start of treatment with Pertuzumab. Inform patients about the risks of embryo-fetal death and birth defects and the need for contraception during and after treatment. Recommend that patients contact their health care provider immediately if they suspect they may be pregnant. If Pertuzumab is administered during pregnancy or if a patient becomes pregnant while receiving Pertuzumab, immediately report exposure to the Genentech Adverse Event Line at 1-888-835-2555. Propose women who may be exposed during pregnancy to enroll in the MotHER Pregnancy Registry by calling 1-800-690-6720 [see Information for patient counseling (17)]. Monitor patients who become pregnant during treatment with Pertuzumab for oligohydramnios. If oligohydramnios occurs, perform fetal tests that are appropriate for gestational age and that are consistent with the standards of care of the healthcare community. The efficacy of intravenous hydration in the management of oligohydramnios due to exposure to Pertuzumab is unknown.

5.2 Left ventricular dysfunction

Decreases in LVEF have been reported with drugs that block HER2 activity, including Pertuzumab. In the randomized trial, Pertuzumab in combination with Trastuzumab and Docetaxel was not associated with increases in the incidence of symptomatic left ventricular systolic dysfunction (LVEF) or decreases in LVEF compared with placebo in combination with Trastuzumab and Docetaxel [see Clinical Studies ( 14.1)]. Left ventricular dysfunction occurred in 4.4% of patients in the group treated with Pertuzumab and in 8.3% of patients in the group treated with placebo. Symptomatic left ventricular systolic dysfunction (congestive heart failure) occurred in 1.0% of patients in the Pertuzumab group and 1.8% of patients in the placebo group [see Adverse reactions (6.1)] . Patients who have received previous anthracyclines or prior radiotherapy in the chest area may have an increased risk of decreased LVEF. Pertuzumab has not been studied in patients with a pretreatment LVEF value of <50%, a previous history of CHF, decreases in LVEF to <50% during previous treatment with Trastuzumab, or conditions that could affect left ventricular function such as uncontrolled hypertension, recent myocardial infarction, severe cardiac arrhythmia that requires treatment or a cumulative prior exposure to anthracyclines at> 360 mg / m2 of doxorubicin or its equivalent. Evaluate LVEF before the start of Pertuzumab and at regular intervals (for example, every three months) during treatment to ensure that LVEF is within the normal limits of the institution. If the LVEF is <40%, or is 40% to 45% with an absolute decrease of 10% or more below the pretreatment value, discontinue the treatment with Pertuzumab and Trastuzumab and repeat the evaluation of the LVEF in approximately 3 weeks. Stop treatment with Pertuzumab and Trastuzumab if the LVEF has not improved or worsened further, unless the benefits to the particular patient outweigh the risks [see Dosage and administration (2.2)].

5.3 Reactions associated with infusion, hypersensitivity reactions / anaphylaxis

Pertuzumab has been associated with infusion and hypersensitivity reactions [see Adverse reactions (6.1)]. An infusion reaction was defined in the randomized trial as any event described as hypersensitivity, anaphylactic reaction, acute infusion reaction or cytokine release syndrome that occurs during an infusion or on the same day as the infusion. The initial dose of Pertuzumab was administered the day before Trastuzumab and Docetaxel to allow examination of the reactions associated with Pertuzumab. On the first day, when only Pertuzumab had been administered, the overall frequency of infusion reactions was 13.0% in the group treated with Pertuzumab and 9.8% in the group treated with placebo. Less than 1% were grade 3 or 4. The most common infusion reactions (> 1.0%) were pyrexia, chills, fatigue, headache, asthenia, hypersensitivity and vomiting. During the second cycle, when all drugs were administered on the same day, the most common infusion reactions in the group treated with Pertuzumab (> 1.0%) were fatigue, dysgeusia, hypersensitivity, myalgia and vomiting. In the randomized trial, the overall frequency of hypersensitivity / anaphylaxis reactions was 10.8% in the group treated with

ES 2 736 005 T3

Pertuzumab and 9.1% in the placebo group. The incidence of grade 3-4 hypersensitivity / anaphylaxis reactions was 2% in the Pertuzumab group and 2.5% in the placebo group according to the Common Terminology Criteria for Adverse Events of the National Cancer Institute. (NCI - CTCAE) (version 3). In total, 4 patients from the Pertuzumab-treated group and 2 patients from the placebo-treated group experienced anaphylaxis. Observe patients carefully for 60 minutes after the first infusion and for 30 minutes after subsequent infusions of Pertuzumab. If a significant reaction associated with the infusion occurs, decrease or interrupt the infusion and administer the appropriate medical treatments. Monitor patients carefully until complete resolution of signs and symptoms. Consider permanent interruption in patients with severe infusion reactions [see Dosage and administration (2.2)].

5.4 HER2 tests

The detection of HER2 protein overexpression is necessary for the selection of appropriate patients for treatment with Pertuzumab because they are the only patients studied and for which benefit has been demonstrated [see Indications and use (1) and Clinical studies (14) ]. The randomized trial required that patients with breast cancer have evidence of HER2 overexpression defined as IHC 3+ by Dako HERCEPTEST® or FISH amplification ratio> 2.0 per Dako HER2 FISH PHARMDX ™ test kit. Only limited data were available for patients whose breast cancer was positive for FISH, but did not demonstrate protein overexpression by IHC. The evaluation of the status of HER2 must be carried out by laboratories with demonstrated capacity in the specific technology used. Incorrect test performance, including the use of suboptimally fixed tissue, non-use of specific reagents, deviation from specific test instructions and non-inclusion of appropriate controls for test validation may lead to unreliable results. .

Adverse reactions

The following adverse reactions are described in more detail in other sections of the label:

• Embryofetal toxicity [see Warnings and precautions (5.1)] • Left ventricular dysfunction [see Warnings and precautions (5.2)] • Reactions associated with infusion, hypersensitivity reactions / anaphylaxis [see Warnings and precautions (5.3)]

6.1 Experience in clinical trials

Because clinical trials are conducted under very different conditions, the rates of adverse reactions observed in clinical trials of one drug cannot be directly compared with the rates observed in clinical trials of another drug and may not reflect rates. observed in clinical practice. In clinical trials, Pertuzumab has been evaluated in more than 1400 patients with various malignancies and treatment with Pertuzumab was mainly performed in combination with other antineoplastic agents.

The adverse reactions described in Table 4 were identified in 804 patients with HER2 positive metastatic breast cancer treated in the randomized trial. Patients were randomized to receive either Pertuzumab in combination with Trastuzumab and Docetaxel or placebo in combination with Trastuzumab and Docetaxel. The median duration of study treatment was 18.1 months for patients in the Pertuzumab group and 11.8 months for patients in the placebo group. No dose adjustment was allowed for Pertuzumab or T rastuzumab. The rates of adverse events that resulted in permanent discontinuation of the entire study treatment were 6.1% for patients in the Pertuzumab group and 5.3% for patients in the placebo group. Adverse events led to the discontinuation of Docetaxel only in 23.6% of patients in the Pertuzumab group and in 23.2% of patients in the placebo group. Table 4 reports the adverse reactions that occurred in at least 10% of the patients in the group treated with Pertuzumab. The most frequent adverse reactions (> 30%) observed with Pertuzumab in combination with Trastuzumab and Docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash and peripheral neuropathy.

The most common adverse reactions grade 3-4 (> 2%) of NCI - CTCAE (version 3) were neutropenia, febrile neutropenia, leukopenia, diarrhea, peripheral neuropathy, anemia, asthenia and fatigue. A higher incidence of febrile neutropenia was observed in Asian patients in both treatment groups compared to patients of other races and other geographic regions. Among Asian patients, the incidence of febrile neutropenia was higher in the group treated with Pertuzumab (26%) compared to the group treated with placebo (12%).

ES 2 736 005 T3

Table 4: Summary of adverse reactions that occur in> 10% of patients in the Pertuzumab treatment group of the randomized trial

<td>Body system / adverse reactions</td><td colspan="2">Pertuzumab + Trastuzumab + Docetaxel</td><td colspan="2">Placebo + Trastuzumab + Docetaxel</td>

<td colspan="2">Frequency Rate%</td><td colspan="2">Frequency Rate%</td>

<td>All grades%</td><td>Grades 3 - 4 %</td><td>All grades%</td><td>Grades 3 - 4 %</td>

<td>General disorders and conditions at the administration site</td><td></td><td></td><td></td><td></td>

<td>Fatigue</td><td> 37,6</td><td> 2,2</td><td> 36,8</td><td> 3,3</td>

<td>Asthenia</td><td> 26,0</td><td> 2,5</td><td> 30,2</td><td> 1,5</td>

<td>Peripheral edema</td><td> 23,1</td><td> 0,5</td><td> 30,0</td><td> 0,8</td>

<td>Inflammation of the mucosa</td><td> 27,8</td><td> 1,5</td><td> 19,9</td><td> 1,0</td>

<td>Pyrexia</td><td> 18,7</td><td> 1,2</td><td> 17,9</td><td> 0,5</td>

<td>Skin and subcutaneous tissue disorders</td><td></td><td></td><td></td><td></td>

<td>Alopecia</td><td> 60,9</td><td> 0,0</td><td> 60,5</td><td> 0,3</td>

<td>Eruption</td><td> 33,7</td><td> 0,7</td><td> 24,2</td><td> 0,8</td>

<td>Nail disorder</td><td> 22,9</td><td> 1,2</td><td> 22,9</td><td> 0,3</td>

<td>Pruritus</td><td> 14,0</td><td> 0,0</td><td> 10,1</td><td> 0,0</td>

<td>Gastrointestinal disorders</td><td></td><td></td><td></td><td></td>

<td>Diarrhea</td><td> 66,8</td><td> 7,9</td><td> 46,3</td><td> 5,0</td>

<td>Sickness</td><td> 42,3</td><td> 1,2</td><td> 41,6</td><td> 0,5</td>

<td>Vomiting</td><td> 24,1</td><td> 1,5</td><td> 23,9</td><td> 1,5</td>

<td>Constipation</td><td> 15,0</td><td> 0,0</td><td> 24,9</td><td> 1,0</td>

<td>Stomatitis</td><td> 18,9</td><td> 0,5</td><td> 15,4</td><td> 0,3</td>

<td>Blood and lymphatic system disorders</td><td></td><td></td><td></td><td></td>

<td>Neutropenia</td><td> 52,8</td><td> 48,9</td><td> 49,6</td><td> 45,8</td>

<td>Anemia</td><td> 23,1</td><td> 2,5</td><td> 18,9</td><td> 3,5</td>

<td>Leukopenia</td><td> 18,2</td><td> 12,3</td><td> 20,4</td><td> 14,6</td>

<td>Febrile neutropenia*</td><td> 13,8</td><td> 13,0</td><td> 7,6</td><td> 7,3</td>

<td>Nervous system disorders</td><td></td><td></td><td></td><td></td>

<td>Peripheral neuropathy</td><td> 32,4</td><td> 3,2</td><td> 33,8</td><td> 2,0</td>

<td>Headache</td><td> 20,9</td><td> 1,2</td><td> 16,9</td><td> 0,5</td>

<td>Dysgeusia</td><td> 18,4</td><td> 0,0</td><td> 15,6</td><td> 0,0</td>

<td>Dizziness</td><td> 12,5</td><td> 0,5</td><td> 12,1</td><td> 0,0</td>

<td>Musculoskeletal and connective tissue disorders</td><td></td><td></td><td></td><td></td>

<td>Myalgia</td><td> 22,9</td><td> 1,0</td><td> 23,9</td><td> 0,8</td>

<td>Arthralgia</td><td> 15,5</td><td> 0,2</td><td> 16,1</td><td> 0,8</td>

<td>Infections and infestations</td><td></td><td></td><td></td><td></td>

<td>Upper respiratory tract infection</td><td> 16,7</td><td> 0,7</td><td> 13,4</td><td> 0,0</td>

<td>Nasopharyngitis</td><td> 11,8</td><td> 0,0</td><td> 12,8</td><td> 0,3</td>

<td>Respiratory, thoracic and mediastinal disorders</td><td></td><td></td><td></td><td></td>

<td>Dyspnoea</td><td> 14,0</td><td> 1,0</td><td> 15,6</td><td> 2,0</td>

<td>Metabolism and nutrition disorders</td><td></td><td></td><td></td><td></td>

<td>Decreased appetite</td><td> 29,2</td><td> 1,7</td><td> 26,4</td><td> 1,5</td>

<td>Eye disorders</td><td></td><td></td><td></td><td></td>

<td>Increased tearing</td><td> 14,0</td><td> 0,0</td><td> 13,9</td><td> 0,0</td>

<td>Psychiatric disorders</td><td></td><td></td><td></td><td></td>

<td>Insomnia</td><td> 13,3</td><td> 0,0</td><td> 13,4</td><td> 0,0</td>

* In this table, this denotes an adverse reaction that has been reported in relation to a fatal outcome.

The following clinically relevant adverse reactions were reported in <10% of patients in the group treated with Pertuzumab:

Skin and subcutaneous tissue disorders: paronychia (7.1% in the group treated with Pertuzumab versus 10 to 3.5% in the group treated with placebo); Respiratory, thoracic and mediastinal disorders: pleural effusion (5.2% in the group treated with Pertuzumab versus 5.8% in the group treated with placebo); Cardiac disorders: left ventricular dysfunction (44% in the Pertuzumab-treated group versus 8.3% in the placebo-treated group) including symptomatic left ventricular systolic dysfunction (LVDV) (1.0% in the Pertuzumab-treated group 1.8% in the placebo group); System disorders

ES 2 736 005 T3 immune: hypersensitivity (10.1% in the group treated with Pertuzumab versus 8.6% in the group treated with placebo).

Adverse reactions reported in patients receiving Pertuzumab and Trastuzumab after Docetaxel discontinuation

In the randomized trial, adverse reactions were reported less frequently after discontinuation of Docetaxel treatment. All adverse reactions in the treatment group with Pertuzumab and Trastuzumab occurred in <10% of patients, with the exception of diarrhea (19.1%), upper respiratory tract infection (12.8%), rash (11, 7%), headache (11.4%) and fatigue (11.1%).

6.2 Immunogenicity

As with all therapeutic proteins, there is the potential for an immune response to Pertuzumab. Patients in the randomized trial were evaluated at multiple time points to detect antibodies against Pertuzumab. Approximately 2.8% (11/386) of the patients in the Pertuzumab-treated group and 6.2% (23/372) of the patients in the placebo-treated group tested positive for anti-Pertuzumab antibodies. Of these 34 patients, none experienced anaphylactic / hypersensitivity reactions that were clearly related to anti-therapeutic antibodies (ATA). The presence of Pertuzumab in the patient's serum at the expected levels at the time of ATA sampling may interfere with the ability of this assay to detect anti-Pertuzumab antibodies. In addition, the assay can detect antibodies against Trastuzumab. As a result, the data may not accurately reflect the true incidence of the development of anti-Pertuzumab antibodies. Immunogenicity data depends largely on the sensitivity and specificity of the test procedures used. Additionally, the observed incidence of a positive result in a test procedure can be influenced by several factors, including sample handling, sample collection time, drug interference, concomitant medication and disease. underlying. For these reasons, comparing the incidence of antibodies against Pertuzumab with the incidence of antibodies against other products can be misleading.

Pharmacological interactions

No pharmacological interactions were observed between Pertuzumab and Trastuzumab or between Pertuzumab and Docetaxel.

Use in specific populations 8.1 Pregnancy

Category D pregnancy

Risk Summary

There are no adequate and well-controlled studies of Pertuzumab in pregnant women. According to findings in animal studies, Pertuzumab can cause fetal harm when administered to a pregnant woman. It is likely that the effects of Pertuzumab are present during all trimesters of pregnancy. Pertuzumab administered to pregnant cynomolgus monkeys resulted in oligohydramnios, delayed fetal renal development and embryofetal death at clinically relevant exposures 2.5 to 20 times greater than the recommended human dose, based on Cmax. If Pertuzumab is administered during pregnancy or if a patient becomes pregnant while receiving Pertuzumab, the patient should be informed about the potential danger to the fetus. If Pertuzumab is administered during pregnancy or if a patient becomes pregnant while receiving Pertuzumab, immediately report exposure to the Genentech Adverse Event Line at 1-888-835-2555. Propose women who may be exposed during pregnancy to enroll in the MotHER Pregnancy Registry by calling 1-800-690-6720 [see Information for patient counseling (17)].

Animal data

Reproductive toxicology studies have been conducted in cynomolgus monkeys. Pregnant monkeys were treated on Gestational Day (GD) 19 with a loading dose of 30 to 150 mg / kg of Pertuzumab, followed by biweekly doses of 10 to 100 mg / kg. These dose levels resulted in clinically relevant exposures 2.5 to 20 times higher than the recommended dose in humans, based on Cmax. Intravenous administration of Pertuzumab from GD19 to GD50 (organogenesis period) was embryotoxic, with dose-dependent increases in embryo-fetal death between GD25 and GD70. The incidences of embryofetal loss were 33, 50 and 85% for mothers treated with biweekly doses of Pertuzumab of 10, 30 and 100 mg / kg, respectively (2.5 to 20 times higher than the recommended dose in

ES 2 736 005 T3 human, based on Cmax.). Oligohydramnios, decrease in relative lung and kidney weights and microscopic evidence of renal hypoplasia consistent with delayed renal development were identified in all Cartuzumab dose groups. Pertuzumab exposure was reported in the descendants of all treated groups, at levels of 29% to 40% of maternal serum levels in GD100.

8.3 Nursing mothers

It is not known whether Pertuzumab is excreted in human milk, but human IgG is excreted in human breast milk. Because many drugs are secreted in human breast milk and due to the potential for serious adverse reactions of Pertuzumab in infants, it must be decided whether to stop breastfeeding or discontinue the drug, taking into account the elimination half-life of Pertuzumab and the importance of drug for the mother [See Warnings and Precautions (5.1), Clinical Pharmacology (12.3)].

8.4 Pediatric use

The safety and efficacy of Pertuzumab have not been established in pediatric patients.

8.5 Geriatric use

Of the 402 patients who received Pertuzumab in the randomized trial, 60 patients (15%) were> 65 years old and 5 patients (1%) were> 75 years old. There were no overall differences in the efficacy and safety of Pertuzumab between these patients and younger patients. Based on a population pharmacokinetic analysis, no significant difference in the pharmacokinetics of Pertuzumab was observed between patients <65 years (n = 306) and patients> 65 years (n = 175).

8.6 Women with the ability to procreate

Pertuzumab can cause embryofetal damage when administered during pregnancy. Patients should be advised on the prevention and planning of pregnancy. Women with the ability to procreate the use of an effective contraceptive should be advised while receiving Pertuzumab and for 6 months after the last dose of Pertuzumab. If Pertuzumab is administered during pregnancy or if a patient becomes pregnant while receiving Pertuzumab, immediately report exposure to the Genentech Adverse Event Line at 1-888-835-2555. Propose women who may be exposed during pregnancy to enroll in the MotHER Pregnancy Registry by calling 1-800-690-6720 [see Information for patient counseling (17)].

8.7 Renal impairment

Pertuzumab dose adjustments are not necessary in patients with mild renal impairment (creatinine clearance [CLcr] 60 to 90 ml / min) or moderate (CLcr 30 to 60 ml / min). No dose adjustment can be recommended for patients with severe renal impairment (CLcr less than 30 ml / min) due to the limited pharmacokinetic data available [see Clinical Pharmacology (12.3)].

8.8 Hepatic impairment

No clinical studies have been conducted to evaluate the effect of liver failure on the pharmacokinetics of Pertuzumab.

OVERDOSE

No drug overdose with Pertuzumab has been reported to date.

Description

Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 (HER2) protein. Pertuzumab is produced by recombinant DNA technology in a culture of mammalian cells (Chinese hamster ovary) that contains the antibiotic, gentamicin. Gentamicin is not detectable in the final product. Pertuzumab has an approximate molecular weight of 148 kDa. Pertuzumab is a sterile, transparent to slightly opalescent, colorless to pale brown liquid for intravenous infusion. Each single-use vial contains 420 mg of Pertuzumab at a concentration of 30 mg / ml in 20 mM L-histidine acetate (pH 6.0), 120 mM sucrose and 0.02% polysorbate 20.

Clinical pharmacology

ES 2 736 005 T3

12.1 Mechanism of action

Pertuzumab targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor 2 (HER2) receptor protein and, therefore, blocks the ligand-dependent heterodimerization of HER2 with other members of the HER family, including EGFR, HER3 and HER4. As a result, Pertuzumab inhibits intracellular signaling initiated by ligand through two major signaling pathways, the mitogen-activated protein kinase (MAP) and phosphoinositide 3-kinase (PI3K). Inhibition of these signaling pathways may result in cell growth arrest and apoptosis, respectively. In addition, Pertuzumab mediates antibody-dependent cellular cytotoxicity (ADCc). While Pertuzumab only inhibited the proliferation of human tumor cells, the combination of Pertuzumab and Trastuzumab significantly increased antitumor activity in xenograft models with HER2 overexpression.

12.2 Pharmacokinetics

Pertuzumab demonstrated a linear pharmacokinetics in a dose range of 2 to 25 mg / kg. Based on a population HR analysis that included 481 patients, the median clearance (CL) of Pertuzumab was 0.24 l / day and the median half-life was 18 days. With an initial dose of 840 mg followed by a maintenance dose of 420 mg every three weeks thereafter, the Pertuzumab concentration in equilibrium was reached after the first maintenance dose. The population's HR analysis did not suggest differences in HR based on age, gender and ethnicity (Japanese vs. non-Japanese). The serum albumin reference level and lean body weight as covariates only exerted a minor influence on HR parameters. Therefore, no dose adjustments are needed based on body weight or reference albumin level. No pharmacological interactions were observed between Pertuzumab and Trastuzumab or between Pertuzumab and Docetaxel in a substudy of 37 patients in the randomized trial. No specific renal failure test has been conducted for Pertuzumab. Based on the results of the population pharmacokinetic analysis, exposure to Pertuzumab in patients with mild renal impairment (CLcr 60 to 90 ml / min, n = 200) and moderate (CLcr 30 to 60 ml / min, n = 71) were similar to that of patients with normal renal function (CLcr greater than 90 ml / min, n = 200). No relationship was observed between CLcr and Pertuzumab exposure in the observed CLcr range (27 to 244 ml / min).

12.3 Cardiac electrophysiology

The effect of Pertuzumab with an initial dose of 840 mg followed by a maintenance dose of 420 mg every three weeks in the QTc interval was evaluated in a subgroup of 20 patients with HER2 positive breast cancer in the randomized trial. No major changes were detected in the mean QT interval (i.e., more than 20 ms) with respect to the placebo based on the Fridericia correction procedure in the trial. A small increase in the average QTc interval (ie, less than 10 ms) cannot be excluded due to the limitations of the trial design.

NON-CLINICAL TOXICOLOGY

13.1 Carcinogenesis, mutagenesis, impaired fertility

There have been no long-term studies in animals to assess the carcinogenic potential of Pertuzumab. No studies have been conducted to evaluate the mutagenic potential of Pertuzumab. No specific fertility studies have been conducted in animals to assess the effect of Pertuzumab. No adverse effects were observed in male and female reproductive organs in repeated dose toxicity studies of up to six months in cynomolgus monkeys.

Clinical studies 14.1 Metastatic breast cancer

The randomized trial was a multi-center, double-blind, placebo-controlled trial of 808 patients with HER2 positive metastatic breast cancer. Breast tumor samples were required to show an overexpression of HER2 defined as an amplification ratio of FISH or IHC 3+> 2.0 determined in a central laboratory. Patients were randomized 1: 1 to receive placebo + Trastuzumab + Docetaxel or Pertuzumab + Trastuzumab + Docetaxel. Randomization was stratified by prior treatment (anti-HER2 treatment or chemotherapy with or without prior adjuvant / neoadjuvant) and geographic region (Europe, North America, South America and Asia). Patients with prior adjuvant or neoadjuvant treatment were required to have a disease-free interval of more than 12 months prior to enrollment in the trial. Pertuzumab was administered intravenously at an initial dose of 840 mg, followed by 420 mg every 3 weeks thereafter. Trastuzumab was administered intravenously at an initial dose of 8 mg / kg, followed by 6 mg / kg every 3 weeks thereafter. Patients were treated with Pertuzumab and Trastuzumab until disease progression, withdrawal of consent or toxicity

ES 2 736 005 T3 unacceptable. Docetaxel was administered as an initial dose of 75 mg / m2 by intravenous infusion every 3 weeks for at least 6 cycles. The dose of Docetaxel could be increased to 100 mg / m2 at the discretion of the investigator if the initial dose was well tolerated.

At the time of the main analysis, the average number of treatment cycles of the study administered was

16.2 in the placebo-treated group and 19.9 in the Pertuzumab group.

The primary endpoint of the randomized trial was progression-free survival (SSP) as assessed by an independent review center (IRF). SSP was defined as the time from the date of randomization to the date of disease progression or death (for any reason) if the death occurred within 18 weeks after the last tumor evaluation. Secondary assessment criteria included overall survival (OS), SSP (evaluated by the researcher), objective response rate (ORT) and duration of response.

The demographic and baseline characteristics of the patients were balanced between the treatment groups. The median age was 54 years (range 22 to 89 years), 59% were white, 32% were Asian and 4% were black. All were women with the exception of 2 patients. 17% of the patients were enrolled in North America, 14% in South America, 38% in Europe and 31% in Asia. The prognostic characteristics of the tumor, including hormonal receptor status (48% positive, 50% negative), the presence of visceral disease (78%) and non-visceral disease only (22%) were similar in the study groups. Approximately half of the patients received prior adjuvant or neoadjuvant chemotherapy or prior anti-HER2 (placebo 47%, Pertuzumab 46%). Among patients with tumors positive for hormonal receptors, 45% received prior adjuvant hormonal treatment and 11% received hormonal treatment for metastatic disease. 11% of patients received prior adjuvant or neoadjuvant Trastuzumab.

The randomized trial demonstrated a statistically significant improvement in the SSP evaluated by IRF in the group treated with Pertuzumab compared to the group treated with placebo [instantaneous risk ratio (CRI) = 0.62 (95% CI: 0.51, 0.75), p <0.0001] and an increase in the median SSP of 6.1 months (median SSP of 18.5 months in the group treated with Pertuzumab compared to 12.4 months in the treated group with placebo) (see Figure 8). The results for the SSP evaluated by the researcher were comparable to those observed for the SSP evaluated by the IRF. Consequential results were observed in several subgroups of patients, including ages (<65 or> 65 years), race, geographic region, prior adjuvant / neoadjuvant anti-HER2 treatment or chemotherapy (yes or no) and previous adjuvant / neoadjuvant Trastuzumab (yes or do not). In the subgroup of patients with negative disease for hormonal receptors (n = 408), the ratio of instantaneous risks was 0.55 (95% CI 0.42, 0.72). In the subgroup of patients with positive disease for hormonal receptors (n = 388), the ratio of instantaneous risks was 0.72 (95% CI 0.55, 0.95). In the subgroup of patients with disease limited to non-visceral metastases (n = 178), the instantaneous risk index was 0.96 (95% CI 0.61, 1.52).

At the time of the SSP analysis, 165 patients had died. More deaths occurred in the placebo-treated group (23.6%) compared to the group treated with Pertuzumab (17.2%). In the interim analysis of the OS, the results were not mature and did not meet the pre-specified detention delimiter for statistical significance. See Table 5 and Figure 10.

ES 2 736 005 T3

Table 5: Summary of the efficacy of the randomized trial

<td>Parameter</td><td>Pertuzumab + Trastuzumab + Docetaxel n = 402</td><td>Placebo + Trastuzumab + Docetaxel n = 406</td><td>CRI (95% CI)</td><td>P value</td>

<td>Survival without progression (independent review) No. of patients with an event Medium months</td><td> 191 (47,5 %) 18,5</td><td> 242 (59,6 %) 12,4</td><td> 0,62 (0,51, 0,75)</td><td> <0,0001</td>

<td>Global survival (intermediate analysis) No. of patients with an event</td><td> 69 (17,2 %)</td><td> 96 (23,6 %)</td><td> 0,64 (0,47, 0,88)</td><td> 0,0053*</td>

<td>Objective response rate (ORR) No. of patients analyzed</td><td></td><td></td><td></td><td></td>

<td>Objective response (RC + RP)</td><td> 343</td><td> 336</td><td></td><td></td>

<td>Full Answer (RC)</td><td> 275 (80,2 %)</td><td> 233 (69,3 %)</td><td></td><td></td>

<td>Partial Response (RP)</td><td> 19 (5,5 %)</td><td> 14 (4,2 %)</td><td></td><td></td>

<td>Median duration of response (months)</td><td></td><td></td><td></td><td></td>

* The CRI value and the p value for the intermediate analysis of overall survival did not meet the predefined detention delimiter (CRI <0.603, p <0.0012).

Method of supply / Storage and handling 16.1 Form of supply

Pertuzumab is supplied in a single-use vial of 420 mg / 14 ml (30 mg / ml) containing a solution without preservatives. NDC 50242-145-01. Store the vials in a refrigerator at a temperature of 2 ° C to 8 ° C (36 ° F to 46 ° F) until the time of use. Keep the vial in the outer packaging to protect it from light.

DO NOT FREEZE. DO NOT SHAKE.

Patient Advice Information

Pregnant women and women with the ability to procreate should be informed that exposure to Pertuzumab can cause fetal harm, including embryo-fetal death or congenital defects [see Warnings and precautions (5.1) and Use in specific populations (8.1)].

Women with the ability to procreate the use of an effective contraceptive should be advised while receiving Pertuzumab and during the 6 months following the last dose of Pertuzumab [see Warnings and Precautions (5.1) and Use in Special Populations (8.6)].

Nursing mothers treated with Pertuzumab should be advised to stop breastfeeding or discontinue treatment with Pertuzumab, taking into account the importance of the drug to the mother [see Use in specific populations (8.3)].

Women who are exposed to Pertuzumab during pregnancy should be proposed to enroll in the MotHER Pregnancy Registry by calling 1-800-690-6720 [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)].

Therefore, complete phase III safety and efficacy data for Pertuzumab as in Example 3 is provided for the article of manufacture in this example. This article of manufacture can be used in a procedure to ensure the safe and effective use of Pertuzumab to treat patients.

EXAMPLE 5

Treatment of early stage breast cancer with Pertuzumab

ES 2 736 005 T3

Anthracyclines (generally used in combination with 5-FU and cyclophosphamide) have a major role in the treatment of breast cancer. Romond et al. NEJM 353 (16): 1673-1684 (2005), and Poole et al. NEJM 355 (18): 1851-1852 (2006).

Taxanes are also an integral part of the standard regimens for the treatment of breast cancer, used in combination with anthracyclines in a regimen known as TAC (Martin et al. NEJM 352 (22): 2302-2313 (2005)) or sequential with anthracyclines in a regimen known as AC-> T (Romond et al., supra; Joensuu et al. NEJM 354 (8): 809-820 (2006)).

Carboplatin is an active and well tolerated chemotherapy agent, and there are studies in breast cancer that show clear efficacy in combination with a taxane and Trastuzumab in a regimen known as TCH (Slamon et al. BCIRG 006. SABS (2007); Robert et al. J. Clin. Oncol. 24: 2786-2792 (2006)). However, in metastatic breast cancer, there are negative data (Forbes et al. BCIRG 007 Proc. Am. Soc. Clin. Oncol. Abstract No. LBA516 (2006)).

A previous neoadjuvant study with Pertuzumab (NeoSphere) evaluated it in combination with Docetaxel and Trastuzumab (Gianni et al. Cancer Research 70 (24) (Suppl. 2) (December 2010)), but not in combination with anthracycline-based chemotherapy or carboplatin.

The following chemotherapy regimens were evaluated in this example:

FEC T breast cancer treatment consisting of 5-fluorouracil, epirubicin and cyclophosphamide.

FEC-> T Sequential chemotherapy, which consists of FEC chemotherapy cycles followed by Docetaxel cycles.

TCH Chemotherapy regimen for the combination of HER2 positive breast cancer comprising taxane (Docetaxel), Carboplatin and Trastuzumab (HERCEPTIN®)

The treatment groups in this study were:

Group A

5-fluorouracil, epirubicin and cyclophosphamide (FEC) cycles followed by Docetaxel (T) (FEC -> T) cycles with Trastuzumab and Pertuzumab administered since the beginning of the chemotherapy regimen (i.e. simultaneously with anthracycline)

5-Fluorouracil (500 mg / m2), epirubicin (100 mg / m2) followed by cyclophosphamide (600 mg / m2) for three cycles, followed by Docetaxel for three cycles with Trastuzumab (8 mg / kg on day 1 of the first epirubicin treatment and 6 mg / kg every 3 weeks thereafter) and Pertuzumab (840 mg on day 1 of treatment with FEC, with 420 mg every 3 weeks thereafter). The initial dose of Docetaxel is 75 mg / m2 for Cycle 4 (first Docetaxel cycle) and then 100 mg / m2 for Cycles 5-6, if a dose-limiting toxicity does not occur. All drugs will be administered intravenously.

OR

B Group

FEC -> T with Trastuzumab and Pertuzumab administered from the start of treatment with taxane (i.e. after anthracycline)

5-Fluorouracil (500 mg / m2), epirubicin (100 mg / m2) followed by cyclophosphamide (600 mg / m2) for three cycles, followed by Docetaxel for three cycles with Trastuzumab (8 mg / kg on day 1 of the first treatment with Docetaxel and 6 mg / kg every 3 weeks thereafter) and Pertuzumab (840 mg on day 1 of the first day of Docetaxel, with 420 mg every 3 weeks thereafter). The initial dose of Docetaxel is 75 mg / m2 for Cycle 4 (first Docetaxel cycle) and then 100 mg / m2 for Cycles 5-6, if a dose-limiting toxicity does not occur. All drugs will be administered intravenously.

OR

Group C

Taxane (Docetaxel), Carboplatin and Trastuzumab (TCH) with Pertuzumab, with both antibodies administered since the beginning of chemotherapy.

Carboplatin (ABC6 with Calvert's formula) followed by Docetaxel on day 1 with Trastuzumab (8 mg / kg on day

ES 2 736 005 T3 of the first treatment with Carboplatin and Docetaxel and 6 mg / kg every 3 weeks thereafter) and Pertuzumab (840 mg on day 1, with 420 mg every 3 weeks thereafter) for six cycles. The dose of Docetaxel is 75 mg / m2 For all cycles. All drugs will be administered intravenously.

All patients will receive Trastuzumab every three weeks for a total of one year from the start of treatment (from Cycle 1 to 17 for patients in Groups A and C and from Cycle 4 to 20 for patients in Group B) whether they receive or no additional chemotherapy.

Main goal

The main objective was assessed when all patients had received six cycles of neoadjuvant treatment; they underwent surgery and all necessary samples were taken or withdrawn from the study, whichever came first.

Secondary objectives

Perform a preliminary evaluation of the activity associated with each regimen, as indicated by the full pathological response rate.

Evaluate the safety profiles of each treatment regimen, including preoperative (neoadjuvant) and postoperative (adjuvant) treatment.

Investigate overall survival, time to clinical response, time to response, disease-free survival and progression-free survival for each treatment group.

Investigate biomarkers that can be associated with the main and secondary efficacy assessment criteria according to each treatment group.

Investigate the rate of conservative breast surgery for all patients with T2-3 tumors for whom a mastectomy was planned at the time of diagnosis.

A global assessment of the risk and benefit of each regime will be carried out.

Overview of the study design

This was an open, randomized, multicenter Phase II trial to assess the tolerability and activity associated with Trastuzumab and Pertuzumab when used in addition to anthracycline-based or carboplatin-based chemotherapy regimens as a neoadjuvant treatment in patients with positive breast cancer for HER2 in early stage and> 2 cm in diameter or locally advanced or inflammatory (see Figure 11).

Six cycles of active chemotherapy were administered. However, if patients were considered to require additional treatment after surgery, it was suggested that those patients who had received FEC-> T should be given CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and that those patients who had received TCH, but considered to require additional chemotherapy, received FEC (5-fluorouracil, epirubicin and cyclophosphamide).

After completion of surgery (and after completion of postoperative chemotherapy, if necessary), patients received radiotherapy according to the local clinical standard and those patients whose tumors were positive for estrogen receptors received hormonal manipulation according to the clinical standard local.

In summary, all patients received at least 6 cycles of active chemotherapy and the two antibodies, Pertuzumab and Trastuzumab plus surgery and radiotherapy (according to the local standard) plus any indicated hormonal manipulation (according to the local standard) and continued receiving Trastuzumab until One year in total.

Patients whose neoadjuvant study treatment was discontinued before surgery were managed according to local practice. Approximately 28 days after the last dose of study medication, patients were asked to perform a final safety assessment (called Final Visit).

Study population

Overview

ES 2 736 005 T3

Female patients, over 18 years of age, with early-stage HER2 positive breast cancer whose primary tumors are> 2 cm without metastases.

Inclusion criteria

one. Female patients with locally advanced, inflammatory or early stage invasive breast cancer, unilateral and histologically confirmed. The initial evaluation of breast cancer should be performed by a doctor with experience in surgery for breast cancer. Patients with inflammatory breast cancer should be able to have a thick needle biopsy.

two. Primary tumor> 2 cm in diameter

3. HER2 positive breast cancer confirmed by a central laboratory. Tumors must be HER2 3+ by IHC or FISH / CISH + (FISH / CISH positivity is mandatory for HER2 2+ tumors).

Four. Availability of FFPE tissue (the method of fixation with buffered formalin will be accepted) for central confirmation of HER2 eligibility (the FFPE tumor tissue will be used later to assess the status of biomarkers).

5. Female patients, age> 18 years.

6. Baseline LVEF> 55% (measured by echocardiography or MUGA).

7. ECOG functional state <1.

8. At least 4 weeks since major unrelated surgery, with full recovery.

Medication and concomitant treatment Allowed treatments

Concomitant treatments are any prescription drug, over-the-counter preparations, herbs or radiotherapy used by a patient at the interval that begins 7 days before the patient is recruited into the study and continues during the study.

The following treatments are allowed during the study:

one. Acceptable contraceptive procedures should be used when the patient or her male partner is not surgically sterilized or the patient does not meet the definition of a postmenopausal study (> 12 months of amenorrhea).

two. H1 and H2 antagonists (eg diphenhydramine, cimetidine)

3. Pain relievers (for example, paracetamol / acetaminophen, meperidine, opioids)

Four. Short-term use of corticosteroids to treat or prevent allergic or infusion reactions

5. Antiemetics (approved prophylactic serotonin antagonists, benzodiazepines, ondansetron, etc.)

6. Drugs to treat diarrhea (for example, loperamide)

7. Colony stimulating factors (for example, G-CSF)

8. Estrogen receptor antagonist (for example, tamoxifen) or aromatase inhibitors (for example, anastrazole, exemestane) after completing postoperative chemotherapy according to local practice.

Treatments excluded

The following treatments are excluded during the study treatment period:

9. Cancer treatments other than those administered in this study, which include cytotoxic chemotherapy, radiation therapy, immunotherapy (except adjuvant radiotherapy for breast cancer after completing chemotherapy or additional adjuvant chemotherapy immediately after surgery, if deemed necessary) and biological antineoplastic treatment.

ES 2 736 005 T3

10. Any targeted treatment.

eleven. Steroid treatment, with the exception of short-term thyroid hormone and corticosteroid replacement therapy, to treat or prevent allergic reactions or infusion.

12. High doses of systemic corticosteroids. The high dose is considered as> 20 mg of dexamethasone per day (or equivalent) for> 7 consecutive days.

13. Any agent in the clinical research phase, except those used for this study.

14. Initiation of medicinal herbs. The use of medicinal herbs initiated before entering the study and continuing during the study are allowed and should be reported in the appropriate CRDe.

fifteen. Any oral hormonal contraceptive, injected or implanted procedure.

RESULTS

The initial characteristics of patients with early-stage breast cancer positive for HER2 are provided in Table 6 below.

Table 6: Baseline characteristics in the security population

<td>Median age, years (interval)</td><td> 49,0 (27-77)</td><td> 49,0 (24-75)</td><td> 50,0 (30-81)</td>

<td>RE and / or positive RPg, n (%)</td><td> 39 (53,4)</td><td> 35 (46,7)</td><td> 40 (51,9)</td>

<td>RE and negative RPg, n (%)</td><td> 34 (46,6)</td><td> 40 (53,3)</td><td> 37 (48,1)</td>

<td rowspan="2">Type of disease, n (%) Operable Locally advanced</td><td> 53 (72,6)</td><td> 54 (72,0)</td><td> 49 (63,6)</td>

<td>Inflammatory</td><td> 5 (6,8)</td><td>4 (5,3)</td><td> 4 (5,2)</td>

<td>HER2 FISH positive, n (%)</td><td> 69 (94,5)</td><td> 69 (92,0)</td><td> 73 (94,8)</td>

<td>Negative FISH, n (%)</td><td> -</td><td> 1 (1,3)</td><td> 2 (2,6)</td>

<td>Unknown, n (%)</td><td> 4(5,5)</td><td> 5 (6,7)</td><td> 2 (2,6)</td>

CBE, clinical breast exam; ECOG PS, Functional Status of the Eastern Cooperative Oncology Group; RE, estrogen receptor; FEC, 5-fluorouracil, epirubicin, cyclophosphamide; FISH, fluorescence in situ hybridization; H, Trastuzumab; IHC, immunohistochemistry; P, Pertuzumab; RPg, progesterone receptor; T, Docetaxel; TCH, Docetaxel / Carboplatin / Trastuzumab

The safety data is shown in Figure 12 and in Tables 7 and 8 below.

Table 7: Global cardiac events

<td>Symptomatic DSVI (grade> 3), n (%)</td><td> -</td><td> 2 (2,7)</td><td> 1 (1,3)</td>

<td>DSVI (all grades), n (%)</td><td> 5(6,9)</td><td> 3 (4,0)</td><td> 5 (6,6)</td>

<td>LVEF decrease> 10% from baseline to <50%, n (%)</td><td> 5(6,9)</td><td> 5 (6,7)</td><td> 5 (6,6)</td>

FEC, 5-fluorouracil, epirubicin, cyclophosphamide; H, Trastuzumab; LVEF, left ventricular ejection fraction; DSVI, left ventricular systolic dysfunction; P, Pertuzumab; T, docetaxel; TCH, Docetaxel / Carboplatin / Trastuzumab

ES 2 736 005 T3

Table 8: Ten most common adverse events of grade> 3 during neoadjuvant treatment

<td>Adverse event, n (%)</td><td>FEC + H + Px3T + H + Px3 n = 72</td><td>FEC x3 T + H + P x3 n = 75</td><td>TCH + P x6 n = 76</td>

<td>Neutropenia</td><td> 34 (47,2)</td><td> 32 (42,7)</td><td> 35 (46,1)</td>

<td>Febrile neutropenia</td><td> 13 (18,1)</td><td> 7 (9,3)</td><td> 13 (17,1)</td>

<td>Leukopenia</td><td> 14 (19,4)</td><td> 9 (12,0)</td><td> 9 (11,8)</td>

<td>Diarrhea</td><td> 3 (4,2)</td><td> 4 (5,3)</td><td> 9 (11,8)</td>

<td>Anemia</td><td> 1 (1,4)</td><td> 2 (2,7)</td><td> 13 (17,1)</td>

<td>Thrombocytopenia</td><td> -</td><td></td><td> 9 (11,8)</td>

<td>Vomiting</td><td> -</td><td> 2 (2,7)</td><td> 4 (5,3)</td>

<td>Fatigue</td><td> -</td><td></td><td> 3 (3,9)</td>

<td>Alanine aminotransferase inc.</td><td> -</td><td> -</td><td> 3 (3,9)</td>

<td>Hypersensitivity to drugs</td><td> 2 (2,8)</td><td> -</td><td> 2 (2,6)</td>

<td colspan="4">FEC, 5-fluorouracil, epirubicin, cyclophosphamide; H, Trastuzumab; P, Pertuzumab; T, docetaxel; TCH, Docetaxel / Carboplatin / Trastuzumab</td>

The efficacy data are provided in Figures 13 and 14, as well as in Tables 9 and 10 below.

Table 9: Clinical response rate during neoadjuvant treatment

<td>Objective response rate, n (%)</td><td> 67 (91,8)</td><td> 71 (94,7)</td><td> 69 (89,6)</td>

<td>Full response rate</td><td> 37 (50,7)</td><td> 21 (28,0)</td><td> 31 (40,3)</td>

<td>Partial response rate</td><td> 30 (41,1)</td><td> 50 (66,7)</td><td> 38 (49,4)</td>

<td>Stable disease, n (%)</td><td> 3 (4,1)</td><td> 1 (1,3)</td><td> 5 (6,5)</td>

<td>Progressive disease, n (%)</td><td></td><td> 1 (1,3)</td><td> -</td>

<td>Without evaluation, n (%)</td><td> 3(4,1)</td><td> 2 (2,7)</td><td> 3 (3,9)</td>

<td colspan="4">FEC, 5-fluorouracil, epirubicin, cyclophosphamide; H, Trastuzumab; P, Pertuzumab; T, docetaxel; TCH, Docetaxel / Carboplatin / Trastuzumab</td>

Table 10: Breast conservation surgery in patients for whom a mastectomy was planned

<td>Achieved, n (%)</td><td> 10 (21,7)</td><td> 6 (16,7)</td><td> 10 (27,0)</td>

<td>Not achieved, n (%)</td><td> 36 (78,3)</td><td> 30 (83,3)</td><td> 27 (73,0)</td>

<td colspan="3">IC, confidence interval; FEC, 5-fluorouracil, epirubicin, cyclophosphamide; H Pertuzumab; T, Docetaxel; TCH, Docetaxel / Carboplatin / Trastuzumab</td><td>, Trastuzumab; P,</td>

CONCLUSIONS • The results of this study indicate a low incidence of symptomatic and asymptomatic DSVI in all groups.

- Simultaneous administration of Pertuzumab plus Trastuzumab with epirubicin resulted in a similar cardiac tolerance compared to sequential administration or the non-anthracycline regimen.

• Neutropenia, febrile neutropenia, leukopenia and diarrhea were the most frequently reported adverse events (grade> 3) in all groups.

• Regardless of the chemotherapy chosen, the combination of Pertuzumab with Trastuzumab in the neoadjuvant context resulted in high rates of complete pathological response (RpC) (57 to 66%).

• TRYPHAENA supports the use of Pertuzumab and Trastuzumab plus anthracycline or carboplatin-based chemotherapy in the neoadjuvant and adjuvant contexts of early-stage breast cancer.

EXAMPLE 6

Co-administration of Pertuzumab and Trastuzumab

In previous phase III clinical trials, Pertuzumab was administered by intravenous (iv) infusion in

ES 2 736 005 T3 IV bags with saline solution to patients with HER2 positive metastatic breast cancer, followed by Trastuzumab and the chemotherapeutic agent Docetaxel also using iv infusions in saline solution. The iv infusion process for Pertuzumab and Trastuzumab lasts approximately 60 to 90 minutes each, with a patient observation period of 30 to 60 minutes after each drug. Due to this treatment regimen per patient, a visit can last up to 7.5 hours in total. As medical payments for drugs and drug delivery services have been under scrutiny in the recent past, emphasis has been placed on business practices to shorten time and increase the use of medical resources in clinical and hospital contexts. Greater efficiency in patient care, compliance and treatment is expected by shortening the time that patients spend in the clinic for each treatment cycle.

As part of the phase III clinical trials of Pertuzumab, Pertuzumab and Trastuzumab are administered sequentially through intravenous (iv) infusion to patients, that is, one drug after another. While Pertuzumab is administered as a fixed dose (420 mg for maintenance, 840 mg for loading), the dose of Trastuzumab is based on weight (6 mg / kg for maintenance doses). To increase comfort and minimize clinical time for patients, the feasibility of co-administration of Pertuzumab with Trastuzumab was evaluated in a single intravenous infusion bag of polyolefin (PO) or polyvinyl chloride (PVC) with 250 ml of 0.9% saline solution. It has been shown that individual monoclonal antibodies are stable in infusion bags (PO and / or PVC) for 24 hours at 5 ° C and 30 ° C. In this study, the compatibility and stability of Pertuzumab (420 mg and 840 mg) mixed with 420 mg of Trastuzumab (dose of 6 mg / kg for a 70 kg patient) or 720 mg (6 mg / kg for one patient) was evaluated 120 kg patient) in IV bags for up to 24 hours at 5 ° C or 30 ° C. Control samples (i.e., Pertuzumab only in an intravenous bag, Trastuzumab only in an intravenous bag) and monoclonal antibody (mAb) mixture samples were evaluated using the existing analytical procedures for Pertuzumab and T rastuzumab, which include color, appearance and clarity (CAC), concentration and turbidity by UV spectrophotometry, particle analysis by HIAC-Royco, size exclusion chromatography (SEC) and ion exchange chromatography (IEC). Additionally, zonal capillary electrophoresis (CZE), isoelectric capillary imaging approach (iCIEF) and power (only the Pertuzumab antiproliferation test) were used to measure mixtures containing 1: 1 Pertuzumab: Trastuzumab and their respective controls (420 mg of Pertuzumab only and 420 mg of Trastuzumab only) alone as a representative case.

The results showed no observable differences with respect to the previous tests in the Pertuzumab and T rastuzumab mixtures between the zero time control (T0) and the sample stored up to 24 hours at 5 ° C or 30 ° C. The physicochemical tests listed above were able to detect both the molecules and the minor variants in the drug mixture, although some overlaps of monoclonal antibody species were observed in the chromatograms. In addition, the drug mixture tested by the Pertuzumab cell proliferation specific inhibition assay showed comparable potency before and after storage. The results of this study showed that mixtures of Pertuzumab and T rastuzumab are physically and chemically stable in an intravenous infusion bag for up to 24 hours at 5 ° C or 30 ° C and can be used for clinical administration if necessary.

Dose I: 840 mg of Pertuzumab / Trastuzumab mixture (420 mg of Pertuzumab and 420 mg of Trastuzumab)

Sample preparation: All procedures were performed aseptically under a laminar flow hood. Samples of IV infusion bags of PO were prepared with three types of drug combinations for this study: 1) 420 mg of Pertuzumab / 420 mg of Trastuzumab mixture, 2) 420 mg of Pertuzumab alone, and 3) 420 mg of Trastuzumab alone. Pertuzumab and Trastuzumab samples alone served as controls.

Trastuzumab was reconstituted with 20 ml of bacteriostatic water for injections (BWFI) and left on the laboratory table for approximately 15 minutes before use. To prepare the sample dose of the Pertuzumab / Trastuzumab mixture, 14 ml of Pertuzumab (420 mg) was diluted directly in the iv infusion bag containing 250 ml nominal of a 0.9% saline solution (excess of ± 25 ml), without removing an equal amount of saline solution, followed by 20 ml of the reconstituted Trastuzumab (420 mg) using an 18 gauge needle at temperature environment. The total concentration of the two proteins combined in the 250 ml iv bag was expected to be approximately 3 mg / ml. Similarly, the iv bag Pertuzumab alone (420 mg) was prepared with 14 ml of the drug at 30 mg / ml diluted directly in an iv infusion bag. The expected final concentration was approximately 1 mg / ml. The IV infusion bag of Trastuzumab alone (420 mg) was also prepared in the same way, except that 20 ml of the drug at 21 mg / ml was added to the bag. The final expected concentration was approximately 1 mg / ml.

The iv bags of PO were mixed thoroughly thoroughly by gentle rocking back and forth several times to ensure homogeneity. After mixing, 10 ml of sample was removed with a syringe from each bag and stored in sterile 15 cc Falcon tubes for use as a sample control diluted at zero time (T0). The iv bags were stored covered with paper

ES 2 736 005 T3 aluminum at 30 ° C for 24 hours (T24). Immediately after storage, the rest of the sample was removed with a syringe from each bag and placed in sterile 250 ml PETG containers. T0 and T24 samples were maintained for up to 24 hours at 5 ° C or analyzed immediately by CAC, UV spectrophotometry (concentration and turbidity), SEC, IEC, CZE, iCIEF, HIAC-Royco, as well as their potency. The product quality of the samples was tested using the SEC and IEC procedures specific to the Pertuzumab and Trastuzumab products, while only the specific potency procedure for Pertuzumab was performed. The other tests used were non-product specific procedures. All tests were qualified for the tests provided in their respective molecules and were used without further optimization of the procedure.

Dose II: 1560 mg of Pertuzumab / Trastuzumab mixture (840 mg of Pertuzumab and 720 mg of Trastuzumab)

Sample preparation: The upper interval of the co-administered dose of mAb (1560 mg of total mixture: 840 mg of Pertuzumab and 720 mg of T rastuzumab) was examined in samples of iv infusion bags of PO and PVC. In the event that an increase in protein aggregation is observed, the propensity to form high molecular weight species (HMWS) will most likely occur at the higher dose of 1560 mg of total mAb instead of in the mixture containing 840 mg. To mitigate the risk during the conditions of use in the high dose range, the IV and PVC infusion bags were studied to ensure that no interactions were observed.

Three types of drug combinations (mixture, 840 mg of Pertuzumab alone and 720 mg of Trastuzumab alone) were prepared and handled similarly to the dose I studied. The Pertuzumab / Trastuzumab mixture contained 28 ml of Pertuzumab (840 mg) diluted directly in iv infusion bags of PO or PVC, followed by 34 ml of the reconstituted Trastuzumab (720 mg) using an 18 gauge needle at room temperature. The total concentration of the two mAbs combined in a single 250 ml iv bag was expected to be approximately 5 mg / ml. For controls, samples of iv infusion bags of Pertuzumab and Trastuzumab were prepared alone and handled similarly to the dose of study I, except that 28 ml of Pertuzumab 30 mg / ml and 34 ml of Trastuzumab 21 mg / were diluted ml directly in each iv infusion bag of PO or PVC. The final expected concentration was approximately 3 mg / ml for the Pertuzumab (840 mg) and Trastuzumab (720 mg) samples alone. The bags were stored uncovered at 5 ° C or 30 ° C for up to 24 hours. T0 and T24 samples were analyzed immediately or maintained for up to 24 to 48 hours at 5 ° C by CAC, UV spectrophotometry (concentration and turbidity), SEC, IEC and HIAC-Royco.

Details of dose types, iv infusion bags, dose and preparation, storage temperatures and tests are summarized in Table 11.

Table 11: Type of IV bag, dose, preparation and study conditions

<td>Bag type iv (approx. 250 ml, NaCl al 0.9%)</td><td>Total dose, concentration</td><td>Dilution (in iv bag of approx. 250 ml)</td><td>Storage temperature (up to 24 hours)</td><td>essays</td>

<td rowspan="3">PO</td><td>840 mg, approx. 3 mg / ml</td><td>Add 14 ml P (~ 30 mg / ml) + 20 ml T (~ 21 mg / ml)</td><td rowspan="3">30 ° C</td><td rowspan="3">CAC, UV spectrophotometry (concentration, turbidity), SEC, IEC, CZE, iCIEF, HIAC-Royco, power</td>

<td>420 mgb, approx. 2 mg / ml</td><td>Add 14 ml P (~ 30 mg / ml)</td>

<td>420 mgb, approx. 1 mg / ml</td><td>Add 20 ml T (~ 21 mg / ml)</td>

<td>PO and PVCa</td><td>1560 mg, approx. 5 mg / ml</td><td>Add 28 ml P (~ 30 mg / ml) + 34 ml T (~ 21 mg / ml)</td><td rowspan="3">5 ° C 30 ° C</td><td rowspan="3">CAC, UV spectrophotometry (concentration and turbidity), SEC, IEC, HIAC-Royco</td>

<td rowspan="2">PO and PVC</td><td>840 mgb, approx. 3 mg / ml</td><td>Add 28 ml P (~ 30 mg / ml)</td>

<td>720 mgb, approx. 3 mg / ml</td><td>Add 34 ml T (~ 21 mg / ml)</td>

to n = 2 b control

P = Pertuzumab; T = Trastuzumab

ES 2 736 005 T3

essays

All samples were kept at 5 ° C or analyzed immediately. Normally, the samples were analyzed within 24 to 48 hours after preparation and storage. The following tests were performed to determine the product quality and short-term stability of samples of the Pertuzumab / Trastuzumab, Pertuzumab alone and Trastuzumab only diluted in iv infusion bags with saline solution. Because several tests, i.e. SEC, IEC, CZE, iCIEF and power, were not optimized for quantitative evaluation of mAb mixtures, only chromatographic or electrophographic overlays of these samples and their individual controls before and after are shown here. from storage at 5 ° C or 30 ° C. For consistency, no values, for example, percentage of peak area, were calculated for the three types of samples from liquid chromatography and electrophoretic tests performed.

Color, appearance and clarity (CAC)

The color, appearance and clarity of the samples were determined by visual inspection under a white and black background white fluorescence light at room temperature. A 3 cc glass vial was filled with 1 ml of each sample for the CAC test. A negative control (purified water) with the corresponding sample volume was used for comparison.

UV-Vis spectrophotometry for concentration measurements

The concentration was determined by measuring the UV absorbance on an HP8453 spectrophotometer by means of the preparation of volumetric samples. The instrument was calibrated with 0.9% saline. Absorbance at Amáx was measured. (278 nm or 279 nm) and 320 nm in a quartz cuvette with a path length of 1 cm for each sample. The absorbance at 320 nm is used to correct the dispersion of the backlight in the solution. The concentration determination was calculated using the absorption capacity of 1.50 (mg / ml)1cm-1 for the Pertuzumab and Trastuzumab molecules.

Amax - A320 1

Protein concentration (mg / ml) = ------------------- χ Dilution factor χ ----------------- ---- length of the

1.50 tray path

Size exclusion chromatography (SEC: specific for Pertuzumab and specific for Trastuzumab)

Each sample was injected into a TOSOHAAS® G3000 SWXL column, 7.8 X 300 mm at room temperature in an AGILENT 1100® HPLC. Eluted peaks were monitored at 280 nm. The chromatographic integrations were analyzed by the CHROMELEON® software. The temperature of the automatic sampler was maintained at 2-8 ° C throughout the series and the mobile phases used were 0.2 M potassium phosphate, 0.25 mM potassium chloride, pH 6.2 and 100 mM potassium phosphate, pH 6.8 for the Pertuzumab test and the Trastuzumab test, respectively. The recommended injection load as specified by the test procedure was 200 pg with an injection volume of 20 pl. The diluted 420 mg sample was injected at a lower load than the recommended amount due to the low concentration of the protein after dilution in the intravenous bags. The maximum injection volume of the HPLC sample loop was 100 pl, which limits the volume that can be injected each time. As a result, injection volumes were modified to 100 pl in 160 pg of protein for the Pertuzumab alone and Trastuzumab alone (420 mg dose group) samples and to 73 pl in 200 pg of protein for the Pertuzumab / Trastuzumab mixture (group dose of 840 mg). The modification in injection volumes has been used in previous studies of iv bags and is necessary when handling low concentration samples.

Ion Exchange Chromatography (IEC)

The analysis of Pertuzumab and Trastuzumab digested with carboxypeptidase B (CpB) for load heterogeneity was used by IEC for each sample. For the Pertuzumab-specific IEC, the samples were analyzed with regular IEC ("regular Pertuzumab IEC") or a modified "fast" version of IEC ("Pertuzumab fast IEC") for a high performance procedure for the purpose of these experiments The IEC tests used a DIONEX® WCX weak cation exchange column equilibrated with solvent A (20 mM MES, 1 mM Na2EDTA pH 6.00) and solvent B (250 mM sodium chloride in solvent A) monitored at 280 nm for Regular IEC of Pertuzumab and Fast IEC of Pertuzumab, while solvent A (10 mM sodium phosphate, pH 7.5) and solvent B (100 mM sodium chloride in solvent A) monitored at 214 nm were used for Trastuzumab in an HPLC AGILENT 1100®. The peaks were eluted at a flow rate of 0.8 ml / min with an increasing gradient of 18% -100% solvent B for 35 minutes and 90

ES 2 736 005 T3 minutes for Pertuzumab regular IEC and Pertuzumab fast IEC, respectively, and 15% -100% solvent B for 55 minutes for Trastuzumab IEC. Column temperatures were maintained at 34 ° C or 42 ° C and ambient for regular Pertuzumab IEC or Rapid Pertuzumab IEC and Trastuzumab IEC, respectively, while the automatic sampler temperature was maintained at 2-8 ° C for the whole process.

Blackout HIAC-ROYCO ™ for subvisible particles

Particle counts in the diluted drug were carried out using the HIAC-ROYCO liquid particle count systemTM Model 9703. The average cumulative numbers of particles at> 10 pm and> 25 pm per milliliter were tabulated in each sample using PHARMSPEC v2.0TM. The test procedure was modified for a small volume procedure, using four 1 ml readings or four 0.4 ml readings per test session while the first reading of each sample was discarded. HIACROYCO ™ samples were degassed under vacuum for approximately 10-15 minutes each. Size less than 10 pm was not collected for this set of samples.

UV-Vis spectrophotometry for turbidity measurements

The optical density of the iv bag samples (1 mg / ml or 3 mg / ml) was measured in a quartz cuvette with a path length of 1 cm in an HP8453 spectrophotometer. Sample readings were calibrated with purified water. Absorbance measurements were recorded at 340 nm, 345 nm, 350 nm, 355 nm and 360 nm and turbidity was expressed as an average of these wavelengths.

Zonal capillary electrophoresis, CZE

The CZE was performed using a PROTEOMELAB PA800 capillary electrophoresis systemTM (Beckman Coulter) with a neutral coating capillary (50 pm x 50 cm). The buffer consisted of ε-amino caproic acid / 40 mM acetic acid, pH 4.5, 0.2% hydroxypropyl methyl cellulose (HPMC). The samples were diluted to 0.5 mg / ml in water and injected into the capillary at 1 psi for 10 seconds. The separation was performed using a voltage of 30 kV for 15 minutes and the species were detected by UV at 214 nm.

CE-SDS-LIF, reduced and not reduced

Each sample was derivatized with 5-carboxytetramethylrodamine succinimidyl ester, a fluorescent dye. After removing the free dye by gel filtration (using NAP-5 columns), non-reduced samples were prepared by adding 40 mM iodoacetamide and heated at 70 ° C for 5 minutes. For the analysis of the reduced samples, the derivatized samples were mixed with SDS to a final concentration of 1% (v / v) and 10 ml of a solution containing 1 M DTT, and heated at 70 ° C for 20 minutes. The prepared samples were analyzed in a Beckman Coulter ProteomeLab PA800 system using a diam. int. 50 mm The 31.2 cm molten silica capillary was maintained at 20 ° C throughout the analysis. Samples were introduced into the capillary by electrokinetic injection at 10 kV for 40 seconds. The separation was performed at a constant voltage of 15 kV in the inverted polarity mode (negative to positive) using a CE-SDS migration buffer as a screening medium. An argon ion laser operating at 488 nm was used for fluorescence excitation with the resulting emission signal monitored at 560 nm.

iCIEF

The distribution of load variants of the Pertuzumab / Trastuzumab, Pertuzumab alone and Trastuzumab mixture was only evaluated using iCIEF using an iCE280 analyzerTM (Convergent Bioscience) with a fluorocarbon coated capillary cartridge (100 pm x 5 cm). The ampholyte solution consisted of a mixture of 0.35% methylcellulose (MC), 0.47% Pharmalyte 3-10 carrier amphibites, 2.66% Pharmalyte 8-10.5 carrier amphibites and pI 7 markers, 05 and 9.77 at 0.20% in purified water. The anolyte was 80 mM phosphoric acid and the catholyte was 100 mM sodium hydroxide, both in 0.10% methylcellulose. The samples were diluted in purified water and CpB was added to each sample diluted in a ratio of enzyme to substrate of 1: 100, followed by incubation at 37 ° C for 20 minutes. The samples treated with CpB were mixed with the ampholyte solution and then focused by introducing a potential of 1500 V for one minute, followed by a potential of 3000 V for 10 minutes. An image of the focused Pertuzumab charge variants was obtained by passing ultraviolet light of 280 nm through the capillary and into the lens of a digital camera with a charge device attached. This image was analyzed below to determine the distribution of the different load variants.

Anti-proliferation potency test

This test procedure is based on the ability of Pertuzumab to inhibit the proliferation of human breast carcinoma cells MDA MB 175 VII. In summary, the cells were seeded in 96-well tissue culture microtiter plates and incubated overnight at 37 ° C under 5% CO2

ES 2 736 005 T3 to allow cell binding. The next day, the culture medium was removed and serial dilutions of each standard, controls and sample (s) were added to the plates. The plates were then incubated for four days at 37 ° C under 5% CO2 and the relative number of viable cells was indirectly quantified using a redox dye, ALAMARBLUE®, according to the manufacturer's protocol. Each sample was analyzed in triplicate and the color changes measured by fluorescence were directly proportional to the number of living cells in the culture. The absorbance of each well was then measured in a 96-well plate fluorescence reader. The results, expressed in relative fluorescence units (RFU), were plotted against antibody concentration. No quantitative measurements were made, nor was it possible, since there was no Pertuzumab / Trastuzumab mix reference available. Therefore, the results are comparisons of dose response curves only.

RESULTS AND ANALYSIS

Dose I: 840 mg of total Pertuzumab / Trastuzumab mixture (420 mg of Pertuzumab and 420 mg of Trastuzumab)

The product quality of the total mixture of 840 mg of Pertuzumab / Trastuzumab (420 mg of Pertuzumab and 420 mg of Trastuzumab), Pertuzumab alone (420 mg) and Trastuzumab alone (420 mg) in iv infusion bags (n = 1) before and after storage at 30 ° C for up to 24 hours, CAC, concentration measurements using UV spectrophotometry, turbidity and HIAC Royco were evaluated (Table 12). IV infusion bags Pertuzumab and Trastuzumab alone are considered controls that were also prepared to assess the ability of the assay to capture appropriate product attributes.

ES 2 736 005 T3

Table 12: Dose of 1840 mg: Stability data for the Pertuzumab / Trastuzumab, Pertuzumab alone or Trastuzumab only in iv IV infusion bags with 0.9% saline solution (n = 1)

<td rowspan="2">Shows</td><td rowspan="2">Type from C bag iv</td><td rowspan="2">mg anti</td><td rowspan="2">Time point Hours)</td><td rowspan="2">Temp. ° C</td><td rowspan="2">CACto liquid</td><td colspan="2">Conc. Turbidity</td><td colspan="2">Dimming light</td>

<td>mg / ml</td><td>AU</td><td>total particles> 10 pm / ml</td><td>total particles> 25 pm / ml</td>

<td>mixture</td><td>PO</td><td> 840</td><td> 0</td><td> 30</td><td>CL, CO</td><td> 2,7</td><td> 0,016</td><td> 1</td><td> 0</td>

<td>pertuzumab /</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>

<td>trastuzumab</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>

<td>pertuzumab</td><td>PO</td><td> 420</td><td> 0</td><td> 30</td><td>CL, CO</td><td> 1,4</td><td> 0,012</td><td> 3</td><td> 0</td>

<td>trastuzumab</td><td>PO</td><td> 420</td><td> 0</td><td> 30</td><td>CL, CO</td><td> 1,5</td><td> 0,012</td><td> 1</td><td> 0</td>

<td colspan="2">saline only</td><td> -</td><td> -</td><td> -</td><td> -</td><td> -</td><td> -</td><td> 2</td><td> 1</td>

<td colspan="2">to Color, Appearance and Clarity:</td><td colspan="5">CL = transparent; SOPL = slightly opalescent, CO</td><td>= colorless.</td><td></td><td></td>

TA = room temperature to Color, appearance and clarity: CL = transparent; SOPL = slightly opalescent, CO = colorless

After storage, the Pertuzumab / Trastuzumab, Pertuzumab alone and Trastuzumab mix samples only appeared as a clear, colorless liquid with no visible particles as observed by CAC. Concentration and turbidity measurements showed no measurable changes in any of the three types of samples after 24 hours at 30 ° C. HIAC Royco particle analysis did not detect more than 6 particles greater than or equal to a size of 10 pm and no particles larger than 25 pm for the Pertuzumab / Trastuzumab, Pertuzumab alone or Trastuzumab mixture only after storage. These results are comparable to the single 0.9% saline solution. The lack of precipitation or visible particles indicates that the mixture and controls are sufficiently stable after dilution in the iv infusion bags with 0.9% saline solution. The Pertuzumab / Trastuzumab mixture diluted in saline solution was subjected to SEC, both specific procedures for Pertuzumab and Trastuzumab, and showed comparable peak profiles between T0 and T24 (Figures 15 and 16). No increases were observed in high molecular weight species (HMWS) and low molecular weight species (LMWS). Similarly, no changes in the main peak were observed in any sample. The main peak and peak area of the HMWS and LMWS overlays cannot be distinguished in the Pertuzumab / Trastuzumab mixture due to the similarity in size between Pertuzumab and Trastuzumab (molecular weight approximately 150 kD). In addition, the comparison of T0 and T24 for the Pertuzumab and Trastuzumab sample alone showed no observable changes in the area of the peak or in the profile, as detected by the two SEC procedures listed above.

Two specific product procedures for IEC of Pertuzumab or Trastuzumab were used to analyze the Pertuzumab / Trastuzumab mixture (Figures 17 and 18). In cation exchange chromatography assays, each molecule typically contains three distinct areas that elute based on relative loading, with acidic variants of early elution, followed by the main peak and, finally, the basic variants of late elution. In the Pertuzumab and Trastuzumab chromatograms alone, the profile presented by the acid variants, the main peak and the basic variants was observed and considered comparable between the starting material and the subsequent storage at 30 ° C. These results are also consistent with previous studies carried out in iv infusion bags with saline solution for Pertuzumab alone or for Trastuzumab alone. For the Pertuzumab / Trastuzumab mixture chromatogram, the Pertuzumab peaks elute first, followed by the Trastuzumab peaks. Due to the nature of the cation exchange separation and the difference in net charge between Pertuzumab (pl ~ 8.7) and Trastuzumab (pl ~ 8.9), two main peaks, or charged main species, are observed in the Pertuzumab mixture / Trastuzumab. In contrast, the SEC test separates based on the hydrodynamic size of the molecule and shows only one major peak due to the similarity in size between Pertuzumab and Trastuzumab. The charged regions of each molecule appear to overlap each other in the Pertuzumab / Trastuzumab mixture. Specifically, the basic variants of Pertuzumab, which are expected to elute in approximately 32 minutes and 35 minutes, appear to overlap with the main peak of Trastuzumab (Figures 17 and 18). In addition, the acidic variants of Trastuzumab, which are expected to elute before the main peak of Trastuzumab, elute along with the basic variants of Pertuzumab and the main peak. Despite the regions of overlapping peaks, the Pertuzumab / Trastuzumab mixture exhibited comparable chromatographic peak profiles before and after storage in iv saline bags for 24 hours at 30 ° C.

Pertuzumab / Trastuzumab, Pertuzumab alone and Trastuzumab only samples are also

ES 2 736 005 T3 analyzed in CE-SDS LIF under non-reduced conditions after storage for 24 hours at 30 ° C. The Pertuzumab / Trastuzumab mixture showed consistent peak profiles without observable changes after storage compared to the starting material (Figures 19 and 20). There is also a very slight variation in the level of the reference value attributed to noise and does not affect the area of the peak. Similar to the cone happens in the SEC, the non-reduced Pertuzumab / Trastuzumab mixture showed only an overlapping monomer that constitutes both the main Pertuzumab and Trastuzumab species. Pertuzumab and Trastuzumab samples alone showed no changes in T0 compared to T24. However, individual molecular attributes, for example the peak level of fragments and the species, between the Pertuzumab / Trastuzumab, Pertuzumab alone and Trastuzumab alone mixture, were observed as expected.

Two main peaks known as the light chain (LC) and heavy chain (HC) are detected at 17 and 21.5 minutes, respectively, when the Pertuzumab / Trastuzumab, Pertuzumab alone and Trastuzumab mixture only underwent CE-SDS LIF reduced with DTT (Figure 20). No increase in fragmentation or concomitant decrease in LC and HC was observed after storage at 30 ° C for the Pertuzumab / Trastuzumab mixture. In addition, no differences in the profile of detectable peaks were observed in the Pertuzumab and Trastuzumab samples alone after storage.

The CZE and iCIEF load separation tests show comparable peak profiles for the Pertuzumab / Trastuzumab mixture after storage at 30 ° C (Figures 21 and 22). Pertuzumab and Trastuzumab alone, when compared to their respective T0, also showed consistent peak profiles without changes after storage. In addition, the presence of several minor species was also observed, although no new peaks were detected after dilution in the saline solution of bag iv. As observed in the load-based IEC test, two main peaks flanked by smaller overlapping peaks can be detected and attributed to the difference in molecular pI.

The potency results based on the comparison of the dose response curve showed no impact on the potency of the Pertuzumab / Trastuzumab mixture stored at 30 ° C for 24 hours compared to its corresponding dose response curve at T0 (Figure 23). Trastuzumab only showed little activity in the Pertuzumab potency test. The dose response curve of the Pertuzumab / Trastuzumab mixture compared to the dose response curve of Pertuzumab or Trastuzumab alone showed that lower doses of the Pertuzumab / Trastuzumab mixture were needed to inhibit cell growth compared with Pertuzumab alone, which suggests that there may be an additive or synergistic effect on the inhibition of cell proliferation of the mixture.

Dose II: 1560 mg of total Pertuzumab / Trastuzumab mixture (840 mg of Pertuzumab and 720 mg of Trastuzumab)

In addition to the study of dose I of 840 mg of total mAb, a higher dose was selected from a mixture of 1560 mg (840 mg of Pertuzumab and 720 mg of T rastuzumab) and its individual drug controls (840 mg of Pertuzumab alone and 720 mg of Trastuzumab alone) to investigate the impact of diluting these three types of mAbs in iv infusion bags of PO or PVC at 5 ° C or 30 ° C for up to 24 hours. The product quality of these iv infusion bags before and after storage it was evaluated by CAC, UV spectrophotometry (concentration and turbidity) and HIAC-ROYCOTM which is summarized in Table 13, and SEC and IEC shown in Figures 24-27.

ES 2 736 005 T3

Table 13: Dose II 1560 mg: Stability data for the Pertuzumab / Trastuzumab, Pertuzumab alone or Trastuzumab alone in iv IV infusion bags with 0.9% saline solution (n = 1 for the control; n = 2 for mix)

<td rowspan="2">Shows</td><td rowspan="2">Bag type iv</td><td rowspan="2">Quantity mg</td><td rowspan="2">Temp. ° C</td><td rowspan="2">Time point Hours)</td><td rowspan="2">CACtoliquid</td><td rowspan="2">Conc. mg / ml</td><td rowspan="2">Turbidity AU</td><td colspan="2">Dimming light</td>

<td>total particles> 10 gm / ml</td><td>total particles> 25 gm / ml</td>

<td>mixture</td><td>PO</td><td> 1560</td><td> 5</td><td> 0</td><td>CL, CO</td><td> 4,9</td><td> 0,013</td><td> 20</td><td> 1</td>

<td>pertuzumab /</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>

<td>trastuzumab</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>

<td>pertuzumab</td><td>PO</td><td> 840</td><td> 5</td><td> 0</td><td>CL, CO</td><td> 2,9</td><td> 0,007</td><td> 1</td><td> 0</td>

<td>trastuzumab</td><td>PO</td><td> 720</td><td> 5</td><td> 0</td><td>CL, CO</td><td> 2,6</td><td> 0,004</td><td> 4</td><td> 0</td>

<td>mixture</td><td>Pvc</td><td> 1560</td><td> 5</td><td> 0</td><td>CL, CO</td><td> 4,9</td><td> 0,016</td><td> 18</td><td> 0</td>

<td>pertuzumab /</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>

<td>trastuzumab</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>

<td>pertuzumab</td><td>Pvc</td><td> 840</td><td> 5</td><td> 0</td><td>CL, CO</td><td> 2,9</td><td> 0,006</td><td> 13</td><td> 0</td>

<td>trastuzumab</td><td>Pvc</td><td> 720</td><td> 5</td><td> 0</td><td>CL, CO</td><td> 2,5</td><td> 0,007</td><td> 7</td><td> 0</td>

<td colspan="2">to Color, Appearance and Clarity:</td><td colspan="2">CL = transparent; SOPL</td><td colspan="3">= slightly opalescent, CO</td><td>= colorless.</td><td></td><td></td>

Two iv infusion bags of PO or PVC were prepared for the Pertuzumab / Trastuzumab mixing condition, while only one iv infusion bag was prepared for the Pertuzumab and Trastuzumab samples alone.

The particles in these bags were determined by visual observation, turbidity measurements and HIACRoyco. All samples appeared transparent and colorless after storage at 5 ° C or 30 ° C for up to 24 hours. No visible particulate material was observed and there were no significant changes in turbidity after storage. For the Pertuzumab / Trastuzumab, Pertuzumab alone and Trastuzumab alone mix, HIAC-Royco showed comparable particle values before and after storage, with an increase from zero to 10 particles per milliliter to> 10 pm and an increase of zero particles per milliliter at> 25 pm for iv infusion bags of both PO and PVC stored at 5 ° C or 30 ° C. Similarly, the Pertuzumab and Trastuzumab samples alone also showed no significant differences in particles before and after storage in iv infusion bags of PO or PVC. For all three types of samples, UV spectrophotometry showed no changes beyond the normal variability of the assay in protein concentration, indicating the absence of adsorption or precipitation of proteins in the iv infusion bags between T0 and T24 hours at 5 ° C or 30 ° C storage.

Pertuzumab / T rastuzumab, Pertuzumab alone and T rastuzumab only samples were analyzed using

ES 2 736 005 T3 the specific SEC and IEC procedures for Pertuzumab or Trastuzumab to assess their physical and chemical stability, respectively, as described above. For the Pertuzumab / Trastuzumab mixture, no changes in the SEC in chromatographic profiles were observed between T0 and T24 hours at 5 ° C or 30 ° C in iv infusion bags of PO or PVC (Figures 24 and 25), with results similar to those of dose I of 840 mg of mixture. In addition, no increase or decrease was observed in high molecular weight species (HMWS), main peak and low molecular weight species (LMWS), indicating a stable dosing solution in the upper ranges of protein content in solution 0.9% saline. Similarly, the Pertuzumab alone and Trastuzumab alone samples also showed no changes after storage in the iv infusion bags.

The IEC analysis, using the specific procedures for Pertuzumab or Trastuzumab, of the Pertuzumab / Trastuzumab mixture was used to assess chemical stability and showed peak profiles of comparable load variants, with no changes observed in relation to the initial time point after of exposure at 5 ° C or 30 ° C in the iv infusion bags of PO or PVC (Figures 26 and 27). Although a significant overlap of the species of the two mAb charge variants was observed, these peak species were not affected by the increase in the mAb content of the iv infusion bag. Pertuzumab alone or Trastuzumab samples only in iv infusion bags of PO or PVC showed no changes before and after exposure at 5 ° C or 30 ° C. These results are consistent with the study of dose I of 840 mg.

CONCLUSION

All physicochemical tests indicate that there are no significant changes in the mixtures (up to 840 mg of Pertuzumab and 720 mg of Trastuzumab for a total dose of 1560 mg) or in individual IV infusion bags (PO or PVC) of Pertuzumab (up to 840 mg) and Trastuzumab (up to 720 mg) for T0 at T24 hours at 5 ° C or 30 ° C. In addition, the potency of the mixture (up to 840 mg) and the individual mAbs before and after storage were comparable. No differences were observed in iv bags which contained the mixture of Pertuzumab and T rastuzumab when compared to the individual mAb components in iv bags throughout this study. The current study also demonstrates that many of the tests used to measure individual mAbs were sufficient to qualitatively characterize the mixture.

EXAMPLE 7

Joint administration of Pertuzumab and Trastuzumab, and polytherapy with vinorelbine

This is a randomized, two-group, open, multicenter, Phase II trial to evaluate Pertuzumab in patients with HER2 positive advanced breast cancer (metastatic or locally advanced) who have not previously received systemic non-hormonal antineoplastic treatment in the metastatic context. . The study design is shown in Figure 28.

Patients are randomized in a 2: 1 ratio to one of two treatment groups:

• Pertuzumab administered in combination with T rastuzumab and vinorelbine (Group A) • Trastuzumab and vinorelbine (control group, Group B)

Group A will consist of two cohorts as follows:

Cohort 1: (first 95 patients): Pertuzumab and Trastuzumab are administered sequentially in separate infusion bags, followed by vinorelbine. Patients will receive Pertuzumab followed by Trastuzumab sequentially in separate infusion bags, followed by vinorelbine.

Pertuzumab (iv infusion)

Administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent 3-week cycle.

Initial infusions of Pertuzumab will be administered for 90 (± 10) minutes and patients will undergo observation for at least 30 minutes from the end of the infusion in search of symptoms related to the infusion, such as fever, chills, etc. The interruption or slowdown of the infusion can reduce these symptoms. If the infusion is well tolerated, subsequent infusions can be administered for 30 (± 10) minutes with patients under observation for another 30 minutes.

Trastuzumab (iv infusion)

On Day 1 of the first treatment cycle as a loading dose of 8 mg / kg, followed by 6 mg / kg on Day 1 of

ES 2 736 005 T3 every subsequent 3-week cycle; to be administered in line with product labeling.

Vinorelbine (iv infusion after Trastuzumab)

On Day 1 and Day 8 of the first treatment cycle at a dose of 25 mg / m2, followed by 30-35 mg / m2 Day 1 and Day 8 of each subsequent 3-week cycle; to be administered in line with product labeling.

Cohort 2: The second 95 patients will receive Pertuzumab and Trastuzumab administered together in a single infusion bag from Cycle 2 onwards, followed by vinorelbine.

Cycle 1 dosage

For the first treatment cycle, Pertuzumab and Trastuzumab will be administered in separate infusion bags as described for Cohort 1.

Vinorelbine will be administered after Pertuzumab and Trastuzumab as described for Cohort 1.

Dosage of subsequent cycles

If the administration of the three drugs was well tolerated in Cycle 1, then on Day 1 of each subsequent 3-week treatment cycle, Pertuzumab 420 mg and Trastuzumab 6 mg / kg will be administered together in a single infusion bag.

The first combined infusion of Pertuzumab and Trastuzumab should be administered for 90 (± 10) minutes with cardiac monitoring and close observation of the reactions associated with the infusion during the procedure, followed by an observation period of 60 minutes. If this first combined infusion is well tolerated, subsequent combined infusions can be administered for 60 (± 10) minutes, followed by a 30-minute observation period with cardiac monitoring.

Vinorelbine will be administered after Pertuzumab and Trastuzumab as described for Cohort 1.

Control group - Group B

A total of 95 patients will be randomized to group B.

Trastuzumab (iv infusion)

On Day 1 of the first treatment cycle as a loading dose of 8 mg / kg, followed by 6 mg / kg on Day 1 of each subsequent 3-week cycle; to be administered in line with product labeling.

Vinorelbine (iv infusion after Trastuzumab)

On Day 1 and Day 8 of the first treatment cycle at a dose of 25 mg / m2 followed by 30-35 mg / m2 Day 1 and Day 8 of each subsequent 3-week cycle; to be administered in line with product labeling.

Criteria of effectiveness evaluation:

Main • To compare the objective global response rates (ORT) evaluated by an independent review committee (IRC) blinded from Pertuzumab administered in combination with Trastuzumab and vinorelbine versus Trastuzumab and vinorelbine

Secondary • Within the Pertuzumab treatment group to compare the efficacy and safety of Pertuzumab and Trastuzumab administered together in a single infusion bag versus conventional sequential administration in separate infusion bags • To compare Pertuzumab administered in combination with Trastuzumab and vinorelbine versus Trastuzumab and vinorelbine with respect to:

◦ TRO evaluated by the researcher ◦ Time to response evaluated by the IRC and the researcher

ES 2 736 005 T3 ◦ Duration of the response assessed by the IRC and the researcher ◦ Survival without progression (SSP) ◦ Time to progression (TTP) ◦ Global survival (SG) ◦ Safety and tolerability

Quality of life (questionnaires EQ-5D and FACT-B)

Inclusion criteria

Patients must meet the following criteria to be eligible for this study according to the schedule of the Evaluation Program:

one. Female or male patients over 18 years.

two. Histological or cytologically confirmed and documented breast adenocarcinoma with metastatic or locally advanced disease not susceptible to curative resection.

3. Positive for HER2 (defined as immunohistochemistry (IHC) 3+ or positive in situ hybridization (ISH)) as assessed by a local laboratory in primary or metastatic tumors (ISH positivity is defined as a ratio of 2.0 or greater for the number of copies of the HER2 gene with respect to the number of signals for CEP17 or, for single probe tests, an HER2 gene count greater than 4).

Four. At least one measurable lesion and / or non-measurable disease evaluable according to the Criteria for Evaluation of Response in Solid Tumors (RECIST) version 1.1.

5. Functional state ECOG 0 or 1.

6. Left ventricular ejection fraction (LVEF) of at least 50%.

7. Negative pregnancy test in women of childbearing age (premenopausal or less than 12 months of amenorrhea after menopause and who have not been surgically sterilized).

8. For women of childbearing age who are sexually active, agree to use a highly effective non-hormonal contraceptive method or two effective non-hormonal contraceptive methods during and for at least 6 months after the study treatment.

9. Fertile men who want and can use effective non-hormonal contraceptive means (barrier contraceptive method along with spermicidal cream or surgical sterilization) for at least 6 months of post-study treatment.

10. Life expectancy of at least 12 weeks.

Exclusion criteria

Patients who meet any of the following exclusion criteria will not be eligible for this study:

one. Prior systemic non-hormonal antineoplastic treatment in the context of metastatic or locally advanced breast cancer.

two. Anti-HER2 agents previously approved or in clinical research phase in any context of breast cancer treatment, except the use of Trastuzumab in the adjuvant or neoadjuvant context.

3. Progression of the disease while receiving Trastuzumab in the adjuvant or neoadjuvant context.

Four. Interval without disease from the end of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrent disease of less than 6 months.

5. History of persistent hematological toxicity of grade 2 or higher (NCI-CTC, version 4.0) resulting from prior adjuvant or neoadjuvant treatment.

ES 2 736 005 T3

6. Radiological tests of central nervous system (CNS) metastases as assessed by CT or MRI

7. Current peripheral neuropathy grade 3 or higher (NCI-CTC, version 4.0).

8. History of other malignancies in the last 5 years, except carcinoma in situ or basal cell carcinoma or cervix.

9. Serious and uncontrolled concomitant disease that would contraindicate the use of any of the drugs in clinical investigation phase used in this study or that would put the patient at high risk of treatment-related complications.

10. Inadequate organ function, evidenced by the following laboratory results:

• Absolute neutrophil count <1,500 cells / mm3 • Platelet count <100,000 cells / mm3 • Hemoglobin <9 g / dl • Total bilirubin greater than the upper limit of the normal range (LSN) (unless the patient has documented Gilbert's syndrome) • AST (SGOT) or ALT (SGPT)> 2.5 x LSN • AST (SGOT) or ALT (SGPT)> 1.5 x LSN with concurrent serum alkaline phosphatase> 2.5 x LSN; serum alkaline phosphatase can be> 2.5 x LSN only if there are bone metastases and AST (SGOT) and ALT (SGPT) <1.5 x LSN • Serum creatinine> 2.0 mg / dl or 177 pmol / l • Reason international standardized (INR) and activated partial thromboplastin time or partial thromboplastin time (aPTT or PTT)> 1.5 x LSN (unless in therapeutic coagulation)

eleven. Uncontrolled hypertension (systolic> 150 mmHg and / or diastolic> 100 mmHg) or clinically significant (i.e. active) cardiovascular disease: stroke (stroke) / stroke or myocardial infarction within 6 months prior to the first study medication , unstable angina, congestive heart failure (CHF) grade II or higher according to the New York Heart Association (NYHA), or severe cardiac arrhythmia requiring medication.

12. Current infection known for HIV, HBV or HCV.

13. Dyspnea at rest due to complications of advanced malignancy or another disease that requires supportive oxygen treatment.

14. Major surgical procedure or significant traumatic injury within 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment.

fifteen. Taking intravenous (iv) antibiotics for infection within 14 days prior to randomization.

16. Current chronic daily treatment with corticosteroids (doses equivalent to or greater than 10 mg / day of methylprednisolone), excluding inhaled steroids.

17. Known hypersensitivity to any of the study drugs or to recombinant human or humanized antibody excipients.

18. History of any treatment in clinical investigation phase within 28 days prior to randomization.

19. Concurrent participation in any clinical trial.

It is anticipated that the treatment in this document will demonstrate the safety and efficacy of the joint administration of Pertuzumab and Trastuzumab from the same intravenous bag (iv) to patients with HER2 positive cancer (exemplified by HER2 positive breast cancer), as well as the safety and efficacy of

ES 2 736 005 T3

Pertuzumab in combination with vinorelbine according to one or more of the primary or secondary efficacy assessment criteria mentioned above.

EXAMPLE 8

Pertuzumab combined with aromatase inhibitors

This example is a randomized, two-group, open, multicenter, phase II study demonstrating the efficacy and safety of Pertuzumab given in combination with Trastuzumab plus an aromatase inhibitor in first-line patients with advanced (metastatic breast cancer) or locally advanced) positive for HER2 and positive for hormonal receptors. The study design is shown in Figure 29.

Main objectives

Compare the progression-free survival (SSP) of Pertuzumab given in combination with Trastuzumab plus an aromatase (AI) versus Trastuzumab plus an AI inhibitor.

Secondary objectives

Compare Pertuzumab given in combination with Trastuzumab plus an AI versus Trastuzumab plus an AI with respect to:

- Global survival (SG)

- Overall response rate (TRO)

- Clinical benefit rate (CBR)

- Duration of the response

- Time until response

- Security and tolerability

- Quality of life (questionnaires EQ-5D)

Trial design

Patients will be randomized in a 1: 1 ratio to one of two treatment groups.

- Pertuzumab in combination with Trastuzumab plus an AI (Group A).

- Trastuzumab plus an AI (control group, Group B).

At the investigator's discretion, patients may also receive induction chemotherapy (a taxane, either Docetaxel or Paclitaxel) in combination with the assigned monoclonal antibody treatment group until the first 18 weeks of the treatment period. In patients receiving induction chemotherapy, treatment with AI will begin after the induction phase of chemotherapy.

The stratification factors for the analysis will be:

- Chosen to receive induction chemotherapy (Yes / No).

- Time elapsed since the adjuvant hormonal treatment (<12 months,> 12 months, or no previous hormonal treatment).

Patients with advanced breast cancer positive for HER2 and positive for hormonal receptors (positive for estrogen receptor (ER) and / or positive for progesterone receptor (RPg)) (metastatic or locally advanced) who have not previously received non-hormonal antineoplastic treatment systemic in the metastatic context.

Inclusion criteria

one. Age greater than or equal to 18 years.

two. Postmenopausal state> 1 year (that meets one or more of the National guide criteria

ES 2 736 005 T3

Comprehensive Cancer Network (NCCN), version 2.2011).

3. Histological or cytologically confirmed and documented breast adenocarcinoma with metastatic or locally advanced disease not susceptible to curative resection.

Four. Positive for HER2 (defined as IHC 3+ or positive ISH) as assessed by a local laboratory in primary or metastatic tumors (ISH positivity is defined as a ratio of 2.0 or greater for the number of copies of the HER2 gene with with respect to the number of signals for CEP17 or, for single probe tests, a HER2 gene count greater than 4).

5. Positive for hormonal receptors, defined as positive for RE and / or positive for RPg evaluated locally as defined in the institutional criteria.

6. At least one measurable lesion and / or a non-measurable disease evaluable according to the Criteria for evaluation of solid tumor response (RECIST) version 1.1.

7. Functional state ECOG 0 or 1.

8. Left ventricular ejection fraction (LVEF) of at least 50%.

9. Life expectancy of at least 12 weeks.

Exclusion criteria

one. Prior systemic non-hormonal antineoplastic treatment in the context of metastatic or locally advanced breast cancer.

two. Interval without disease from the end of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence of less than 6 months.

3. Anti-HER2 agents previously approved or under clinical investigation in any breast cancer treatment context, except for the use of Trastuzumab and / or lapatinib in the neoadjuvant or adjuvant context.

Four. Progression of the disease while receiving Trastuzumab and / or lapatinib in the adjuvant context.

5. History of persistent hematological toxicity of grade 2 or higher (NCI-CTC, version 4.0) resulting from prior adjuvant or neoadjuvant treatment.

6. Radiological tests of metastases in the central nervous system (CNS) as assessed by CT or MRI.

7. Current peripheral neuropathy grade 3 or higher (NCI-CTC, version 4.0).

8. History of other malignancies in the last 5 years, except carcinoma in situ or basal cell carcinoma or cervix.

10. Inadequate organ function, evidenced by the following laboratory results:

- Absolute neutrophil count <1,500 cells / mm3

- Platelet count <100,000 cells / mm3

- Hemoglobin <9 g / dl

- Total bilirubin greater than the upper limit of the normal range (LSN) (unless the patient has documented Gilbert's syndrome)

- AST (SGOT) or ALT (SGPT)> 2.5 x LSN

- AST (SGOT) or ALT (SGPT)> 1.5 x LSN with concurrent serum alkaline phosphatase> 2.5 x LSN; serum alkaline phosphatase can be> 2.5 x LSN only if there are bone metastases and AST (SGOT) and ALT (SGPT)

ES 2 736 005 T3 <1.5 χ LSN

- Serum creatinine> 2.0 mg / dl or 177 pmol / l.

- International normalized ratio (INR) and activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT)> 1.5 χ LSN (unless in therapeutic coagulation).

12. Current infection known for HIV, HBV or HCV.

13. Dyspnea at rest due to complications of advanced malignancy or another disease that requires supportive oxygen treatment.

14. Major surgical procedure or significant traumatic injury within 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment.

fifteen. Lack of physical integrity of the upper gastrointestinal tract, clinically significant malabsorption syndrome or inability to take oral drugs.

16. Taking intravenous antibiotics for infection within 14 days prior to randomization.

17. Current daily chronic corticosteroid treatment (10 mg / day dose of methylprednisolone equivalent), excluding inhaled steroids.

18. Known hypersensitivity to any of the study drugs or to recombinant human or humanized antibody excipients.

19. History of any treatment in clinical investigation phase within 28 days prior to randomization.

twenty. Concurrent participation in any clinical trial.

Group A

Pertuzumab (iv infusion)

Administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent 3-week cycle.

Initial infusions of Pertuzumab will be administered for 90 (± 10) minutes and patients will undergo observation for at least 30 minutes from the end of the infusion for symptoms related to the infusion, such as fever, chills, etc. The interruption or slowdown of the infusion can reduce these symptoms. If the infusion is well tolerated, subsequent infusions can be administered for 30 (± 10) minutes with patients under observation for another 30 minutes.

Trastuzumab (intravenous infusion administered after Pertuzumab): On Day 1 of the first treatment cycle as a loading dose of 8 mg / kg, followed by 6 mg / kg on Day 1 of each subsequent 3-week cycle; to be administered in line with product labeling.

AI (oral)

Administered according to product labeling (anastrozole: 1 mg once daily; letrozole: 2.5 mg once daily).

Induction chemotherapy

Patients receiving induction chemotherapy until the first 18 weeks of the treatment period will receive a taxane (Docetaxel every 3 weeks or paclitaxel weekly) administered according to the corresponding product labeling. Chemotherapy will be given after infusions of monoclonal antibodies (Pertuzumab and / or Trastuzumab).

ES 2 736 005 T3

In patients receiving induction chemotherapy, treatment with AI will begin after the induction phase of chemotherapy.

Control group - Group B

Trastuzumab (iv infusion)

On Day 1 of the first treatment cycle as a loading dose of 8 mg / kg, followed by 6 mg / kg on Day 1 of each subsequent 3-week cycle; to be administered in line with product labeling.

AI (oral)

Administered according to product labeling (anastrozole: 1 mg once daily; letrozole: 2.5 mg once daily).

Induction chemotherapy

Same as for the drug group in clinical research phase.

Criteria of evaluation of main effectiveness

SSP (defined as the time from randomization to the first radiographically documented progression of the disease or death from any cause, whichever comes first).

Secondary efficacy assessment criteria

- SG

- TRO

- CBR

- Duration of the response

- Time until response

Security

- Incidence and severity of adverse events (AA) and serious adverse events (AAG)

- Incidence of ICC

- LVEF throughout the study

- Abnormalities in laboratory tests

It is anticipated that the combination of Pertuzumab, Trastuzumab and AI will be safe and effective in the patient population and that the addition of Pertuzumab to Trastuzumab and an AI will extend progression-free survival (SSP) compared to Trastuzumab plus an AI without Pertuzumab.

EXAMPLE 9

Pertuzumab to improve overall survival (OS) in cancer patients

Background: In the CLEOPATRA study of Example 3 above, 808 patients with metastatic breast cancer positive for first-line HER2 (1L) were randomized to treatment with Placebo + Trastuzumab + Docetaxel (Pla + T + D) or Pertuzumab + Trastuzumab + Docetaxel (P + T + D). The primary assessment criterion for progression-free survival independently revised significantly improved with P + T + D versus Pla + T + D (instantaneous risk ratio (CRI) = 0.62; P <0.0001; medium, 18, 5 vs. 12.4 months) (Example 3 above). This example includes a second intermediate analysis of overall survival (OS) after a longer follow-up.

Procedures: This intermediate global survival (SG) analysis was performed by applying the Lan-DeMets α expense function with the O'Brien-Fleming Detention Delimiter (OBF) to maintain the global Type I error at 5%. According to the number of SG events observed, the OBF delimiter for

ES 2 736 005 T3 the statistical significance in this analysis was P <0.0138. The logarithmic order test, stratified by prior treatment status and geographic region, was used to compare OS among groups in the population by intention to treat. The Kaplan-Meier approach was used to estimate the median of OS in both groups; A stratified Cox proportional hazard model was used to estimate the CRI and 95% CI. Subgroup analyzes of SG were performed for stratification factors and other key reference characteristics.

Results: At the time of this analysis, the median follow-up was 30 months and 267 deaths had occurred (69% of the events planned for the final analysis). The results showed a statistically significant improvement in OS in favor of P + T + D (CRI = 0.66; 95% confidence interval (CI), 0.52-0.84; P = 0.0008). This CRI represents a 34% reduction in the risk of death. The analysis reached statistical significance and, therefore, the confirmatory OS analysis is considered. The median OS was 37.6 months in the Pla group and has not yet been reached in the P group. The treatment effect was generally consistent in predefined subgroups based on reference variables and stratification factors, including: previous (neo) adjuvant treatment (CRI = 0.66; 95% CI, 0.460.94); no prior (neo) adjuvant treatment (CRI = 0.66; 95% CI 0.47-0.93); T (neo) anterior adjuvant (CRI = 0.68; 95% CI, 0.30-1.55); negative disease for hormonal receptors (CRI = 0.57; 95% CI, 0.41 to 0.79); and positive disease for hormonal receptors (CRI = 0.73; 95% CI, 0.50-1.06). Kaplan-Meier estimates of SG rates show a survival benefit with P + T + D at 1, 2 and 3 years.

Table 14: Pertuzumab benefit in overall survival

<td></td><td colspan="3">Survival rates,%</td>

<td>2 years</td><td> 69,4</td><td> 80,7</td><td> 11,3</td>

<td>3 years</td><td> 50,4</td><td> 65,8</td><td> 15,4</td>

The majority of patients received cancer treatment after discontinuation of the study treatment (64% Pla group, 56% P group). Subsequent treatment with agents directed against HER2 (T, lapatinib, T emtansin) was balanced between the groups. The causes of death remained unchanged since the first intermediate analysis of OS, the most common cause being progressive disease. Adverse events that led to death were rare and balanced between the groups.

Conclusions: The treatment of patients with CML 1L positive for HER2 with P + T + D compared to Pla + T + D was associated with an improvement in OS, which was both statistically and clinically significant. These results show that HER2 blockade combined with chemotherapy using the P + T + D regimen can be considered a reference treatment for patients with CMM positive for HER2 in the context of 1L.

This data on the GS can be included in the package leaflet with prescription information about Pertuzumab in an article of manufacture as in Example 4 above, for example.

EXAMPLE 10

Pertuzumab and Trastuzumab with a taxane as a first-line treatment for patients with HER2 positive advanced breast cancer (PERUSE)

Background: Pertuzumab (P), a humanized monoclonal antibody, inhibits the downward signaling of HER2 by binding to the dimerization domain of the receptor and preventing heterodimerization with other members of the HER family. The epitope recognized by P is different from the one linked by Trastuzumab (H), so its complementary mechanisms of action result in a more thorough block of HER2. Data from the phase III CLEOPATRA trial showed a significant improvement in SSP in patients receiving P + H + docetaxel compared to H + docetaxel + placebo as a first-line treatment for metastatic breast cancer (CM) positive for HER2.

Trial design: This is a phase IIIb, multicenter, open-label, single-group study of patients with breast cancer positive for metastatic or locally recurrent HER2 who have not been treated with systemic non-hormonal antineoplastic treatment for metastatic cancer. Patients will receive, P: 840 mg of initial dose, 420 mg c3s iv; H: 8 mg / kg initial dose, 6 mg / kg c3s iv; taxane: docetaxel, paclitaxel or nab-paclitaxel according to local guidelines. The treatment will be administered until the disease progresses or until an unacceptable toxicity. A planned modification of the protocol will allow patients positive for hormonal receptors to receive endocrine treatment together with P + H after completing the taxane treatment, in line with clinical practice.

ES 2 736 005 T3

Eligibility criteria: At the start of the study, patients should have a LVEF of> 50%, a PS ECOG of 0, 1, or 2, a disease-free interval of> 6 months and should not have received previous anti-HER2 agents for the treatment of metastatic CM. Prior H and / or lapatinib are allowed in the (neo) adjuvant context, provided there is no disease progression during treatment. Patients should not have experienced other malignancies in the last 5 years, except for carcinoma in situ of the cervix or basal cell carcinoma. There should be no clinical or radiographic evidence of CNS metastases or clinically significant cardiovascular disease.

Specific objectives: As H was not widely available in the (neo) adjuvant context before CLEOPATRA recruitment, a relatively low proportion of CLEOPATRA patients had previously received H. The PERUSE trial will evaluate the safety and tolerability of P + H + a taxane of choice as a first-line treatment for patients with metastatic or locally advanced CM positive for HER2 in a population of patients who would like to have experienced a broader exposure to treatment H previous.

Statistical procedures: The primary assessment criteria of the PERUSE study are safety and tolerability. Secondary assessment criteria include SSP, SG, TRO, CBR, duration of response, time to response and CdV. The final analysis will be carried out when 1500 patients are followed up for at least 12 months after the last patient has received the last treatment of the study, unless it has been lost during the follow-up, the consent has been withdrawn or has passed away, or if the sponsor finishes the study prematurely. Safety analyzes are planned for after enrollment of ~ 350, 700 and 1000 patients. Additionally, a data and safety monitoring board will review the safety data after ~ 50 patients have been enrolled and then every 6 months.

It is anticipated that Pertuzumab and Trastuzumab with a taxane will be effective as a first-line treatment for patients with HER2 positive advanced breast cancer according to the protocol in this example.

EXAMPLE 11

Pertuzumab in combination with chemotherapy in ovarian cancer with low HER3

Epithelial ovarian cancer, together with primary peritoneal carcinoma and fallopian tube, is the fifth leading cause of cancer-related death in women in Europe (Bray et al. Int. J. Cancer 113: 977-90 (2005) ). Ovarian cancer is often not diagnosed until it has progressed to an advanced stage, at which time the standard treatment is surgical resection followed by chemotherapy. Although the addition of taxanes to platinum-based chemotherapy has resulted in approximately 80% of patients achieving a complete response (CR), the disease reappears in most patients, and more than 50% of patients diagnosed with Epithelial ovarian cancer eventually die from their disease (Du Bois et al. Cancer 115: 1234-1244 (2009)). After the failure of platinum-based chemotherapy, there are few therapeutic options. Patients with platinum-sensitive disease (disease recurrence occurs more than 6 months after the last platinum-based chemotherapy cycle) often undergo platinum-based treatment and have a progression-free survival (SSP) of approximately 9-10; however, for patients with platinum resistant primary disease, the prognosis is considerably worse. For these patients, the new treatment with platinum-based chemotherapy or surgery is not reasonable; in contrast, patients with platinum resistance are often treated with single agent chemotherapy such as topotecan, pegylated liposomal doxorubicin (PLD), paclitaxel and gemcitabine.

Objective response rates for patients with platinum resistant disease range between 10 and 20%, while the median progression-free survival (SSP) varies between 3.5 and 4 months. Platinum resistant disease is not curable; Treatment goals for these patients include symptom relief, prolonged survival and improvements in quality of life (CdV). In general, the results of the main clinical trials conducted in the last 20 years show that the median SSP for patients with advanced disease ranges between 16 and 23 months, while the median overall survival (OS) varies between 31 and 65 months.

Most ovarian cancer cell lines and many ovarian cancer biopsy samples express all members of the HER receptor family (Campiglio et al. J. Cell Biochem 73: 522-32 (1999)). EGFR and HER2 have been studied more extensively and multiple agents targeting the receptor or associated intracellular tyrosine kinases have been tested.

In a recent study, quantitative analyzes of the HER2 protein showed that malignant ovarian tumors have significantly higher levels of HER2 compared to benign ovarian tumors and normal ovaries. In addition, a correlation between HER2 and HER3 protein levels has been observed (Steffensen et al. Int J Oncol. 33: 195-204 (2008)). Studies in cell culture systems have

ES 2 736 005 T3 demonstrated that heregulin-activated HER3-HER2 heterodimers produce the strongest transformation and proliferation responses of any possible receptor combination (Pinkas-Kramarski et al. EMBO J. 15: 2452-67 (1996); Riese et al. Mol Cell Biol 15: 5770-6 (1995) Errata in: Mol Cell Biol 16: 735 (1996)). The potency of these biological responses is probably the result of double and effective activation of the MAP kinase and PI3 kinase pathways. In addition, HER3 is the most potent activator of the PI3 kinase / AKT pathway (Olayioye et al. EMBO J 19: 3159-67 (2000)). Studies in breast cancer cell lines amplified with HER2 show that HER3 but not EGFR was critical for HER2 signaling, and that HER3 inhibited growth in three-dimensional culture and induced rapid regression of xenograft tumor in vivo (Lee-Hoeflich et al. Cancer Res 68): 5878-87 (2008)).

Additionally, HER3 expression has been implicated as a possible risk factor in ovarian cancer (Tanner et al. J Clin Oncol 24: 4317-23 (2006)).

In a multicenter Phase II trial (TOC2689g) in patients with advanced ovarian cancer who had a recurrence after platinum treatment or were refractory to platinum-based chemotherapy, patients who enrolled in Cohort 1 (n = 61) received a loading dose of 840 mg of Pertuzumab, followed by 420 mg of Pertuzumab on Day 1 of each 3-week cycle, and patients in Cohort 2 (n = 62) received 1050 mg of Pertuzumab on Day 1 of each 3-week cycle. Similar results were observed in both cohorts in terms of overall and median SSP response rate. Eight patients (4 of each cohort) had evidence of stable disease (EE) that lasted at least 6 months. The median SSP and OS were 6.6 weeks and 52.7 weeks, respectively, for the global population.

The results of this study led to two randomized Phase II trials in platinum-sensitive and platinum-resistant populations. The TOC3258g study evaluated the efficacy and safety of gemcitabine + Pertuzumab versus gemcitabine + placebo in patients with advanced ovarian, primary peritoneal or fallopian tube cancers resistant to platinum-based chemotherapy (Amler et al. J Clin Oncol 26: 5552 (2008)). The study allowed patients to receive Pertuzumab at the time of disease progression. There was a median SSP of 2.6 months in the gemcitabine + placebo group and 2.9 months in the gemcitabine + Pertuzumab group. The median OS was similar between the treatment groups. Of the most common adverse events (AA), those that increased (in at least 6 patients) in the cohort treated with Pertuzumab included fatigue, nausea, diarrhea, back pain, dyspepsia, stomatitis, headache, epistaxis, rhinorrhea, rash and grade 3-4 neutropenia.

In the BO17931 study, 149 ovarian cancer patients who had a recurrence 6 months after a platinum-based treatment were randomized to receive a combination of paclitaxel and carboplatin or gemcitabine with or without Pertuzumab. After 6 treatment cycles, chemotherapy was discontinued and patients in the chemotherapy group + Pertuzumab continued to receive Pertuzumab only for up to 11 additional cycles (a total of 17 cycles of Pertuzumab). There were no significant differences in the SSP or the SG for the global group. The median SSP was 34.1 weeks for the chemotherapy group + Pertuzumab versus 31.3 for the chemotherapy group alone; however, an exploratory subgroup analysis of HER3 mRNA expression with an untreated interval of 6 to 12 months indicated a trend towards clinical benefit in patients expressing high levels of HER3 mRNA (Kaye et al. J Clin Oncol 26: 5520 (2008)).

Tissue tissue samples from patients included in both randomized Phase II studies were examined by polymerase chain reaction with quantitative reverse transcriptase (qRT-PCR) to determine mRNA expression levels of hEr EGFR, HER2 receptors , HER3 and two HER ligands: anfirregulina and betacelulina.

Only the expression of tumor HER3 mRNA was associated with a significant difference in the SSP. For patients who achieved a clinical response, RP was observed in 9 patients in the gemcitabine + Pertuzumab group and in 3 in the gemcitabine + placebo group. Six of the patients who received gemcitabine + Pertuzumab with RP had tumor HER3 mRNA levels lower than the median level. In contrast, no patient in the gemcitabine + placebo group whose levels of HER3 mRNA in the tumor were lower than the median level of the study population experienced RP. Another 6 patients achieved RP and all these patients had levels of HER3 mRNA in the tumor at or above the median level of the study population. Of these patients, 3 received gemcitabine + Pertuzumab and 3 received gemcitabine + placebo, suggesting that there is no effect of Pertuzumab in this population.

Patients with low expression of HER3 mRNA (lower than the median level of the study population) demonstrated an instantaneous risk ratio (CRI) of SSP of 0.32 in contrast to 1.68 for patients with mRNA expression of HER3 greater than or equal to the median level; that is, the effect of adding Pertuzumab was in the opposite direction. No significant benefit was detected in OS for patients with low expression of HER3 mRNA; however, a trend towards higher OS was observed in patients receiving Pertuzumab. The OS for patients with a high mRNA expression of HER3 demonstrated a CRI of 1.59.

ES 2 736 005 T3

To assess the prognostic value, the expression of the HER3 mRNA was correlated with the SSP and the SG for the patients of the gemcitabine + placebo group. The median SSP was 1.4 months for patients with low expression of HER3 mRNA (n = 35), compared with 5.5 months for patients with high expression of HER3 mRNA (n = 24). Similarly, the median OS for patients with low expression of HER3 mRNA was 8.4 months, compared with 18.2 months for patients with high expression of HER3 mRNA.

In study BO17931, in patients with low expression of HER3 mRNA (below the median level of this study population), no treatment effect was observed. However, in an exploratory analysis of patients with an untreated interval of 6 to 12 months, there was a trend towards the benefit of the combination of chemotherapy with Pertuzumab in terms of SSP.

Overview of this study

This is a multicenter trial with two parts; a part 1 of non-randomized security discussion and a part 2, double-blind, randomized.

Part 1 will be carried out to assess the safety and tolerability of Pertuzumab in a new combination with two chemotherapeutic agents (topotecan or paclitaxel). Part 2 of the trial is a prospective, double-blind, placebo-controlled, two-group, multicenter, Pertuzumab trial in combination with chemotherapy (topotecan, paclitaxel or gemcitabine). Patients will receive trial medication until disease progression according to the criteria of Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, disease progression according to the criteria of the CA-125 evaluable disease of Gynecologic Cancer Intergroup (GCIG), unacceptable toxicity, withdrawal of consent or death. The SSP will be evaluated in Part 1 of the trial, but due to the small number of patients and SSP events per cohort, the results will only be descriptive. The trial design for Part 1 of the study is provided in Figure 30.

In Part 2 of the trial, patients will be randomized in a 1: 1 ratio to receive:

- Group A: Pertuzumab in combination with chemotherapy (topotecan, paclitaxel or gemcitabine), or

- Group B: Pertuzumab-placebo plus chemotherapy (topotecan, paclitaxel or gemcitabine).

The medication allocation of the study will be double-blind as to whether the patient receives Pertuzumab or Pertuzumab-placebo. The chemotherapy agent assigned will be at the discretion of the investigator.

The stratification factors for Part 2 of the trial will be:

- Selected chemotherapy cohort (topotecan vs. paclitaxel vs. gemcitabine).

- Previous antiangiogenic treatment (yes vs. no). If a patient has previously participated in a blind trial with an antiangiogenic agent, he will be enrolled in the same stratum with patients known to have previously received an antiangiogenic agent.

- Interval without treatment (IST) from platinum treatment (strictly less than 3 months vs. 3 to 6 months inclusive, before the first treatment of the study).

The trial design for Part 2 of the study is provided in Figure 31.

Main objectives of the study:

Part 1: The main objective of Part 1 of this study is to determine the safety and tolerability of Pertuzumab in combination with topotecan or paclitaxel.

Part 2: The main objective of Part 2 of this study is to determine if Pertuzumab plus chemotherapy is superior to placebo plus chemotherapy as measured by the SSP.

Secondary objectives of the study:

Part 1: The secondary objective of Part 1 of this study is to descriptively evaluate Pertuzumab's SSP in combination with topotecan or paclitaxel.

Part 2: The secondary objectives of Part 2 of this study are to determine whether Pertuzumab plus chemotherapy is superior to placebo plus chemotherapy with respect to:

ES 2 736 005 T3

- SG.

- Objective response rate.

- Interval without biological progression (ISPbio).

- Security and tolerability.

- CdV.

Criteria of effectiveness evaluation

The following efficacy assessment criteria will be measured in Part 1 of the trial:

- SSP, which is defined as the time from randomization in Part 1 of the trial to disease progression according to RECIST version 1.1 or according to the GClG criteria in the CA-125 evaluable disease or death from any cause, whichever comes first.

The criteria for evaluating efficacy for Part 2 of the trial are the following:

- SSP, which is defined as the time from randomization in Part 2 of the trial to disease progression according to RECIST version 1.1 or according to the GCIG criteria in the CA-125 evaluable disease or death for whatever reason, whichever comes first.

- SG, which is defined as the time from randomization in Part 2 of the trial until death from any cause.

- Objective response rate (TRO), which will be based on RECIST version 1.1 and will be assessed using the best overall response (MRG) (confirmed); defined as the best response recorded from the start of treatment in Part 2 of the trial to the progression / recurrence of the disease (taking as reference the PD, the smallest measurements recorded since the start of treatment in Part 2 of the trial). Patients must undergo two consecutive evaluations of partial response (RP) or complete response (CR) to be considered as responders. RP or CR should be confirmed by 2 consecutive tumor evaluations separated by at least 4 weeks. Only patients with measurable disease at the start of the study will be included in the objective response analysis.

- Patients who have a response according to RECIST version 1.1 and who use the 50% response criteria for CA-125 are defined as responders, while patients who only have one response as defined by RECIST are defined as responders according to RECIST. Patients who do not have a response according to RECIST, but have a defined response using the 50% response criteria for CA-125 are defined as responders according to CA-125.

- PFI bio, defined based on a progressive series elevation of the serum CA-125 (evaluated according to the CGIG criteria) as the time from the date of randomization in Part 2 of the trial until the first documented increase in the levels of CA-125 to: twice the upper limit of the normal range (for patients with CA-125 normal pretreatment or CA-125 high pretreatment and initial normalization during treatment), or twice the nadir value (for patients with high initial CA-125 who did not normalize during treatment).

Security Assessment Criteria

In Part 1 of the study, safety and tolerability will be assessed after all patients have received 3 cycles of treatment.

In addition, the safety assessment criteria for this study will be evaluated in Parts 1 and 2 of the study, and are as follows:

- Incidence, nature and severity of all AA, serious adverse events (AAG), AA with NCI-CTCAE version 4.0 degrees> 3 and AA that caused premature withdrawal of study medication.

- Premature withdrawal of the study and treatment of the study.

- Cardiac disorders / Incidence of congestive heart failure

- Abnormalities in laboratory tests.

ES 2 736 005 T3

- Left ventricular ejection fraction (LVEF)

Inclusion criteria

one. Female patients over 18 years.

two. Low levels of HER3 mRNA expression (concentration ratio equal to or less than 2.81, as assessed by qRT-PCR on a COBAS z480® instrument).

3. Histological or cytologically confirmed and documented epithelial ovarian cancer that is resistant or refractory to platinum (defined as progression within 6 months after the end of a minimum of 4 cycles of platinum treatment or progression during platinum treatment).

Four. At least one measurable lesion and / or non-measurable disease according to version 1.1 of RECIST, or evaluable cancer antigen disease 125 (CA-125) according to the criteria of the Gynecologic Center Intergroup (GCIG). The following histological types are suitable:

- Adenocarcinoma not otherwise specified

- Clear cell adenocarcinoma

- Endometrioid adenocarcinoma

- Brenner's malignant tumor

- Mixed epithelial carcinoma including mixed malignant tumors of Müller

- Mucinous adenocarcinoma

- serous adenocarcinoma

- Transitional cell carcinoma

- undifferentiated carcinoma

5. Functional status of the Eastern Cooperative Oncology Group (ECOG) from 0 to 2.

6. LVEF greater than or equal to 55%.

Dosage and administration of Pertuzumab

Pertuzumab and Pertuzumab-placebo will be administered as an intravenous infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent 3-week cycle. The initial Pertuzumab / Pertuzumab-placebo infusion will be administered for 60 minutes, followed by a 60-minute observation period in a sitting position if the infusion is well tolerated, subsequent infusions can be administered for 30 minutes, followed by a period of 30-minute observation, after which the chemotherapeutic agent will be administered. Prior medication should be implemented in accordance with local practices and chosen chemotherapy.

Dosage and administration of topotecan

Topotecan should be administered at 1.25 mg / m2 as an intravenous infusion of 30 minutes daily on Days 1 to 5 every 3 weeks, according to the instructions in the summary of the characteristics of the product.

Dosage and administration of paclitaxel

Paclitaxel should be administered at 80 mg / m2 as an iv infusion of 1 hour on Days 1, 8, 15 and 22. Pharmacists should follow the summary of the characteristics of the product to obtain information on the preparation and administration of the dose of 80 mg / m2.

Dosage and administration of gemcitabine

Gemcitabine (only Part 2 of the study) should be administered at 1000 mg / m2 as an intravenous infusion of 30 minutes on Days 1 and 8 every 3 weeks according to the instructions described in the summary of the characteristics of the product.

ES 2 736 005 T3

HER3 mRNA expression

Patients who specifically consent to the collection and testing of samples of major tumor tissue will be asked to assess the level of HER3 mRNA, including the levels of mRNA and proteins of other HER family receptors, for example, HER2, before they give their consent to participate in the trial. Only patients with tumors that express low levels of HER3 mRNA will be eligible to participate in the trial.

During the initial screening of the HER3 mRNA levels, other HER family receptors (eg, EGFR, HER2 or HER4) will be evaluated at the mRNA level and / or protein level in parallel to the HER3 evaluation, to obtain information more complete status of the HER family receptors by mRNA level.

The cut-off value defined for eligibility for the study is defined as a concentration ratio <2.81 as assessed by qRT-PCR on a COBAS z480® instrument using the “HER2 & HER3 mRNA expression assay (qRT- PCR) in COBAS® ”provided by Roche Molecular Diagnostics. The justification of the definition of cut is based on a cut modeling in previous studies, as well as a transformation function that had to be introduced since the test was changed to a new instrument, the COBAS Z480®. It is anticipated that 40-50% of patients screened will have levels of HER3 mRNA below the cut-off value of 2.81 and that 30% of patients expressing low levels of HER3 mRNA will not be eligible for enrollment due to other inclusion / exclusion criteria.

Before screening, the presentation of a tumor sample fixed with formalin and included in paraffin from the primary tumor of the original surgery will be required for all patients; Cytology samples are not acceptable replacements. Patients will be evaluated for the level of HER3 mRNA expression, as well as the levels of mRNA and protein expression of other HER family receptors through the use of a qRT-PCR and IHC assay. Such evaluation of the expression of the HER receptor mRNA / protein will be performed after obtaining the informed consent of the patient at any time after the main surgery and before screening.

It is anticipated that Pertuzumab in combination with topotecan or paclitaxel will be safe and effective in patients with epithelial ovarian cancer, primary peritoneal or fallopian tube.

In addition, it is anticipated that Pertuzumab plus chemotherapy (topotecan, paclitaxel or gemcitabine) will be superior to placebo plus chemotherapy in patients with epithelial ovarian cancer, primary peritoneal or fallopian tube, where efficacy is measured by SSP.

ES 2 736 005 T3

LIST OF SEQUENCES <110> Genentech, Inc. et al.

<120> PERTUZUMAB, TRASTUZUMAB, DOCETAXEL AND CARBOPLATIN FOR THE TREATMENT OF BREAST CANCER IN THE EARLY PHASE <130> P4753R1-WO <141> 2012-10-11 <150> US 61 / 547,535 <151> 10-14-2011 < 150> US 61 / 567.015 <151> 05-12-2011 <150> US 61 / 657.669 <151> 08-06-2012 <150> US 61 / 682.037 <151> 08-10-2012 <150> US 61 / 694,584 <151> 08-29-2012 <160> 22 <210> 1 <211> 195 <212> PRT <213> Homo sapiens <400> 1

<td colspan="2">Thr gln one</td><td>Val</td><td>Cys</td><td>Thr 5</td><td>Gly</td><td colspan="3">Thr Asp Met</td><td>Lys 10</td><td colspan="2">Leu Arg</td><td>Leu</td><td>Pro</td><td>To fifteen</td>

ES 2 736 005 T3

<210> 2 <211> 124 <212> PRT <213> Homo sapiens <400> 2

<td>Thr one</td><td>Val</td><td>Cys</td><td colspan="2">Gly wing 5</td><td colspan="2">Gly Cys</td><td>To</td><td colspan="3">Arg Cys Lys 10</td><td>Gly</td><td>Pro</td><td>Leu</td><td>Pro fifteen</td>

<210> 3 <211> 169 <212> PRT <213> Homo sapiens <400> 3

Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu Val Arg Ala Val 15 1015

Thr Ser Ala Asn lie Gln Glu Phe Ala Gly Cys Lys Lys lie Phe

2530

Gly Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp Pro Ala

4045

Ser Asn Thr Ala Pro Leu Gln Pro Glu Gln Leu Gln Val Phe Glu

5560

Thr Leu Glu Glu lie Thr Gly Tyr Leu Tyr lie Ser Ala Trp Pro 65 7075

ES 2 736 005 T3

<210> 4 <211> 142 <212> PRT <213> Homo sapiens <400> 4

Cys His Gln Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro 15 1015

Thr Gln Cys Val Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys 20 2530

Val Glu Glu Cys Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val 35 4045

Asn Ala Arg His Cys Leu Pro Cys His Pro Glu Cys Gln Pro Gln

5560

Asn Gly Ser Val Thr Cys Phe Gly Pro Glu Ala Asp Gln Cys Val

7075

Ala Cys Ala His Tyr Lys Asp Pro Pro Phe Cys Val Ala Arg Cys

8590

Pro Ser Gly Val Lys Pro Asp Leu Ser Tyr Met Pro lie Trp Lys 95 100 105

Phe Pro Asp Glu Glu Gly Ala Cys Gln Pro Cys Pro lie Asn Cys

110 115120

Thr His Ser Cys Val Asp Leu Asp Asp Lys Gly Cys Pro Wing Glu 125 130135

Gln Arg Ala Ser Pro Leu Thr

140 <210> 5 <211> 107 <212> PRT <213> Mus musculus <400> 5

ES 2 736 005 T3

100 105

He Lys <210> 6 <211> 119 <212> PRT <213> Mus musculus <400> 6

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly 15 1015

Thr Ser Val Lys He Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr 20 2530

Asp Tyr Thr Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu 35 4045

Glu Trp He Gly Asp Val Asn Pro Asn Ser Gly Gly Ser He Tyr

5560

Asn Gln Arg Phe Lys Gly Lys Ala Ser Leu Thr Val Asp Arg Ser

7075

Be Arg He Val Tyr Met Glu Leu Arg Be Leu Thr Phe Glu Asp

8590

Thr Wing Val Tyr Tyr Cys Wing Arg Asn Leu Gly Pro Ser Phe Tyr 95 100 105

Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser

110115 <210> 7 <211> 107 <212> PRT <213> Artificial sequence <220>

<223> The sequence is synthesized.

<400> 7

ES 2 736 005 T3

70 75

Be Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln

8590

Tyr Tyr lie Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu

100105 lie Lys <210> 8 <211> 119 <212> PRT <213> Artificial sequence <220>

<223> The sequence is synthesized.

<400> 8

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly

1015

Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr PheThr

2530

Asp Tyr Thr Met Asp Trp Val Arg Gln Wing Pro Gly Lys GlyLeu

4045

Glu Trp Val Wing Asp Val Asn Pro Asn Ser Gly Gly Ser lieTyr

5560

Asn Gln Arg Phe Lys Gly Arg Phe Thr Leu Ser Val Asp ArgSer

7075

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala GluAsp

8590

Thr Wing Val Tyr Tyr Cys Wing Arg Asn Leu Gly Pro Ser PheTyr

100105

Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val SerSer

110115 <210> 9 <211> 107 <212> PRT <213> Artificial sequence <220>

<223> The sequence is synthesized.

ES 2 736 005 T3 <400> 9

<td>Asp one</td><td>lie</td><td>Gln</td><td>Met</td><td>Thr 5</td><td>Gln</td><td>Be</td><td>Pro</td><td>Be</td><td>Be 10</td><td>Leu</td><td>Be</td><td>To</td><td>Be</td><td>Val fifteen</td>

<td>Gly</td><td>Asp</td><td>Arg</td><td>Val</td><td>Thr twenty</td><td>lie</td><td>Thr</td><td>Cys</td><td>Arg</td><td>To 25</td><td>Be</td><td>Gln</td><td>Be</td><td>lie</td><td>Be 30</td>

<td>Leu</td><td>Leu</td><td>lie</td><td>Tyr</td><td>To fifty</td><td>To</td><td>Be</td><td>Be</td><td>Leu</td><td>Glu 55</td><td>Be</td><td>Gly</td><td>Val</td><td>Pro</td><td>Be 60</td>

lie Lys <210> 10 <211> 119 <212> PRT <213> Artificial sequence <220>

<223> The sequence is synthesized.

<400> 10

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly 15 1015

Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr PheSer

2530

Be Tyr Wing Met Be Trp Val Arg Gln Wing Pro Gly Lys GlyLeu

4045

Glu Trp Val Wing Val lie Ser Gly Asp Gly Gly Ser Thr TyrTyr

5560

Wing Asp Ser Val Lys Gly Arg Phe Thr lie Ser Arg Asp AsnSer

7075

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala GluAsp

8590

Thr Wing Val Tyr Tyr Cys Wing Arg Gly Arg Val Gly Tyr SerLeu

100105

Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val SerSer

110115 <210> 11 <211> 214 <212> PRT <213> Artificial sequence

ES 2 736 005 T3 <220>

<223> The sequence is synthesized.

<400>11

Asp He Gln Met Thr Gln Be Pro Be Be Leu Be Wing Be Val 15 1015

Gly Asp Arg Val Thr lie Thr Cys Lys Ala Ser Gln Asp Val Ser

2530 Lie Gly Val Wing Trp Tyr Gln Gln Lys Pro Gly Lys Wing Pro Lys

4045

Leu Leu lie Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser

5560

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie

7075

Be Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln

8590

Tyr Tyr lie Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu

100105 lie Lys Arg Thr Val Wing Wing Pro Ser Val Phe lie Phe Pro Pro

110 115120

Be Asp Glu Gln Leu Lys Be Gly Thr Ala Be Val Val Cys Leu

125 130135

Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val

140 145150

Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu

155 160165

Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr

170 175180

Leu Ser Lys Wing Asp Tyr Glu Lys His Lys Val Tyr Wing Cys Glu

185 190195

Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn 200 205210

Arg Gly Glu Cys <210> 12 <211> 448 <212> PRT <213> Artificial sequence <220>

<223> The sequence is synthesized.

<400> 12

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly 15 10 15

ES 2 736 005 T3

Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr 20 2530

Asp Tyr Thr Met Asp Trp Val Arg Gln Wing Pro Gly Lys Gly Leu 35 4045

Glu Trp Val Wing Asp Val Asn Pro Asn Ser Gly Gly Ser lie Tyr 50 5560

Asn Gln Arg Phe Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser 65 7075

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Wing Glu Asp 80 8590

Thr Wing Val Tyr Tyr Cys Wing Arg Asn Leu Gly Pro Ser Phe Tyr 95 100 105

Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala 110 115120

Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 125 130135

Ser Thr Ser Gly Gly Thr Ala Wing Leu Gly Cys Leu Val Lys Asp 140 145150

Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu 155 160165

Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 170 175180

Leu Tyr Be Leu Be Be Val Val Thr Val Pro Be Be Be Leu 185 190195

Gly Thr Gln Thr Tyr lie Cys Asn Val Asn His Lys Pro Ser Asn 200 205210

Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 215 220225

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 230 235240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie 245 250255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295300

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 305 310315

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu

320 325330

ES 2 736 005 T3

<210> 13 <211> 214 <212> PRT <213> Artificial sequence <220>

<223> The sequence is synthesized.

<400>13

Asp lie Gln Met Thr Gln Be Pro Be Be Leu Be Wing Be Val 15 1015

Gly Asp Arg Val Thr lie Thr Cys Arg Ala Ser Gln Asp Val Asn 20 2530

ES 2 736 005 T3

Thr Val Wing Trp Wing Tyr Gln Gln Lys Pro Gly Lys Pro Wing Lys 35 4045

Leu Leu lie Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser 50 5560

Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr lie 65 7075

Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln 80 8590

His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu 95 100 105 Lie Lys Arg Thr Val Ala Wing Pro Ser Val Phe lie Phe Pro Pro 110 115120

Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu 125 130135

Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val 140 145150

Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu

155 160165

Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr

170 175180

Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu

185 190195

Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn

200 205210

Arg Gly Glu Cys <210>14 <211>449 <212>PRT <213> Secuencia artificial

10<220>

<223> La secuencia es sintetizada.

ES 2 736 005 T3

Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp 80 8590

Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr 95 100105

Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 110 115120

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser 125 130135

Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys 140 145150

Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 155 160165

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 170 175180

Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 185 190195

Leu Gly Thr Gln Thr Tyr lie Cys Asn Val Asn His Lys Pro Ser

200 205210

Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys

215 220225

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly

230 235240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

245 250255 lie Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser

260 265270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val

275 280285

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn

290 295300

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp

305 310315

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys VaL Ser Asn Lys Ala

320 325330

Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gln

335 340345

Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu

350 355360

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe

365 370375

Tyr Pro Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gln Pro

380 385390

ES 2 736 005 T3

<210> 15 <211> 217 <212> PRT <213> Secuencia artificial <220>

<223> La secuencia es sintetizada.

<400>15

Val His Ser Asp lie Gin Met Thr Gln Ser Pro Ser Ser Leu Ser 15 1015

Ala Ser Val Gly Asp Arg Val Thr lie Thr Cys Lys Ala Ser Gln

2530

Asp Val Ser lie Gly Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys

4045

Ala Pro Lys Leu Leu lie Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly

5560

Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr

7075

Leu Thr lie Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr

8590

Cys Gln Gln Tyr Tyr lie Tyr Pro Tyr Thr Phe Gly Gln Gly Thr

100105

Lys Val Glu lie Lys Arg Thr Val Ala Ala Pro Ser Val Phe lie

110 115120

Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val 125 130135

Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln

140 145150

Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser

155 160165

Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 170 175180

Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr

185 190195

ES 2 736 005 T3

Ala Cys Glu Val Thr His Gln

200

Gly

Leu

Ser

205

Ser

Pro

Val

Thr

Lys

210

Ser Phe Asn Arg Gly Glu Cys

215 <210> 16 <211> 449 <212> PRT <213> Secuencia artificial <220>

<223> La secuencia es sintetizada.

<400>16

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly 15 1015

Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr 20 2530

Asp Tyr Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu

4045

Glu Trp Val Ala Asp Val Asn Pro Asn Ser Gly Gly Ser lie Tyr

5560

Asn Gln Arg Phe Lys Gly 65

Lys Asn Thr Leu Tyr Leu 80

Thr Ala Val Tyr Tyr Cys 95

Phe Asp Tyr Trp Gly Gln

110

Ser Thr Lys Gly Pro Ser 125

Ser Thr Ser Gly Gly Thr

140

Tyr Phe Pro Glu Pro Val 155

Thr Ser Gly Val His Thr

170

Leu Tyr Ser Leu Ser Ser 185

Gly Thr Gln Thr Tyr lie

200

Thr Lys Val Asp Lys Lys 215

His Thr Cys Pro Pro Cys 230

ES 2 736 005 T3

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie

245 250255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

260 265270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu

275 280285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser

290 295300

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp

305 310315

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu

320 325330

Pro Ala Pro lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gln Pro

335 340345

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro

350355

Ser Arg Glu Glu Met

360

Thr Lys Asn Gln Val

365

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr

370375

Pro Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gln ProGlu

380 385390

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp GlySer

395 400405

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg TrpGln

410 415420

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala LeuHis

425 430435

Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro GlyLys

440445 <210>17 <211>10 <212> PRT <213> Secuencia artificial <220>

<223> La secuencia es sintetizada.

<220>

<221> Xaa <222>10 <223> Xaa es preferentemente D o S <400>17

Gly Phe Thr Phe Thr Asp Tyr Thr Met Xaa 1510 <210>18 <211>17 <212> PRT <213> Secuencia artificial

ES 2 736 005 T3 <220>

<223> La secuencia es sintetizada.

<400> 18

Asp Val Asn Pro Asn Ser Gly Gly Ser lie Tyr Asn Gln Arg Phe 15 10 15

Lyg Gly <210> 19 <211> 10 <212> PRT <213> Secuencia artificial <220>

<223> La secuencia es sintetizada.

<400> 19

Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr 15 10 <210> 20 <211> 11 <212> PRT <213> Secuencia artificial <220>

<223> La secuencia es sintetizada.

<400> 20

Lys Ala Ser Gln Asp Val Ser He Gly Val Ala 15 10 <210> 21 <211> 7 <212> PRT <213> Secuencia artificial <220>

<223> La secuencia es sintetizada.

<220>

<221> Xaa <222> 5 <223> Xaa es preferentemente R o L <220>

<221> Xaa <222> 6 <223> Xaa es preferentemente Y o E <220>

<221> Xaa <222> 7 <223> Xaa es preferentemente T o S <400> 21

Ser Ala Ser Tyr Xaa Xaa Xaa

5 <210> 22 <211> 9 <212> PRT <213> Secuencia artificial

ES 2 736 005 T3 <220>

<223> La secuencia es sintetizada.

<400> 22

Gln Gln Tyr Tyr lie Tyr Pro Tyr Thr

1 5

ES 2 736 005 T3

Contents103

140 members in 33 offices

This recordMember, by publication datePriority claim23 more offices are in the list below

Priority claims11

Priority claims
Document	Office	Kind	Date
201161547535P	United States of America	–	2011-10-14
201161547535	United States of America	P	2011-10-14
201161567015P	United States of America	–	2011-12-05
201161567015	United States of America	P	2011-12-05
201261657669P	United States of America	–	2012-06-08
201261657669	United States of America	P	2012-06-08
201261682037P	United States of America	–	2012-08-10
201261682037	United States of America	P	2012-08-10
201261694584P	United States of America	–	2012-08-29
201261694584	United States of America	P	2012-08-29
2012059683	United States of America	W	2012-10-11

Members140

Family members, oldest first
Document	Office	Kind
CA2788253A1	Canada	A1	2013-04-14
CA3104165A1	Canada	A1	2013-04-14
CA3167799A1	Canada	A1	2013-04-14
US2013095172A1	United States of America	A1	2013-04-18
WO2013055874A2	World Intellectual Property Organization (WIPO)	A2	2013-04-18
WO2013055874A3	World Intellectual Property Organization (WIPO)	A3	2013-06-20
AU2012322797A1	Australia	A1	2014-03-20
IL231350A0	Israel	A0	2014-04-30
IL231350D0	Israel	D0	2014-04-30
MX2014004021A	Mexico	A	2014-04-30
CR20140170A	Costa Rica	A	2014-05-23
SG11201401432XA	Singapore	A	2014-05-29
KR20140075725A	Republic of Korea	A	2014-06-19
AU2012322797A8	Australia	A8	2014-06-26
PH12014500733A1	Philippines	A1	2014-06-30
CL2014000889A1	Chile	A1	2014-07-25
EP2766040A2	European Patent Office (EPO)	A2	2014-08-20
JP2014530235A	Japan	A	2014-11-17
PE20142363A1	Peru	A1	2015-01-30
CN104334189A	China	A	2015-02-04
IN2703CHN2014A	India	A	2015-07-03
HK1202242A	Hong Kong, China	A	2015-09-25
HK1202242A1	Hong Kong, China	A1	2015-09-25
EA201490779A1	Eurasian Patent Organization (EAPO)	A1	2015-11-30
AU2012322797B2	Australia	B2	2016-04-21
NZ621367A	New Zealand	A	2016-04-29
US2016175438A1	United States of America	A1	2016-06-23
AU2016204962A1	Australia	A1	2016-08-04
SG10201606756PA	Singapore	A	2016-10-28
KR20170023195A	Republic of Korea	A	2017-03-02
BR112014007521A2	Brazil	A2	2017-12-12
JP2017222663A	Japan	A	2017-12-21
UA116095C2	Ukraine	C2	2018-02-12
AU2016204962B2	Australia	B2	2018-03-08
BR112014007521A8	Brazil	A8	2018-04-10
AU2018203970A1	Australia	A1	2018-06-21
ZA201401259B	South Africa	B	2019-01-30
NZ732854A	New Zealand	A	2019-03-29
US2019117769A1	United States of America	A1	2019-04-25
EP2766040B1	European Patent Office (EPO)	B1	2019-05-15
CN109908341A	China	A	2019-06-21
PT2766040T	Portugal	T	2019-07-11
PH12014500733B1	Philippines	B1	2019-07-17
DK2766040T3	Denmark	T3	2019-07-22
LT2766040T	Lithuania	T	2019-08-12
RS58944B1	Serbia	B1	2019-08-30
SI2766040T1	Slovenia	T1	2019-08-30
EA201991164A1	Eurasian Patent Organization (EAPO)	A1	2019-09-30
MX2019009153A	Mexico	A	2019-10-14
HRP20191247T1	Croatia	T1	2019-10-18
HUE044352T2	Hungary	T2	2019-10-28
AU2018203970B2	Australia	B2	2019-11-21
MY172326A	Malaysia	A	2019-11-21
AU2019261666A1	Australia	A1	2019-11-28
PL2766040T3	Poland	T3	2019-11-29
ES2736005T3This record	Spain	T3	2019-12-23
EP3598981A2	European Patent Office (EPO)	A2	2020-01-29
EA034390B1	Eurasian Patent Organization (EAPO)	B1	2020-02-03
JP6646785B1	Japan	B1	2020-02-14
JP2020033353A	Japan	A	2020-03-05
KR102099991B1	Republic of Korea	B1	2020-04-14
ZA201701050B	South Africa	B	2020-05-27
EP3598981A3	European Patent Office (EPO)	A3	2020-06-10
JP2020090507A	Japan	A	2020-06-11
US2020206348A1	United States of America	A1	2020-07-02
NZ750877A	New Zealand	A	2020-09-25
US2020376120A1	United States of America	A1	2020-12-03
US2021015919A1	United States of America	A1	2021-01-21
CA2788253C	Canada	C	2021-02-16
UA123092C2	Ukraine	C2	2021-02-17
PH12019500519A1	Philippines	A1	2021-06-14
AU2019261666B2	Australia	B2	2021-08-05
SG10202110077QA	Singapore	A	2021-10-28
IL286921A	Israel	A	2021-10-31
JP2022062010A	Japan	A	2022-04-19
CN114984205A	China	A	2022-09-02
US2022362379A1	United States of America	A1	2022-11-17
MY194408A	Malaysia	A	2022-11-30
CA3104165C	Canada	C	2023-02-21
KR102502545B1	Republic of Korea	B1	2023-02-21
KR20230028585A	Republic of Korea	A	2023-02-28
IL231350B1	Israel	B1	2023-04-01
IL301603A	Israel	A	2023-05-01
KR20230073340A	Republic of Korea	A	2023-05-25
CN116236569A	China	A	2023-06-09
CN116271011A	China	A	2023-06-23
CN116271013A	China	A	2023-06-23
CN109908341B	China	B	2023-06-27
JP7303957B1	Japan	B1	2023-07-05
CA3167799C	Canada	C	2023-07-11
IL231350B2	Israel	B2	2023-08-01
JP2023109779A	Japan	A	2023-08-08
JP2023109780A	Japan	A	2023-08-08
EP4234033A2	European Patent Office (EPO)	A2	2023-08-30
EP4234034A2	European Patent Office (EPO)	A2	2023-08-30
US2023277663A1	United States of America	A1	2023-09-07
US2023277664A1	United States of America	A1	2023-09-07
EP4241849A2	European Patent Office (EPO)	A2	2023-09-13
EP4234033A3	European Patent Office (EPO)	A3	2023-09-20
EP4234034A3	European Patent Office (EPO)	A3	2023-09-20

Showing 100 of 140